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ABSTRACT OF THE DISSERTATION 
AZIDO- AND TRIAZOLYL-MODIFIED NUCLEOSIDE/TIDE ANALOGUES: 
CHEMISTRY, FLUORESCENT PROPERTIES, AND ANTICANCER ACTIVITIES 
By 
Zhiwei Wen 
Florida International University, 2018 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
Two classes of C5 azido-modified pyrimidine nucleosides were synthesized and 
explored as radiosensitizers. The 5-azidomethyl-2'-deoxyuridine (AmdU) was prepared 
from thymidine and converted to its cytosine counterpart (AmdC). The 5-(1-azidovinyl) 
modified 2'-deoxyuridine (AvdU) and 2'-deoxycytidine (AvdC) were prepared employing 
regioselective Ag-catalyzed hydroazidation of 5-ethynyl pyrimidine substrates with 
TMSN3. AmdU and AmdC were converted to 5'-triphosphates AmdUTP and AmdCTP, 
and incorporated into DNA-fragments via polymerase-catalyzed reaction during DNA 
replication and base excision repair. Radiation-mediated prehydrated electrons formed in 
homogeneous aqueous glassy (7.5 M LiCl) systems in the absence of oxygen at 77 K led 
to site-specific formation of π-type aminyl radicals (RNH•) from AmdU, AmdC, AvdU, 
and AvdC. The ESR spectral studies and DFT calculations showed RNH• undergo facile 
conversion to thermodynamically more stable σ-type iminyl radicals, R=N•. For AmdU, 
conversion of RNH• to R=N• was bimolecular involving α-azidoalkyl radical as 
intermediate; however, for AvdU, RNH• tautomerized to R=N•. Our work provides the 
first evidence for the formation of RNH• attached to C5 position of azidopyrimidine 
vii 
 
nucleoside and its facile conversion to R=N• under reductive environment. These aminyl 
and iminyl radicals can generate DNA damage via oxidative pathways. The azido-
nucleosides were successfully applied as radiosensitizers in EMT6 cancer cells in both 
hypoxic and normoxic conditions. To explore the generation and reactivity of 
2'-deoxyguanosin-N2-yl radical (dG(N2-H)•) postulated to generate from guanine moiety 
towards •OH, 2-azido-2'-deoxyinosine (2-N3dI) was prepared by conversion of 2-amino 
group in protected dG into 2-azido via diazotization with tert-butyl nitrite followed by 
displacement with azide and deprotection. The investigation of dG(N2-H)• generated from 
2-N3dI and its subsequent reactions using ESR will be discussed. 
Cycloaddition between 5-ethynylpyrimidine or 8-ethynylpurine nucleosides and 
TMSN3 in the presence of Ag2CO3, CuI, or CuSO4/sodium ascorbate provided N-
unsubstituted 1,2,3-triazol-4-yl analogues of the parental DNA bases (i.e. 5-TrzdU, 
5-TrzdC, 8-TrzdA, and 8-TrzdG). These novel triazolyl nucleosides showed excellent 
fluorescent properties: 8-TrzdA exhibits the highest quantum yield (ΦF) of 44% while 
8-TrzdG had ΦF of 9%. The 5-TrzdU and 5-TrzdC showed a large Stokes shift of ~110 nm. 
The application of these fluorescent nucleosides to cell imaging and DNA modifications 
will also be discussed. 
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1. INTRODUCTION 
1.1. Anticancer nucleoside/tide analogues 
Globally, cancer is the second most common cause of death and is responsible for one 
out of every six deaths. The cancerous cells undergo uncontrolled growth, avoid 
programmed cell death, as well as invade into tissues and form metastases. It was estimated 
that there will be around 1.7 million new cancer cases and around 600 thousand deaths 
caused by cancer in USA in 2018 (Table 1).1 Cancer, a genetic disease,  arises from the 
changes to genes, which would be inherited from parents, unrepaired errors during cell 
divisions, or DNA damages from certain environmental exposure (like unhealthy diet, 
tobacco, etc.)  
Table 1. Estimated new cases of cancer and deaths in USA, 2018 
 Estimated New Cases Estimated Deaths 
All Sites 1,735,350 609,640 
Digestive system 319,160 160,820 
Genital system 286,390 62,330 
Breast 268,670 41,400 
Respiratory system 253,290 158,770 
Urinary system 150,350 33,170 
Others 457,490 153150 
Types of treatments of cancer include surgery, radiotherapy, chemotherapy, 
immunotherapy, hormone therapy, targeted therapy, and stem cell transplant. As a chemist, 
I am most interested in the chemotherapy, radiotherapy, and their combination. Among the 
anticancer drugs, nucleoside/tide analogues (NAs) have been approved by US Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) and been in clinical 
use for the treatment of various cancers for about 49 years since the first approved 
nucleoside analogue, i.e., cytarabine, for the treatment of acute myeloid leukemia.2 Some 
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currently approved NAs as anticancer agents are summarized in Figure 1, in which the 
modifications to the natural nucleoside/tides were highlighted in red.  The approval of some 
new nucleoside/tide analogues drugs in the past decade proves that nucleoside/tide 
analogues still have excellent potential for the cancer treatment.  
 
Figure 1. Approved anticancer nucleoside/tide drugs 
The differences between the nucleoside/tide analogues and their counterpart are tiny 
(Figure 1). Like gemcitabine 4, its difference from its counterpart deoxycytidine is the two 
fluorine atoms at C2' position instead of two hydrogen atoms. Nevertheless, this tiny 
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difference endows the NAs with anticancer properties.3 As demonstrated in Figure 2, firstly 
the NAs are taken up into cells through nucleoside transporters, organic anion/cation 
transporters, or peptide transporters.2 Then, the nucleosides mimic natural nucleosides and 
are metabolically phosphorylated by nucleoside kinase, nucleoside monophosphate kinase 
and nucleoside diphosphate kinase. The NAs would interact with and inhibit important 
proteins. Nucleotides may also be incorporated into DNA/RNA and block the division of 
cancer cells. The inhibition of important proteins (enzymes) and incorporation into DNA 
would both lead to the apoptosis of tumor cells. 2,3 
 
Figure 2. General mechanisms of anticancer activities of nucleoside/tide analogues 
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1.2. Cancer radiosensitization 
1.2.1. Radiotherapy  
Radiotherapy and its combination with other treatments (e.g., surgery, chemotherapy) 
are applied for the treatment of most common types of cancers to cure or control tumors.4,5  
Even though new types of cancer treatment with better selectivity against cancerous cells,6 
like immunotherapy and targeted therapy, are emerging, almost half of all the cancer 
patients are still treated with radiotherapy.7  
The mechanism of ionizing radiation during the radiotherapy is illustrated in Scheme 
1. The interaction of ionizing radiation with materials inside cancerous cells includes direct 
and indirect effects.7,8 Water in the cells undergo radiolysis to give ionized water cation 
(H2O•+) and electrons. The water cation reacts with another water to yield reactive oxygen 
species (ROS) hydroxyl radicals (HO•), which is related to oxidative DNA damage.9  The 
electron generated from water radiolysis is solvated to offer prehydrated electron e-aq, 
which further interact with oxygen to give superoxide (O2•-) or with hydronium (H3O+) to 
give hydrogen atom (H•). The electrons are related to the reductive DNA damage. 
Approximately, the electrons with low energy are responsible for 67% of DNA damage, 
while the highly reactive HO• is responsible for the remaining 33%.10 This DNA damage 
caused by the radicals generated from the radiolysis of water is named as indirect effect 
(Scheme 1). On the other hand, the ionizing radiation would also directly ionize the base 
or backbones of DNA fragments, which is named as direct effect.  
DNA damage from the ionizing radiation includes damage to base or sugar, 
single/double-strand breaks, cross-linking of DNA and other biomolecules like DNA or 
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proteins, and so on. The DNA lesion frequency is revealed in Table 2.11 The DNA damage 
results in the death of cancerous cells.12-14  
 
Scheme 1. The rationale for the direct/indirect effects of irradiation in radiotherapy 
Table 2. The approximate number of DNA lesions per Gy per cell induced by ionizing 
radiation 
DNA damage induced by ionizing radiation Approximate number/Gy in one cell 
DNA DSB (double-strand breaks) 40 
DNA SSB (single-strand breaks) 1000 
DNA-DNA cross-links 30 
DNA-protein cross-links 150 
Damage at base 2,000 
Damage at sugar-phosphate backbone 1,000 
1.2.2. Radiosensitizers (Radiosensitizing agents) 
A high dose of ionizing radiation leads to both acute and cumulative side effects,15 thus 
it is significant to enhance the radiosensitiveness of tumor cells during radiotherapy to 
lower the dose of radiation required for same surviving fraction. Radiosensitizers have been 
developed to enhance the sensitiveness of cancerous cells to radiotherapy.3,16 Radiotherapy 
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employing radiosensitizers is used for most cancer patients and improves the survival 
compared to radiotherapy alone.3 Radiosensitizers include small molecules, 
macromolecules, and nanomaterials.8 The most conventional radiosensitizers include 
halogenated nucleosides, gemcitabine, and platinum analogues.3,7 
The C5 halogenated pyrimidine bases and nucleosides are well-investigated as 
radiosensitizers in cancer radiotherapy.3,7,17,18 5-Bromo-2'-deoxyuridine (5-BrdU, 12, 
Figure 3) has been recognized as a radiosensitizing agent with potential clinical 
applications.17 However, owing to toxicity of 5-BrdU, it did not show any increase in 
patient survival during phase III clinical trials and the trials were called off.19 On the other 
hand, 5-fluorouracil (5-FU, 13, Figure 3) via protracted venous infusion has become a 
typical treatment of rectal20 and pancreatic cancers.21 The radiosensitizing effect of 5-
fluorouracil is believed to derive from its inhibition of thymidylate synthase, which stops 
the DNA replication. The complex protracted venous infusion lasting for one to two 
months may lead to infection and/or thrombosis. As a consequence, capecitabine (7, 
Xeloda, Figure 1) was developed as a prodrug suitable for oral taken.22 Capecitabine is 
used for the treatment of colorectal cancer, breast cancer, oesophageal cancer, and gastric 
cancer.23 
 
Figure 3. Structures of C5 halogenated pyrimidine bases and nucleosides 
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Gemcitabine (4, Figure 1) was explored as radiosensitizer to enhance the sensitiveness 
of human colon carcinoma cells to radiation.24 The radiosensitizing effect of gemcitabine 
is a result of inhibition of ribonucleotide reductase, which depletes the dATP pools. The 
cells progressing into S phase suffer from the depletion of dATP and the consequent 
misincorporation and misrepair of wrong bases, which generate DNA lesions that lead to 
the cell apoptosis.3 
In addition to the nucleoside-based radiosensitizers, there are various non-nucleosides-
based radiosensitizing agents, among which platinum analogues have been applied 
clinically as a radiosensitizers to treat various cancerous tumors.3  
 
Figure 4. Platinum analogues applied clinically as a radiosensitizers 
Cisplatin analogues (Figure 4) are well known to interfere with DNA replication by 
forming 1,2-intrastrand crosslinks with two adjacent guanine/guanine (90%) along DNA 
fragment as well as with adjacent guanine and adenine, which induces apoptosis of fast 
proliferating cells (Figure 5).25 The mechanisms of the radiosensitizing effect of cisplatin 
analogues include formation of more toxic platinum intermediates from the interaction 
between the cisplatin and free radicals induced by irradiation (Irradiated hypoxic solutions 
of cisplatin were more toxic than unirradiated solutions),26 enhanced uptake of carboplatin 
into cells induced by irradiation,27 and repression of DNA repair.28 
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Figure 5. Mechanism of the anticancer activity of cisplatin 
1.2.3. Hypoxia and hypoxia-selective radiosensitizers 
Tumor cells replicate quickly and require nutrients from blood vessels. As solid tumors 
grow, angiogenesis allows the generation of new vascular beds to support the cancerous 
cells.29 Nevertheless, the morbid tumor vascular bed formed during the angiogenesis is 
twisting and irregular and thus lacks the ability to deliver blood to every part of the tumors. 
As a consequence, solid tumors encompass regions with transient and chronic low 
concentration of oxygen, which is named as transient hypoxia and chronic hypoxia, 
respectively.30-32  
The partial pressure of oxygen (pO2) in human tumors is less than 5 mmHg, while the 
pO2 in the surrounding normal cells is higher than 30 mmHg. As discussed in section 1.2.1 
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and shown in Scheme 1, oxygen is essential for the sensitiveness of cancerous cells in 
radiotherapy. The tumor cells under hypoxic microenvironment are resistant to 
radiotherapy and chemotherapy.30 On the other hand, the existence of hypoxia, unique 
features of solid tumors that is not found in normal cells, offers an chance for tumor-
selective therapy.  
One of the strategies exploiting the tumor hypoxia is to design prodrugs activated by 
hypoxia. Tirapazamine (17, TPZ, Scheme 2), the first developed specific cytotoxin for 
hypoxia, was demonstrated for its antitumor activity.33  The mechanism for the hypoxia-
selectivity of TPZ 17 was shown in Scheme 2.30 TPZ 17 undergoes one-electron reduction 
by reductases or aquated electron from radiolysis of water to give tirapazamine radicals 
(TPZ•). TPZ• further decays to hydroxyl radical (HO•) or benzotriazinyl radical (BTZ•), 
which poisons the topoisomerase II and leads to DNA double-strand breaks.33 
 
Scheme 2. The mechanism for the hypoxia-selectivity of tirapazamine 
However, the cells under hypoxic condition usually lack reductase enzymes and 
cofactors. Thus, developing radiosensitizers activated by irradiation-induced prehydrated 
electron is more attractive than activation by enzymes. Cobalt(III) complexes,34 
nitrobenzyl quaternary ammonium salts,35 and oxypropyl-substituted 5-fluorouracil 
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derivatives36 (Figure 6) were demonstrated to be capably triggered by ionizing radiation 
under hypoxic conditions. Nevertheless, none of the compounds has yet shown undisputed 
radiosensitizations in hypoxic tumors. As a result, more effort and research should be 
dedicated to the development of new hypoxia-selective radiosensitizers activated by 
irradiation. 
 
Figure 6. Radiosensitizers activated by irradiation-induced prehydrated electron 
1.3. Azido-modified nucleoside/tide analogues as biological probe for click reaction 
Because of the various novel properties, azido modified small molecules and 
biomacromolecules have been designed and investigated for a variety of applications 
including serving as biological probes for cycloaddition click reaction for bioconjugation, 
anticancer and antiviral agents, and potential radiosensitizers.37-42 
The absence of azides in almost all creatures and their inert reactivity with water, 
amines, oxidant, or other functional groups abundant in biological systems endow the 
azides with exquisite bioorthogonality. The bioorthogonal ligations employing azides 
include Staudinger ligation of azides with phosphines as wells as click reactions between 
azides and strain-promoted alkyne or  terminal alkyne catalyzed by copper (Table 3).43  
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Table 3. Azido-modified biomolecules for labeling and tracking   
Chemical 
Reporter 
Reactive partner 
(R' = probe) 
Ligation Product 
 
R-N3 
 
Target R: 
Nucleic acid 
Protein 
Glycan 
Lipid 
 
Staudinger Ligation 
 
 
Cu-catalyzed Cycloaddition 
 
 
Strain-promoted Cycloaddition 
  
In 2002, Sharpless and Meldal brought the Huisgen [3+2] cycloaddition between azide 
and alkyne  into focus by employing copper as a catalyst.44,45 The copper-catalyzed [3+2] 
azide-alkyne cycloaddition (CuAAC) could proceed smoothly under mild reaction 
condition in aqueous media to form 1,2,3-triazoles, and thus is biocompatible. The toxic 
copper limits the application of CuAAC in living cells and animals. The strain-promoted 
azide-alkyne cycloaddition (SPAAC) “click” reactions developed by Bertozzi in 200446 
expanded the application of [3+2] azide-alkyne cycloaddition in covalent interaction of 
biomolecule/biomolecule and biomolecule/probe in living systems. Azide as a reactive 
reporter introduced into a target biomolecule like nucleic acid, protein, glycans, and lipids 
reacts with probe or other biomolecules modified with terminal alkyne/cyclooctyne via 
CuAAC or SPAAC to label and track biomolecules.43,47 CuAAC and SPAAC are broadly 
used for bioorthogonal conjugation, new drug discovery, and proteomic profiling.48-51 
The chemically stable 5-azidomethyl-2'-deoxyuridine (AmdU, 18, Figure 7), as 
opposed to the highly photolyzable 5-azido-2'-deoxyuridine (5-AdU),52 serves as a 
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substrate for the synthesis of clickable triazoles.40,53-57 AmdU 18 was able to be 
metabolically incorporated into DNA in living cells for click labeling of DNA.40 
 
Figure 7. Azido-modified pyrimidine nucleoside/tide analogues 
1.4. Anticancer and radiosensitizing properties of azido-modified nucleoside/tide 
analogues 
1.4.1. Anticancer activities of azido-modified nucleoside/tide analogues 
Azido-modified pyrimidine nucleoside analogues were reported to exhibit anticancer 
and antiviral activities. The 3'-azido-3'-deoxythymidine (3'-AZT, 22, Figure 7), first 
prepared by Horwitz in 1964,58 has been widely investigated for its anticancer and antiviral 
activities. The 3'-AZT has been commonly used to treat HIV positive patients benefit from 
its antihuman telomerase reverse transcriptase activity59 and also used as a radiosensitizer 
for tumors of patients also carrying HIV.60 The mechanism of the formation of reactive 
aminyl radical responsible for the radiosensitivity of 3'-AZT will be detailed in section 1.5.  
The AmdU 18 and its monophosphate (AmdUMP 19, Figure 7)61,62 inhibited 
thymidylate synthetase activity derived from calf thymus and Ehrlich ascites tumor.61,63 
They also inhibited thymidine kinase activity64 and consequently affected the growth of 
murine sarcoma 180 and L1210,41,62 and the replication of herpes simplex virus type 1 
(HSV-1).41,65,66 The AmdU 5'-triphosphate (AmdUTP, 20) was found to be a substrate for 
DNA polymerases and PCR amplification.57 Moreover, the clickable triazole adducts of 
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5-AdU67 were incorporated into oligodeoxynucleotides; but, an attempt to synthesize  the 
peptide-siRNA covalent conjugates from AmdU-derived triazole was unsuccessful.53 
The 5-(1-azidovinyl)-2'-deoxyuridine (AvdU, 21) proved inhibitory to the replication 
of HSV-1 and VZV and became highly cytostatic against HSV-1 and HSV-2 TK gene 
transfected FM3A tumor cells; the cytostatic effect was enhanced by 5-fold after short 
exposure to UV irradiation at 254 nm.68 AvdU 21 showed also anti-mycobacterial activities 
in submicromolar range.69  
1.4.2. Azido-modified nucleoside/tide analogues as radiosensitizers 
The 3'-AZT 22 (Figure 7) has been employed as a radiation sensitizer in radiotherapy 
of tumors for HIV positive patients.60 Zhou and his colleagues reported their results on the 
investigation of the effects of 3'-AZT 22 combining with γ-radiation on telomere length, 
activity of telomerase, DNA single/double-strand breaks, and of its radiosensitizing effects 
in human malignant glioma cell line U251.70 The 3'-AZT 22 suppressed the telomerase 
activity and slowed down DNA strand breaks repair. The changes in radiosensitivity were 
quantified by the sensitization enhancement ratio (SER). The 3'-AZT 22 (800 μM) 
enhanced the radiosensitivity at 2 Gy γ-radiation of U251 cells with SER of 1.37. The 
3'-AZT 22 also increased the radiosensitivity of Hep-2 cells.71  
In addition to the radiosensitizing effect, 3'-AZT 22 was also reported to enhance 
cytotoxicity of the anticancer drugs in the irradiated cancerous cells.  The 3'-AZT 22 was 
able to enhance the radiosensitizing effects of (E)-2'-deoxy-(fluoromethylene)cytidine 
(FMdC) on human colon cancer cells.72  Various concentration (25 μM to 100 μM) of 22 
was added immediately before irradiation of the cancerous cells treated with FMdC. The 
combination of FMdC and 3'AZT 22 gave SER ranging from 1.25 to 2.26.  
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1.5. Formation of aminyl radicals on prehydrated one-electron attachment to 
azido-modified nucleosides and their subsequent reactions 
The formation of neutral and reactive aminyl radicals on prehydrated one-electron 
attachment to azido-modified nucleosides in γ-irradiated aqueous glassy (7.5 M LiCl) 
systems was characterized using electron spin resonance spectroscopy (ESR).42,73 
γ-Irradiated chloride ion in glassy system at 77 K produced chlorine radical and electron 
(Scheme 3), which was solvated to yield aquated electron.  Electron attachment to the azido 
group led to azide anion radical intermediate I (RN3•-), which formed nitrene anion radical 
intermediate II (RN•¯) after the loss of N2. Subsequently, rapid protonation of RN•¯ from 
the solvent led to RNH• formation.  
 
Scheme 3. The mechanism of formation of aminyl radicals on electron attachment to azido 
compounds in γ-irradiated aqueous glassy system 
Radical at C5' position (C5'•) was reported to cause DNA strand breaks and associate 
unaltered base release.9 To prove that the ring-opened C4'• is an intermediate in mechanism 
of C5'• mediated unaltered base release, methyl 2-azido-2-deoxy-α-D-lyxofuranoside (23, 
Scheme 4) as well as other azido-modified pentofuranoses were prepared and used for the 
ESR study (Scheme 4).73 In methyl 2-azido-2-deoxy-α-D-lyxofuranoside, the aminyl 
radical (I, Scheme 4) at the 2 position undergoes intramolecular H-abstraction to give C5'• 
(II), which further undergoes intramolecular conversion to the ring-opened C4'• (III). 
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Scheme 4.  Formation of aminyl radicals in methyl 2-azido-2-deoxy-α-D-lyxofuranoside 
and subsequent intramolecular H-atom transfer and ring opening 
In 3'-AZT 22, the aminyl radical at the C3'-site of sugar moiety underwent a 
bimolecular H-atom abstraction either from the methyl group at C5 to give dUCH2•, from 
the C5'-atom to give C5'•, or from the C3'-atom to give C3'• of a proximate 3'-AZT 
(Scheme 5A).42 On the other hand, the aminyl radical at the C3' site from 3'-azido-2',3'-
dideoxyguanosine (3'-AZddG, 24) resulted in one-electron oxidation of guanine base to 
give G(N1-H)• (Scheme 5B). The radicals formed at sugar are known to lead to strand 
breakage in RNA (Scheme 6A) and DNA (Scheme 6B), and further affects the apoptosis 
of cancer cells.9,17 The structural DNA damage, like formamidopyrimidines (e.g., FapyG) 
and 8-oxopurines (e.g., 8-oxoG), formed from the guaninyl radicals are cytotoxic.74   
 
Scheme 5. Prehydrated one-electron attachment to azido group on 3'-AZT(A) and 
3'-AZddG (B): Aminyl radical formation and subsequent reactions 
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Scheme 6. Mechanism of RNA/DNA single-strand breaks upon generation of sugar 
radicals 
The azido group in 3'-AZT 22 rather than the thymine moiety was proved to be the 
predominant site of electron capture, as a result of the higher electron affinity of the azido 
group in 22 than the most electron affinic DNA base, thymine.42 The formation of the 
reactive aminyl radicals in γ-irradiated system and their subsequent reactions provides a 
plausible mechanism for the radiosensitizing effects of 3'-AZT60,70,72,75 and meanwhile 
suggest that the azido-modified nucleoside/tide analogues are possible to be explored as 
potential radiosensitizing agents in hypoxia (bioreductive) microenvironments. 
17 
 
1.6. Electron-hole transfer in DNA 
As discussed at section 1.2.1 (Scheme 1), hydroxyl radical HO• generated from 
ionizing irradiation causes DNA damage by reaction with guanine residues having the 
lowest oxidation potential.76,77  Deeper understanding of the pathways for γ-radiolysis 
damage to nucleic acids and how cancerous cells respond to radiotherapy would help the 
design of new treatments and improve current-existing therapies. Thus, it is essential to 
understand reactions of guanine with the reactive radicals, like hydroxyl radical during the 
radiolysis, and the subsequent reactions. 
 
Scheme 7. Radical reactions of guanine with hydroxyl radicals and subsequent reactions 
One-electron oxidation of guanine 25 by oxidants leads to the formation of G•+, which 
undergoes deprotonation to give guanyl radical 27 (Scheme 7).78 The reaction between the 
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guanine 25 and hydroxyl radical was studied using optical absorption. On the basis of the 
absorption, the major radical (65%) was assigned to C5• generated from the addition of 
HO• at C4, which further dehydrate to yield radical 27.79,80 In addition to the 28, 17% of 
HO• involves in the addition at C8 to provide radical 29, which is further converted into 
8-oxoG 30 and FapyG 31 via oxidation and reduction, respectively. In 2009, Chatgilialoglu 
reevaluate the reactivity of guanine towards HO•. Based on the DFT-TD calculations they 
assign the major radical to guan-N2-yl radical (G(N2-H)•, 26).81 The more favored 
formation of 26 from H-atom abstraction from 25 by HO• than the formation of 28 was 
further established by a Car-Parrinello molecular dynamics study.82        
The 8-substituted (e.g., Cl, Br 32, I, and N3) guanine derivatives were designed for 
investigating the formation and tautomerizations of one-electron-oxidized guanine.77 The 
pulse radiolysis technique with optical absorption detection and DFT calculations reveal 
the formation of radicals 26 as well as N3• with iminic and aminic forms, the tautomers of 
27.77,83,84 
As mentioned in section 1.5, ESR could be applied as a powerful tool to characterize 
radicals from the reaction between guanine and HO•. Nevertheless, ESR was not popular 
for identifying the radicals in previous research. An attempt was made to use ESR to 
investigate the formation of dG(N2−H)• 26 from hydrazine was not successful and  the 
resulting product dG was the evidence for the formation of 26 during the photolysis.85  
On the basis of the formation of aminyl radicals on prehydrated one-electron 
attachment to 3'-AZT 2242 (detailed at section 1.5), it is possible to explore azido-modified 
guanine derivatives as efficient precursors for investigation of elusive guanine-based 
aminyl radical under reducing conditions. 
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1.7. Fluorescent nucleosides for investigating nucleic acid structure, location, 
activation, and interactions 
The natural purine and pyrimidine bases in nucleic acids have weak fluorescent 
properties (Figure 8).86 Modified fluorescent nucleoside analogues with minimal 
perturbation to the natural DNA/RNA structures have attracted attention for their 
application to studying the perturbations to the nucleic acids such as abasic site from 
depurination/depyrimidination,87 base flipping,88 interaction between DNA/RNA and 
ligands,89,90 and so on.91,92 
 
Figure 8. Fluorescence of the natural purine and pyrimidine bases 
Recently, Dr. Kool at Stanford University published a comprehensive review in Nature 
Chemistry on the design of various fluorescent nucleobases and their application as 
powerful tools for investigating DNA and RNA.93 The modification to purines (Figure 9A) 
and pyrimidines (Figure 9B)  includes substitution, conjugated ring substitution, ring 
structure modification, conjugated linker extension, and ring fusion. This type of 
modifications shown in Figure 9 preserves the hydrogen bonding structures (highlighted in 
red), and thus retains the abilities of paring to their counterparts and some or most of the 
enzyme recognition. This group of fluorescent nucleobases is named as canonical 
fluorescent nucleobases.  
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Figure 9. Canonical fluorescent nucleobase analogues 
On the other hand, non-canonical fluorescent nucleobases with more varied 
photophysical properties have also been developed (Figure 10). Since the fluorophore 
structures are not necessarily confined to the natural nucleobases, theoretically they can be 
any fluorescent architectures. The more widely varied emissive spectra would allow 
non-canonical fluorescent nucleobases wider applications in biochemistry and biology. 
Accompanying the advantages, the shortcomings of non-canonical fluorescent nucleobases 
consist of the loss of base-paring ability and limited recognition by base-related enzymes.  
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Figure 10. Non-canonical fluorescent nucleobases 
The novel fluorescent properties, especially the varied quantum yield under different 
microenvironments, make fluorescent nucleosides valuable tools for investigating nucleic 
acid interactions, location, activities, and structure. Some examples are shown in Figure 11. 
Serva and coworkers employed 2-aminopurine for the study on DNA base flipping (Figure 
11A).88 Kim and coworkers used 8-pyrenylethynyl-2'-deoxyadenosine to detect base 
mismatch (Figure 11B).94 Tor and coworkers at UCSD explored the 5-furyl-2'-
deoxyuridine to locate abasic sites at DNA duplex (Figure 11C).87 They also used 
5-furyluridine to examine the interaction between RNA fragments and small molecules and 
to detect small molecules utilizing the increasing fluorescent intensity with increasing 
concentration of small molecules (Figure 11D).89 In Dr. Wnuk's lab, the strain-promoted 
azide-alkyne cycloaddition (SPAAC) “click” reactions were applied to form fluorescent 
triazoles in cells for cell imaging.51 The frequency domain fluorescence lifetime imaging 
microscopy (FD-FLIM) in MCF-7 cells is shown in Figure 11E. 
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Figure 11. Fluorescent nucleobase serving as powerful tools for investigating the 
perturbations to nucleic acids 
Among the fluorescent nucleosides, I was most interested in the triazolyl adenosine 
nucleosides because of their complex and interesting different fluorescent properties varied 
by N1 or C4 of the triazolyl moiety attached to the adenine base. The 2- or 8-azidopurine 
and 5-azidopyrimidine nucleosides were synthesized and ligated with cyclooctynes via 
strain promoted click chemistry to form 2- or 8-(1,2,3-triazol-1-yl) (ΦF = 0.6-10.6%) and 
5-(1,2,3-triazol-1-yl) pyrimidine (ΦF = 0.9-1.3%) for the application to living cell 
fluorescent imaging (e.g., 33 in Figure 12).51 The 2-(1,2,3-triazol-1-yl)adenosine analogues 
34 with triazole at C2 position gave relatively higher quantum yield of 20%,95 while 
8-(1,2,3-triazol-1-yl)-7-deazapurine nucleoside analogues 35 showed moderate quantum 
yields (ΦF = 0.2-1.4%)  and a large Stocks shifts.96 The photo-physical characterization of 
a series of 2-(4-amino-5-(1H-1,2,3-triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidin-7-yl) and 
2-(4-amino-3-(1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) analogues 
showed that compounds with a nitrogen atom in position 8 showed an approximately 
ten-fold increase in quantum yield (ΦF = ~5%) and decreased Stokes shift compared to 
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analogues with a carbon atom in position 8 (ΦF = ~0.6%).97 The 8-(1H-1,2,3-Triazol-4-
yl)adenosine derivatives 37 and 38 with the base attached to C4 position of triazole had 
promising quantum yield as high as 64%.98 It is noteworthy that the 8-(1,2,3-triazol-1-yl) 
adenosines 33 and 36 display fluorescence properties with significantly lower quantum 
yields than the 8-(1,2,3-triazol-4-yl) adenosines 37 and 38.99 
ΦF = 11%   ΦF = 20%   
ΦF = 0.21-0.64%   ΦF = 3-38%   ΦF = 49-64%   
ΦF = 0.2-1.4%   
 
Figure 12. Structure and the fluorescent properties of N-substituted triazoles 
According to the criteria87 of designing new fluorescent nucleosides: (i), sensitiveness 
to the microenvironment, (ii) absorption and emission at long wavelengths, (iii), high 
emission quantum efficiency, (iv) minimalistic modification, N-unsubstituted 1H-1,2,3-
triazol-4-yl modified adenine analogues as well as the other three nucleic acid bases would 
have novel fluorescent properties.   
The 5-(1H-1,2,3-triazol-4-yl)-2'-deoxyuridine (5-TrzdU, 39, Scheme 8) was 
synthesized by general CuAAC click reaction to give 40 followed by POM-deprotection 
(Scheme 8).100 The 5-TrzdU was also prepared via nucleobase-exchange reaction catalyzed 
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by thymidine phosphorylase from thymidine (41) to 1H-1,2,3-triazol-4-yl.101 The 5-TrzdU 
incorporated into DNA via solid-phase ODN synthesis stacks in the major groove and 
increases the stability of the DNA duplex.100  
 
Scheme 8. Strategies for the synthesis of 5-TrzdU 
The strategies developed for the synthesis of N-unsubstituted triazoles (Scheme 9) 
includes the [3+2] cycloaddition of terminal alkynes and trimethylsilyl azide (TMSN3) 
using CuI as catalyst,102 Pd103 or p-toluenesulfonic acid104 catalyzed cyclization between 
activated alkene and sodium azide, and deprotection of N-substituted triazole intermediates 
prepared by general CuAAC click reactions.96,105,106 All of these reaction conditions may 
be applied to synthesize the N-unsubstituted triazoles-modified nucleosides.  
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Scheme 9. Reported strategies for the synthesis of N-unsubstituted triazoles 
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1.8. Concept of prodrugs 
The anticancer activity of drugs would be limited by their inadequate diffusion into 
cancerous cells, especially into cells of a solid tumor under hypoxic condition.107 Designing 
chemically modified prodrugs, which are inactive, bio-reversible derivatives of active drug 
molecules, is a promising strategy to enhance pharmacokinetics of drug delivery. As shown 
in Figure 13, first prodrugs can pass through the physiological membranes more easily than 
the drugs. After entering the cells, the prodrugs undergo an enzymatic and/or chemical 
transformation and then the active parent drug can be released. Around 20% of all small 
molecular drugs approved in 2000-2008 were prodrugs.108 Even though designing a new 
prodrug can be challenging, the prodrug approach shows a practical path to minimize some 
undesirable properties of investigational drugs or commercially available drugs. Designing 
proTides is another gorgeous strategy that skips the metabolic phosphorylation and 
meanwhile increases the uptake of drugs.109  
 
Figure 13. A simplified illustration of the prodrug concept  
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2. RESEARCH OBJECTIVES 
The discovery of copper-catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) 
developed by Sharpless and Meldal in 200244,45 as well as strain-promoted azide–alkyne 
cycloaddition (SPAAC) “click” reactions developed by Bertozzi in 200446 led to the 
application of azide as a reactive reporter introduced into a target biomolecule like nucleic 
acid, protein, glycans, and lipids to label and track biomolecules.43,47 Click chemistry is 
now widely used for bioorthogonal conjugation, new drug discovery, and proteomic 
profiling.48-51 However, in my dissertation I have explored the application of the azide 
group beyond the click chemistry. On the basis of the original discovery from Sevilla's 
group42 on the formation of neutral and reactive aminyl radicals upon one-electron 
attachment to the azido group in 3'-AZT, I have investigated C5 azido-modified pyrimidine 
nucleosides as precursors to the reactive aminyl radicals. I also planned to investigate their 
application as anticancer radiosensitizing agents. 
Objective 1: Exploring C5 azido-modified pyrimidine nucleosides as radiosensitizers   
The first objective of my dissertation was to investigate if C5 azido-modified 
pyrimidine nucleosides (AmdU 18, AvdU 21, AmdC 42, AvdC 43, Figure 14) can act as 
radiosensitizers under both normoxic and hypoxic microenvironments. To serve as useful 
radiosensitizing agents, the C5 azido-modified pyrimidine nucleosides are required to a) 
be easily synthesized chemically and be stable under biological environment, b) be able to 
generate active radicals under normoxic and/or hypoxic condition, c) be able to be 
incorporated into DNA and not block further polymerization, d) and eventually show 
radiosensitizing effect in cancerous cells. 
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Figure 14. 2'-Deoxyuridine and 2'-deoxycytidine with azidomethyl and azidovinyl 
modified at C5 
Initially, I chose to synthesize and explore the chemistry and biochemistry of AmdU 
18. Contrary to the 5-azido-2'-deoxyuridine, in which the azido group is attached directly 
to the pyrimidine base, AmdU 18 was reported to be stable in aqueous solution.40 AmdU 
was also reported to be able to be enzymatically57 and metabolically40 incorporated into 
DNA. AmdU could be conveniently prepared by bromination of protected thymidine and 
subsequent displacement of bromide with sodium azide.40 The 5-Azidomethyl-2'-
deoxycytidine (AmdC, 42), in turn, could be obtained by conversion of the uracil ring in 
the protected AmdU to cytosine. Another class of C5 azido-modified pyrimidine 
nucleosides I explored were 5-azidovinyl derivatives of 2'-deoxyuridine (AvdU, 21) and 
2'-deoxycytidine (AvdC, 43) in which azido group is attached to sp2 hybridized carbon. 
The synthesis of AvdU 21 and AvdC 43 could be accomplished via silver-catalyzed 
hydroazidation of 5-ethynyl pyrimidines nucleoside substrates. 
The formation of aminyl radicals on electron attachment to azido-modified nucleosides 
in γ-irradiated aqueous glassy (7.5 M LiCl) systems and the subsequent reactions would be 
characterized using electron spin resonance (ESR). Unlike elongation terminator 3'-AZT 
22, the 5-azidomethyl (18 and 42) and 5-azidovinyl (21 and 43) pyrimidine nucleosides 
with modification moieties at the 5-postion of pyrimidine bases were expected not only 
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able to be metabolically/enzymatically incorporated into DNA but also allow DNA 
elongation after incorporation during the DNA replication. To test this hypothesis, the 
corresponding C5 azido-modified nucleoside triphosphates will be synthesized and 
evaluated for their ability for polymerase-catalyzed incorporation and further extension 
during DNA replication and base excision repair (BER). The radiation response of cells in 
the presence of azido-modified nucleosides in vitro will be examined in both aerobic and 
hypoxic condition of selected cancerous cells. 
Objective 2: 2-Azido-2'-deoxyinosine as probe to investigate elusive guanine-based 
aminyl radical 
The second objective of my dissertation was to explore the generation and reactivity of 
2'-deoxyguanosyl radical 45 postulated to be generated during the ambident reactivity of 
the guanine moiety in 2'-deoxyguanosine (dG) towards hydroxyl radicals (HO•) by direct 
hydrogen abstraction from the NH2 moiety rather than the addition at C4 position
81 (Figure 
15). Based on the previous knowledge that one-electron reduction of azido group generates 
aminyl radicals,42,73 I proposed that 2-azido-2'-deoxyinosine (2-N3dI, 44) could serve as 
convenient substrate for the  generation of elusive guaninyl aminyl radical 45. If successful, 
the structure of radical 45, its tautomers, and subsequent reactions will be investigated to 
understand nucleic acid damage pathways induced by γ-radiolysis.  
 
Figure 15. A plausible generation of 2'-deoxyguanosin-N2-yl radical (dG(N2-H)•) from 2-
azido-2'-deoxyinosine 
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Synthesis of the 2-N3dI 44 could be accomplished by conversion of 2-amino group in 
the protected 2'-deoxyguanosine into 2-azido group via diazotization reaction with tert-
butyl nitrite followed by nucleophilic displacement with azide and deprotection. The 
formation of 2-aminyl radical from 2-N3dI 44 and subsequent radical transfers will be 
characterized using electron spin resonance (ESR). 
Objective 3: N-unsubstituted 1,2,3-triazol-4-yl nucleosides: Chemistry and 
fluorescent properties 
Fluorescent nucleosides serve as powerful molecular tools for investigating nucleic 
acid structures, activities, locations, and interaction with other biomolecules or small 
molecules.93 The N-alkyl/aryl substituted 1,2,3-triazol-4-yl adenine showed higher 
quantum yield than 1,2,3-triazol-1-yl adenine.98,99 In light of the criteria of designing new 
fluorescent nucleosides, i.e., high emission quantum efficiency and minimalistic 
modification, the third objective of my dissertation was to synthesize N-unsubstituted 8-
(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine (8-TrzdA, 46). I also plan to expand this goal to 
other three nucleosides of natural DNA and prepare 8-(1H-1,2,3-triazol-4-yl)-2'-
deoxyguanosine (8-TrzdG, 47), 5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (5-TrzdC, 48), 
and 5-(1H-1,2,3-triazol-4-yl)-2'-deoxyuridine (5-TrzdU, 39) (Figure 16). 
 
Figure 16. Fluorescent N-unsubstituted 1,2,3-triazol-4-yl nucleosides 
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From several strategies developed for the synthesis of N-unsubstituted 1,2,3-triazoles, 
I expect Yamamoto's procedure for the cycloaddition of alkynes with TMSN3 catalyzed by 
CuI102 should provide C5-pyrimidine and C8-purine triazol-4-yl nucleosides. Other 
catalysts, like CuSO4/sodium ascorbate and Ag2CO3 will be also tried to optimize the 
cycloaddition between alkynyl nucleosides and TMSN3. The N-unsubstituted 1,2,3-triazol-
4-yl nucleosides (46-48 and 39) would be converted to 5'-triphosphates and their 
incorporation into DNA by polymerase-catalyzed reactions will be investigated. If triazolyl 
derivatives show good fluorescent properties they will be also explored for the potential 
application in cell imaging and investigating the perturbations to nucleic acids. 
Objective 4: Antiviral and cytostatic evaluation of 5-(1-halo-2-sulfonylvinyl) and 
5-(2-furyl)uracil nucleoside prodrugs 
My fourth objective was to evaluate the antiviral and cytostatic activities of the 
prodrugs recently synthesized in Dr. Wnuk's lab, uracil nucleosides substituted at C5 with 
1-halo-2-sulfonylvinyl (Figure 17, 49)110 or heteroaren-2-yl scaffolds (Figure 17, 50).111 In 
order to have a comprehensive biological evaluation of these uracil nucleosides analogues, 
I planned to increase uptake of compounds into cells by improving the lipophilicity of these 
compounds by esterification of the hydroxy group at sugar (Figure 17, 51) and/or 
incorporation of a permanent long lipophilic alkyl chain in the furan ring (Figure 17, 52). 
 
Figure 17. 5-(1-Halo-2-sulfonylvinyl) and 5-(2-furyl) uracil nucleosides prodrugs  
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3. RESULTS AND DISCUSSION 
3.1. Pyrimidine nucleosides with azidomethyl and azidovinyl modification at C5 
position: Chemistry and biology 
3.1.1. Synthesis of AmdU, AmdC, and their phosphoramidite analogues 
The 5-azidomethyl-2'-deoxyuridine (AmdU, 18) was synthesized from thymidine 41 
by successive (a) protection of sugar hydroxyl with tert-butyldimethylsilyl group (to give 
53), (b) i, bromination with N-bromosuccinimide (NBS); followed by ii, displacement of 
bromide with NaN3 (to give 54), and (c) desilylation with tetra-n-butylammonium fluoride 
(TBAF) with overall 45% yield (Scheme 10).40,54 The 1H NMR data of 18 were in good 
agreement with those published [e.g., δ 4.06 (s, 2H, CH2N3)].40 Treatment of 54 with 
2,4,6-triisopropylbenzenesufonyl chloride (TIPBSCl), in the presence of triethylamine 
(TEA)/ 4-dimethylaminopyridine (DMAP) followed by in situ displacement of the 
resulting aryl sulfate with NH4OH provided 55. Subsequent desilylation with TBAF 
provided 5-azidomethyl-2'-deoxycytidine (AmdC, 42) in 76% overall yield from 54 
(Scheme 10). Treatment of AmdU 18 with acetyl anhydride in the presence of DMAP/TEA 
in ACN at room temperature for 1 h gave more lipophilic 3',5'-di-O-acetyl-AmdU 56 (70%). 
 
Reagents and conditions: (a) TBDMSCl, imidazole, 50 oC, overnight. (b) (i) NBS, 
azobisisobutyronitrile (AIBN), benzene, reflux, 1 h; (ii) NaN3, DMF, 60 oC, 1 h. (c) TBAF, THF, 
rt, 4 h. (d) (i) TIPBSCl, TEA, DMAP, CH2Cl2, rt, 1h; (ii) aq. NH4OH/THF, rt overnight. (e) acetic 
anhydride, DMAP, TEA, ACN, rt, 1 h. 
Scheme 10. Synthesis of AmdU 18 and AmdC 42 
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Since the synthesis of AmdU required multistep procedure (including protection and 
deprotection steps), I attempted synthesis of AmdU directly from thymidine via direct C-
H activation of the methyl group (Scheme 11) using C-H azidation protocols reported for 
the synthesis of alkyl azide.112 Thus, treatment of thymidine 41 with tosyl azide 57 in the 
presence of Na2S2O8 and base showed that all the starting material was converted to a new 
spot on TLC, which had same Rf as AmdU. Potassium iodide and sodium thiosulfate 
solutions were used to quench excess oxidant Na2S2O8. The reaction residue was column 
chromatographed to give a new product which was confirmed to be 5-(dimethoxymethyl)-
2'-deoxyuridine 58113 rather than AmdU 18. The presence of two methoxy group at the 
3.22 and 3.24 ppm in 1H NMR and downfield shifted signal for acetal carbon at 97.9 ppm 
in 13C NMR was diagnostic for structure 58. The spectroscopic data for 58 were also in 
agreement with the reported data for acetal 58 prepared by reaction of 2'-deoxyuridine-5-
aldehyde with MeOH.113 Modification of the procedure shown in Scheme 11 (like 
removing the tosyl azide 57) would provide a convenient one-step synthesis of 5-
(dimethoxymethyl)-2'-deoxyuridine 58, which can serve as precursor to 5-formyl-2'-
deoxyuridine. Compound 58 showed anti-orthopoxvirus activity in micromolar range.113 
 
Scheme 11. Attempted one-step synthesis of AmdU 
To study the formation of aminyl radicals and their subsequent reactions along DNA 
fragments, I made an attempt to introduce AmdU 18 into oligonucleotides using solid-
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phase oligodeoxynucleotides (ODN) synthesis (Scheme 12). Such a phosphoramidite 
approach  is believed to be not applicable for the synthesis of azido-modified ODN 
presumably due to Staudinger reduction.114 The synthesis of phosphoramidite precursor 
5'-(4,4'-dimethoxytrityl)-3'-(N,N-diisopropylamino-2-cyanoethoxychlorophosphinyl)-
AmdU (5'-DMT-3'-CEP-AmdU, 60) for solid-phase ODN synthesis is shown in Scheme 
12. Thus, AmdU 18 was selectively tritylated with 4,4'-dimethoxytrityl chloride (DMTCl) 
at the 5'-position to give 5'-DMT-protected AmdU 59. The phosphitylation at the 
3'-position of 59 with N,N-diisopropylamino-2-cyanoethoxychlorophosphine in the 
presence of N,N-diisopropylethylamine (DIEA) was completed in 10 min to give two 
phosphoramidite diastereomers 60. The DCM solution of 60 after extraction was dried over 
anhydrous Na2SO4 and used for solid-phase ODN synthesis without any further treatment. 
 
Reagents and conditions: (a) DMTCl, pyridine, rt, 2 h; (b) 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite, DIPEA, DCM, rt, 10 min. 
Scheme 12. Synthesis of AmdU phosphoramidite precursor for potential solid-phase 
preparation of azido-modified DNA fragments 
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For NMR and HRMS characterization, the solvent after extraction was removed under 
high vacuum [ice/acetone bath (-10 oC)]. The residue was column chromatographed 
(hexane/EtOAc/TEA) to give 5'-DMT-3'-CEP-AmdU 60 as a separable mixture of two 
diastereomers with 75.6% isolated yield as white solid. The structure of the 
phosphoramidite 60 was confirmed by 1H NMR, 13C NMR, 31P NMR as well as HRMS 
(see experimental section for completed data). The 1H NMR and 31P NMR of one of the 
two diastereomers (first eluted from column) is shown in Figure 18. The single 31P peak at 
148.8 ppm (Figure 18, B) indicates that phosphoramidite were obtained as single 
diastereomers after column chromatography. Interestingly, contrary to AmdU where 
methylene protons for CH2N3 group in 
1H NMR resonates as singlet at δ 4.06, 
diastereotopic protons in CH2N3 group of 60 were split into two doublets (δ 3.32 and 3.57, 
2J = 13.4 Hz; Figure 18A). 
The CH2Cl2 solution of phosphoramidite 60 can be stored under -20 
oC for over two 
months. However, it decomposes within 24 h when stored in a solid form even under low 
temperature (-20 oC) or in solution at ambient temperature. Figure 19 showed formation of 
new peaks resulting from decomposition of 60 (CD2Cl2/rt/15 h) in both 
1H NMR (δ 5.67-
6.28 ppm: presumed signal from the terminal olefin CH2=CHCN) and 
31P NMR (δ 12.70, 
14.34) spectra. Phosphoramidite 60 was also found to be unstable (removal of DMT-group) 
in CHCl3, and thus during any process, CHCl3 would be avoided.  
It is noteworthy that 60 is one of the first examples of azidonucleoside phosphoramidite 
building blocks which we attempted to employ for the synthesis of azido-modified DNA 
fragments using solid-phase ODN synthesis.  
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Figure 18. 1H (A) and 31P (B) NMR spectra of AmdU phosphoramidite 60 single 
diastereomer 
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Figure 19. 1H (A) and 31P (B) NMR spectra showing decomposition of phosphoramidite 
60 (in CD2Cl2 at room temperature for 15 h) 
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3.1.2. Synthesis of AvdU and AvdC by Ag2CO3 catalyzed hydroazidation 
From several methods  developed for the synthesis of vinyl azides,37,115-117 I adopted 
hydroazidation of alkyne with trimethylsilyl azide (TMSN3) in the presence of Ag2CO3 as 
catalyst.115 Thus, reaction of readily available acetyl-protected 5-ethynyl-2'-
deoxyuridine110,118 62 with TMSN3 in the presence of Ag2CO3 produced regioselectively 
α-vinyl azide 64 in 52% yield (Scheme 13). Deacetylation of 64 yielded 5-(1-azidovinyl)-
2'-deoxyuridine (AvdU, 21) in 90% yield. Peaks of the two terminal olefin protons at δ 
5.00 ppm and 5.91 ppm in 1H NMR and two vinylic carbons at δ 101.3 and 137.4 ppm in 
13C NMR were diagnostic for structure 21. 
 
Reagents and conditions: (a) TMSN3, Ag2CO3, H2O, DMF, 80 oC, 1 h; (b) NH3/MeOH, 0 oC to rt, 
overnight. (c) TIPBS-Cl, DMAP, TEA, CH2Cl2, rt, 1 h; (d) aq. NH3, THF, rt, overnight. 
Scheme 13. Strategies for the synthesis of 5-(1-azidovinyl)-2'-deoxyuridine (AvdU, 21) 
and 5-(1-azidovinyl)-2'-deoxycytidine (AvdC, 43). 
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Hydroazidation of the 3',5'-di-O-acetyl-5-ethylnyl-2'-doxycytidine 63a119 with 
TMSN3/Ag2CO3 gave desired vinyl azide 65 in addition to a fluorescent by-product, which 
was characterized as 3',5'-di-O-acetyl-5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (diAc-5-
TrzdC, 83, see Table 5 at section 3.3.1.1). The chemistry of these 1,2,3-triazol-4-yl 
analogues will be further discussed at section 3.3. Deacetylation of 65 provided 
5-(1-azidovinyl)-2'-deoxycytidine (AvdC, 43) in 51% overall yield from 63a. AvdC 43 
was also obtained in a 34% yield by hydroazidation of the unprotected 5-ethynyl-2'-
deoxycytidine120 63b. A third method to prepare AvdC 43 was developed via conversation 
of uracil ring in 64 to a cytosine counterpart. Thus, treatment of 64 with 
2,4,6-triisopropylbenzenesulfonyl chloride (TIPBSCl) followed by treatment of the 
resulting 4-O-TIPBS-protected intermediate 66 with aq. NH3 afforded AvdC 43.  
The vinylazides were reported to be involved in thermal- and photo-induced 
reactions,121 thus the decomposition of AvdU 21 under UV was carried out to investigate 
the potential application of AvdU 21 as a UV-activated/enhanced drug (Scheme 14). The 
UV-induced reaction was performed in a dark box equipped with a 254 nm UV lamp 
(UVG-11, 4 W, 0.16 Amps). After 1.5 h UV irradiation, AvdU 21 in the MeOH solution 
was all converted to two major products, which were characterized by NMR to be 
5-formyl-2'-deoxyuridine 67 and 5-azirinyl-2'-deoxyuridine 68. This result would support 
the reported enhancement of the cytotoxicity of AvdU by UV light.68   
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Scheme 14. Decomposition of AvdU under 254 nm UV 
Synthesis 3'-CEP-5'-DMT-AvdU 70 (Scheme 15) was also attempted following the 
procedure developed for AmdU (Scheme 12). Treatment of AvdU 21 with DMTCl in 
pyridine provided 5'-DMT-AvdU (69, 60%). After the phosphitylation, the desired 
phosphoramidite diastereomers could be observed on TLC with 90% conversion. However 
attempted purification on silica gel column resulted in excessive decomposition most 
probably as a result of the higher reactivity of the vinyl azide,121 as compared to the alkyl 
azides, towards   Staudinger reduction.    
 
Reagents and conditions: (a) DMTCl, pyridine, rt, 2 h; (b) 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite, DIPEA, DCM, rt, 10 min. 
Scheme 15. Attempted 3'-phosphitylation of AvdU 21 
41 
 
3.1.3.  Polymerase-catalyzed incorporation of AmdU 5'-triphosphate and AmdC 
5'-triphosphate into DNA 
3.1.3.1. Synthesis of C5 azido-modified pyrimidine nucleotides 
I attempted to synthesize C5 azido-modified pyrimidine nucleotide to investigate their 
polymerase-catalyzed incorporations into DNA. Moreover, these nucleotides can be used 
to study the effect of phosphate moiety on the subsequent radical reactions of the initial 
aminyl radicals generated from the azido group.  
For the triphosphorylation, tributylammonium pyrophosphate (TBAPP, 73), one of the 
necessary starting materials, was prepared by modified ion-exchange procedure using 
DOWEXR 50WX2 hydrogen form (Scheme 16).122 Sodium pyrophosphate 71 aqueous 
solution (0.5 M, pH = 9) was passed through DOWEX resin (15 g resin per 1mmol sodium 
pyrophosphate) to give pyrophosphoric acid 72 aqueous solution (pH = 1), into which 2 
equivalents of tributylamine (TBA) was added. The resulting mixture was stirred at rt until 
homogeneous solution (pH = 4-5) was obtained. Water was evaporated and coevaporated 
with acetonitrile to dry. The residue was dried under high vacuum for 24 h to give TBAPP 
73 as a pale solid, into which argon was filled and DMF was added to prepare 0.5 M 
solution for the triphosphorylation. The Dowex Resins can be recycled by washing the 
column with 2 column volumes of 5% (1.5 M) HCl and then with sufficient DI water until 
the pH return to be around 6.   
 
Scheme 16. Preparation of tributylammonium pyrophosphate (TBAPP) 
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AmdU 5'-monophosphate (AmdUMP, 19, 70%, Scheme 17) was prepared via the 
phosphorylation of AmdU 18 with POCl3 employing modified Yoshikawa protocols
123,124 
in the presence of proton sponge followed by quenching of the crude reaction mixture with 
triethylammonium bicarbonate buffer (TEAB) and purification on a DEAE-Sephadex 
column. The reaction of AmdU 18 with POCl3 in the presence of proton sponge followed 
by addition of 0.5 M TBAPP in DMF and then tributylamine (TBA) yielded AmdU 
5'-triphosphate (AmdUTP, 20, 76%, Scheme 17) after DEAE-Sephadex purification. The 
phosphates were characterized by 1H, 13C, 31P NMR as well as HR-MS (see experimental 
section for the data). The 31P NMR showed two doublet peaks at δ -10.80 (J = 19.8, γ) and 
δ -11.64 (J = 19.8, α) as well as one triple peak at δ -23.25 (J = 19.7, β). The proton sponge 
was used to accelerate the phosphorylation and provide reaction conditions suitable for 
acid-labile deoxynucleosides by neutralizing the formed HCl.123 The AmdC 42 was 
converted to AmdC 5'-triphosphate (AmdCTP, 74, 23%) by analogous phosphorylation 
(Scheme 17).  
 
(a) PO(OMe)3, POCl3, proton sponge, 0 oC, 30 min; (b) TBAPP, TBA, DMF, 0 oC, 2 min. 
Scheme 17. Synthesis of AmdUMP, AmdUTP, and AmdCTP 
I was planning to synthesize AvdU 5'-triphosphate (AvdUTP 76, Scheme 18), 
following the analogous phosphorylation of AvdU 21, but because of the instabilities of 
azidovinyl unit in AvdU the reactions provided 5-acetyl-2'-deoxyuridine 5'-triphosphate 
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75125 rather than the desired AvdUTP 76. To circumvent instability of vinylazide moiety 
in the phosphorylation reactions, post-synthetic route was also designed for the synthesis 
of 76 (Scheme 19). Thus, 5-ethynyl-2'-deoxyuridine 5'-triphosphate 78 was prepared from 
77 (46%) employing analogous phosphorylation conditions. However, the hydroazidation 
of 78 also yielded 5-acetyl-2'-deoxyuridine 5'-triphosphate 75. Addition of 10 eq. Et3N into 
the hydroazidation reaction to stabilize the product 76 also failed. The presence of two 
peaks at the 5.04 and 5.54 ppm in the crude 1H NMR indicated the formation of desired 
AvdUTP 76, which was not stable and decompose in the reaction residue. Because of the 
instabilities of the AvdUTP 76, the enzymatic incorporation of AvdU 21 into DNA 
fragment could not be carried out.  
 
(a) PO(OMe)3, POCl3, proton sponge, 0 oC, 30 min; (b) TBAPP, TBA, DMF, 0 oC, 2 min. 
Scheme 18. Attempted synthesis of AvdUTP 76 
 
 (a) PO(OMe)3, POCl3, proton sponge, 0 oC, 30 min; (b) TBAPP, TBA, DMF, 0 oC, 2 min. (c) 
TMSN3, Ag2CO3, H2O, DMF, 80 oC, 1 h 
Scheme 19. Attempted post-synthetic procedure for AvdUTP 76 
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3.1.3.2. Polymerase-catalyzed incorporation of AmdUTP and AmdCTP into DNA 
Since DNA replication is essential for proliferation of cancer cells, and cancer radiation 
therapy can induce DNA damage and initiate DNA repair such as base excision repair 
(BER) during which nucleotides are incorporated into double-strand DNA (dsDNA) by 
replication and repair DNA polymerases, it is important to determine whether an AmdUTP 
can also be incorporated into dsDNA during DNA replication and repair. The incorporation 
of AmdUTP will provide new insights into the potential application of AmdU 18 in cancer 
treatment. In collaboration with Dr. Liu from our department, I determined the 
incorporation of an AmdUTP 20 into dsDNA by the E. coli Klenow fragment of DNA 
polymerase I (pol I) and human repair DNA polymerase, DNA polymerase  (pol ) using 
AmdUTP 20 and synthesized oligonucleotide substrates that mimic the intermediates 
formed during DNA replication and repair (see section 4.2 for the DNA fragments 
sequences and other details). The incorporation of an AmdUTP 20 by the Klenow fragment 
and pol  during DNA leading and lagging strand synthesis, and BER was examined with 
an open template, one-nucleotide gap substrates, and one-nucleotide substrate containing 
a 5'-THF (a tetrahydrofuran ring which mimics a sugar residue) at the downstream strand, 
respectively (Figure 20). The results showed that the Klenow fragment at 0.1-5 U 
efficiently inserted an AmdUTP 20 with all the substrates to basepair with a template A 
(Figure 20A, lanes 2-6; Figure 20B, lanes 8-12; Figure 20C, lanes 14-17). With the open 
template, the Klenow fragment also continuously inserted an AmdUTP 20 to mispair with 
a template G, T and T, respectively (Figure 20A, lanes 2-6). On the other hand, pol  
incorporated only one AmdUTP 20 in the open template substrate at a concentration of 
10 nM (Figure 20D, lane 6), whereas it efficiently incorporated one AmdUTP to fill in the 
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one-nucleotide gap with the gapped substrate at concentrations of 0.5-10 nM (Figure 20E, 
lanes 8-12). Similarly, AmdUTP 20 was efficiently incorporated into one-nucleotide gap-
THF substrate by both pol I (Figure 20C, lanes 14-17) and pol  (Figure 20F, lanes 14-17) 
at 0.5-5 U and 1-25 nM, respectively.  
 
Figure 20. Incorporation of AmdUTP 20 into duplex DNA by pol I and pol β. 
Measurement of incorporation of an AmdUTP by Klenow fragment on the open template (A) and 
one-nucleotide gap substrate (B), and the one-nucleotide gap substrate containing a 5'-THF at the 
downstream strand (C). Measurement of incorporation of an AmdUTP by pol β on the open 
template (D) and one-nucleotide gap substrate (E), and substrate containing a 5'-THF at the 
downstream strand (F). Lanes 1, 7, and 13 represent substrate only. Lanes 2-6, 8-12, and 14-17 
represent the products resulting from incorporation of an AmdUTP. 
 
Further characterization of incorporation of the nucleotide in the presence of the other 
three nucleotides dATP, dGTP and dCTP, showed that an AmdUTP 20 inserted by pol I 
and pol  was further extended by the polymerases. Pol I (0.5-5 U) extended an AmdUTP 
and continued to perform DNA synthesis to the end of the template with all substrates 
(Figure 21A-C), whereas pol  at the concentrations of 1-25 nM extended the AmdUTP 
and further synthesized 9-10 nucleotides (Figure 21D-F). The results indicate that the 
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polymerase readily inserted the nucleotide into dsDNA and continued to extend the 
nucleotide during DNA replication and repair.  
 
Figure 21. Extension of an incorporated AmdUTP 20 into a duplex DNA by pol I (A-C) 
and pol β (D-E) during DNA leading and lagging strand synthesis and BER. 
DNA synthesis by pol I on the open template (A), one-nucleotide gap substrate (B), and one-
nucleotide gap substrate with a 5'-THF (C). DNA synthesis by pol β on the open template (D), one-
nucleotide gap substrate (E), and one-nucleotide gap substrate with a 5’-THF (F). Lanes 1, 6, and 
11 represent substrate only. Lanes 2-5, 7-10, and 12-15 represent DNA synthesis products. 
 
To further examine if AmdU residues incorporated by DNA polymerases can be ligated 
into duplex DNA during DNA replication and repair, we determined the formation of 
ligation products resulting from incorporation of AmdUTP in the presence of dATP, dGTP 
and dCTP with the one-nucleotide gap substrates without or with a THF residue that 
mimics a sugar residue. We found that with the one-nucleotide gap substrate, pol I ranging 
from 0.5-5 U efficiently incorporated AmdUTP and other nucleotides, and this allowed 
conversion of all of the substrates into the ligation products, i.e. ligated products by 10 nM 
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DNA ligase I (LIG I; Figure 22A, lanes 2-5). For the one-nucleotide gap substrate, 
incorporation of AmdUTP by pol  at 1 nM only resulted in a small amount of ligated 
products (Figure 22C, lane 2). With increasing concentrations of pol  from 5 nM to 25 
nM, the amount of the ligated products significantly increased (Figure 22C, lanes 3-5) 
indicating that increased incorporation of AmdUTP 20 facilitated the production of ligated 
products.  
 
Figure 22. Ligation after incorporation of AmdUTP 20 into duplex DNA during lagging 
strand maturation and BER.  
Measurement of ligation products, i.e. DNA lagging strand maturation products resulting from 
incorporation of AmdUTP by pol I (A) and pol β (C) on the one-nucleotide gap substrate. Lanes 1 
represents substrate only. Lanes 2-5 represent the ligation products resulting from incorporation of 
AmdU. Measurement of repaired products resulting from BER mediated by incorporation of 
AmdUTP by pol I (B) and pol β (D) on the one-nucleotide gap substrate with a 5'-THF at the 
downstream primer. Lane 6 represents substrate only. Lanes 7-10 represent repaired products 
resulting from incorporation of AmdUTP. 
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To determine if AmdUTP 20 incorporated by pol I and pol β can be also ligated into a 
dsDNA during DNA BER, we further determined the incorporation of 20 during BER with 
the one-nucleotide gap substrate with a 5'-phosphorylated THF residue in the presence of 
10 nM LIG I and 10 nM flap endonuclease 1 (FEN1). We found that similar to its 
incorporation of AmdUTP with the one-nucleotide gap substrate, pol I (0.5, 1, 2, and 5 U) 
performed strong DNA synthesis activity leading to the production of the full-length repair 
products (Figure 22B, lanes 7-10). The results indicate that AmdUTP can be efficiently 
incorporated into duplex DNA by Pol I during BER. On the other hand, incorporation of 
AmdUTP by pol β (1, 5, 10, and 25 nM) also resulted in the repaired products (Figure 22D, 
lanes 7-10). However, the repaired products resulting from pol β contain the repair products 
with the full-length or with the size that is one-nucleotide shorter than the full-length. With 
increasing concentrations of pol β, the amount of the full-length repaired products was 
significantly increased, whereas that of the short repair products was significantly 
decreased (Figure 22D, compare lanes 8-10 with lane 7). The result suggests that inefficient 
incorporation of AmdUTP 20 by a low concentration of pol β resulted in a gap during BER. 
This subsequently allowed the template to loop out leading to ligation and production of 
the short repaired product during BER. 
Our results further indicate that AmdUTP 20 can be efficiently incorporated into 
dsDNA by DNA replication and repair polymerases during DNA replication and repair. 
This is consistent with a recent finding showing that AmdU were efficiently incorporated 
into newly synthesized DNA in human cancer cells.40 Our results further demonstrated that 
the incorporation of AmdU in cancer cells is mediated by DNA replication and repair 
polymerases. 
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The incorporation of a AmdCTP 74 by pol  during DNA leading and lagging strand 
synthesis, and BER was also examined with an open template, one-nucleotide gap substrate, 
and one-nucleotide gap-THF substrate, respectively (Figure 23; see section 4.2 for the 
DNA fragments sequences and other details). The results showed that pol  at 1-25 nM 
efficiently inserted a AmdCTP in all three substrates to basepair with a template G (Figure 
23A, lanes 2-5; 23B, lanes 6-10; 23C, lanes 12-15). Compared with the incorporation of 
an AmdUTP by pol β (Figure 20), 1 nM pol β incorporated a significant amount of an 
AmdCTP into the open template substrate (Figure 23A, lane 2), whereas the same 
concentration of pol β failed to incorporate an AmdUTP (Figure 20D, lane 3). Also, pol β 
at 10 nM incorporated an AmdUTP on the substrate with significantly reduced amount 
(Figure 20D, lane 6) compared with its incorporation with AmdCTP (Figure 23A, lane 4). 
Similarly, for the one-nucleotide gap substrate with or without a 5'-THF pol β at 1 nM, 
5 nM, and 10 nM, incorporated an AmdUTP 20 with a reduced amount (Figure 20E, lanes 
8-12 and Figure 20F, lanes 14-17) compared with its incorporation of an AmdCTP 74 at 
the same concentrations (Figure 23B, lanes 7-10 and Figure 23C, lanes 12-15). 
 
Figure 23. Incorporation of AmdCTP into duplex DNA by pol β. 
Incorporation of a AmdCTP by pol β on the open template (A), one-nucleotide gap substrates (B), 
and one-nucleotide gap-THF substrates. Lanes 1, 6, and 11 represent substrate only. Lanes 2-5, 
7-10, and 12-15 illustrate the products resulting from incorporation of a AmdCTP by pol β. 
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3.1.4. One-electron formation of aminyl radicals from 5-azidomethyl and 
5-azidovinyl pyrimidine nucleosides and their subsequent reactions 
The combination of ESR spectral studies and theoretical calculations provide evidences 
of radiation-produced electron-mediated formation of π-type aminyl radical (RNH•) and 
of its conversion to the σ-type iminyl radical (R=N•) in samples of AmdU 18 (Figure 24), 
AmdC 42 (Figure 25), AvdU 21 (Figure 26) and AvdC 43 in glassy systems (7.5 M 
LiCl/D2O).    
3.1.4.1. Formation of π-type RNH• and its bimolecular conversion to the σ-type R=N• 
in AmdU and AmdC  
The ESR spectra of AmdU 18 after radiation-produced prehydrated one-electron 
attachment at 77 K and stepwise annealing as well as simulated spectra are shown in Figure 
24. Spectra in Figure 24A presents the ESR spectrum (blue) of the radicals formed by 
radiation (absorbed dose = 500 Gy at 77 K) -produced prehydrated electron attachment to 
18 (2.2 mg/mL) in supercooled homogeneous glassy (7.5 M LiCl/D2O) solutions at 77 K. 
Figure 24A has a total hyperfine splitting of ca. 178.5 G. Center of this spectrum does 
not show the reported doublet126-128 due to U•¯. Wings of this spectrum show line 
components due to axially symmetric anisotropic nitrogen hyperfine coupling due to a 
single nitrogen. Sum of two isotropic β-proton couplings of ca. 93.5 G is assigned to the 
central doublet. The HFCCs at Figure 24A are nearly-identical to the reported HFCCs 
values for T(C5')-ND• generated from 5'-azido-5'-deoxythymidine (5'-AZT),42 thus Figure 
24A is assigned to the π-type U-(5-CH2)-ND• generated from AmdU 18 (Scheme 20). The 
simulated spectrum (red) superimposed in Figure 24A nicely matches the line components 
due to nitrogen hyperfine couplings at the wings, the sharp outer peak of the doublet, and 
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qualitatively the broad line components at the center of the blue spectrum. Detailed analysis 
of HFCC will be published elsewhere.129  
 
Figure 24. ESR spectra of AmdU 18 after radiation-produced prehydrated one-electron 
attachment at 77 K and stepwise annealing as well as simulated spectra 
(A) ESR spectrum (blue) after radiation-produced prehydrated one-electron addition to AmdU 18 
at 77 K in 7.5 M LiCl/D2O. Spectra (B) to (E) were obtained via stepwise annealing of the sample 
for 15 min at 140, 160, 165, and 170 K. All spectra were recorded at 77 K. The red spectra in (A), 
(D) and in (E) are the simulated spectra. The radiation produced background Cl2•¯ spectrum has 
been subtracted from spectra A and B for clarity. 
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Scheme 20. Formation of π-type aminyl radical from AmdU 18 and its bimolecular 
conversion to the σ-type iminyl radical 
After subsequent annealing of AmdU sample at 140 K in the dark for 15 min, spectrum 
was recorded at 77 K and is shown in Figure 24B. Upon stepwise warming, new line 
components are gradually developed at the center of these spectra. The line components 
are due to a C-centered α-azidoalkyl radical U-(5-CH•)-N3 formed via a bimolecular 
H-atom abstraction by U-(5-CH2)-ND• from a proximate AmdU 18 (Scheme 20). After 
subsequent stepwise annealing for 15 min in the dark at 160 K, 165 K, and 170 K, spectra 
have been recorded at 77 K and are shown in blue color in (C) to (E). Although line 
components due to the U-(5-CH•)-N3 are present at the center of spectrum in (C), these 
line components become prominent with good resolution at the center of the blue spectrum 
in (D) but are not observed at the center of the blue spectrum in (E).  
The calculated HFCCs of the C-centered radicals (U-(5-CH•)-N3 using 
B3LYP/6-31G** method are found to be very similar to the HFCCs of the blue spectrum 
at Figure 24D. The simulated (red) spectrum of the U-(5-CH•)-N3 superimposed on the 
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center of blue spectrum in Figure 23D well matches the blue spectrum. See Ref129 for the 
theoretical calculation details. The π-type U-(5-CH2)-ND• from 18 undergoing bimolecular 
H-atom abstraction (Scheme 20) was studied employing samples of 5'-azido-2'5'-
dideoxyuridine 79 with different concentrations (0.5 mg/mL and 5 mg/mL), which is also 
detailed in Ref129. 
The broad central doublet of 82 G found in the blue spectrum in Figure 24E is due to 
one β-H of the methylene group that is attached to the C5 of the uracil base. In addition, 
anisotropic N HFCCs are very similar to those of H2C=N•.130 The simulated spectrum 
superimposed in (E) matched nicely with the blue spectrum.  Therefore, the blue spectrum 
in (E) was assigned to the σ-type iminyl radical, U-(5-CH)=N•. 
These results show that conversion of π-type U-(5-CH2)-ND• to σ-type U(C5-H)=N• 
was bimolecular involving an α-azidoalkyl radical as intermediate (Scheme 20). α-
Azidoalkyl radicals are known to undergo facile conversion to the σ-iminyl radicals.131-133 
ESR spectra of AmdC 42 after radiation-produced prehydrated one-electron attachment 
at 77 K and stepwise annealing as well as simulated spectra are shown in Figure 25. It is 
noted that AmdC 42 also shows the formation of C-(5-CH2)-ND• at 77 K along with its 
subsequent conversion to the σ-type iminyl radical, C-(5-CH)=N• in the temperature range 
(77 to 160 K) accompanied with decrease of total hyperfine splitting that is similar to 
U-(5-CH)=N• (Figure 25).  
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Figure 25. ESR spectra of AmdC after radiation-produced prehydrated one-electron 
attachment at 77 K and stepwise annealing as well as simulated spectra 
Spectra (A-D) were obtained from AmdC 42 (2.4 mg/mL) by subtraction of 250 G Cl2•¯ spectrum 
from the individual experimentally recorded spectrum. (A) ESR spectrum (blue) after radiation-
produced prehydrated one-electron addition to AmdC at 77 K in 7.5 M LiCl/D2O. Spectra (B, blue) 
to (E, blue) were obtained from the same sample of 7 via stepwise annealing of the sample for 15 
min at 134, 140, 150 and at 160 K. All spectra were recorded at 77 K. All spectra were recorded at 
77 K. The experimental spectra from AmdU 18 (2.2 mg/mL, sea-green) are superimposed in (A), 
(C), (D), and (E) for comparison. The red spectra in (A) and in (E) are the simulated spectra. 
3.1.4.2. Formation of π-type aminyl radical (RNH•) and its unimolecular conversion 
to the σ-type iminyl radical (R=N•) in AvdU and AvdC  
The 77 K ESR spectrum (black) of the radicals formed by radiation (absorbed dose = 
500 Gy at 77 K)-produced prehydrated electron attachment to AvdU 21 (1 mg/mL) in 
supercooled homogeneous glassy (7.5 M LiCl/D2O) solutions is shown in Figure 26A. This 
spectrum shows line components due to D-atoms, and due to axially symmetric anisotropic 
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nitrogen HFCCs due to a single nitrogen. Furthermore, it also showed line components due 
to two anisotropic protons of the =CH2 in AvdU 21 (or AvdC 43). Therefore, the (A) was 
assigned to the π-type aminyl radical, U-(5-C=CH2)-ND•. The ESR spectrum in (A) 
establishes that formation of U-(5-C=CH2)-ND• from 21 (Scheme 21) happens following 
the same pathway shown in Scheme 20. The simulated a spectrum (red) superimposed in 
Figure 26(A) nicely matches the line components of the black spectrum and supports the 
assignment of the black spectrum to the π-type aminyl radical, U-(5-C=CH2)-ND•. 
 
Figure 26. ESR spectra of AvdU 21 after radiation-produced prehydrated one-electron 
attachment at 77 K and stepwise annealing as well as simulated spectra 
(A) ESR spectrum (black) after radiation-produced prehydrated one-electron addition to AvdU at                   
77 K in 7.5 M LiCl/D2O. Spectra (B) to (D) were obtained via stepwise annealing of the sample for 
15 min at 135, 150 and 165 K. All spectra were recorded at 77 K. The red spectra in (A) and (D) 
are the simulated spectra. The background Cl2•¯ spectrum has been subtracted from spectra A and 
B for clarity. 
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Scheme 21. Tautomerization of the π-type aminyl radical generated from AvdU 21 to the 
σ-type iminyl radical 
ESR spectra (black) obtained upon progressively annealing the AvdU sample for 15 
min in the dark at 135 K, at 150 K and at 165 K, are shown in Figure 26B-D. Comparison 
of the black spectrum in (D) with the black spectra in (A)-(C) shows that upon progressive 
annealing, height of the singlet at the center increases; concomitantly, height of the line 
components due to the two anisotropic -CH2 protons decreases and eventually disappears 
upon annealing at 165 K. The black spectrum in (D) is only due to axially symmetric 
anisotropic nitrogen HFCCs. We assign this spectrum to the σ-type iminyl radical, 
U-(5-C-CH3)=N•. The simulated a spectrum (red) superimposed on the experimental 
spectrum in Figure 26D nicely matches the line components of the black spectrum and 
supports the assignment of the black spectrum to the σ-type iminyl radical, 
U-(5-C-CH3)=N•. Note that the axially symmetric anisotropic nitrogen HFCCs and the 
g-values of U-(5-C-CH3)=N• are found to be identical to the reported values of σ-type 
iminyl radicals from one-electron oxidized 1-methylcytosine and its derivatives.130  
 Thus, our ESR spectral studies show that the radiation-produced electron mediated 
U-(5-C=CH2)-ND• undergoes a facile tautomerization to U-(5-C-CH3)=N• (Scheme 21). 
Nearly identical spectra were obtained from matched samples of 21 and 43. Therefore, we 
conclude that, a facile tautomerization of the radiation-produced electron-mediated π-type 
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aminyl radical, C-(5-C=CH2)-ND•, to thermodynamically more stable σ-type iminyl 
radical, C-(5-C-CH2D)=N•, also occurs in 43. 
Increasing the concentration (1 to 5 mg/mL) of AvdU 21 in the solution appeared to 
have no effect on the extent of facile conversion from π-type RNH• to σ-type iminyl radical 
from the spectra recorded under the same microwave power, modulation, and gain. From 
these results, we conclude that the facile tautomerization from RNH• to iminyl radical 
observed in the samples of 21 and 43 occurs via very rapid intramolecular H-atom transfer 
from the aminyl group to the double bonded CH2 group in the π-type RNH•. The rapid 
H-atom transfer process that is involved in the tautomerization, is, most possibly, the 
proton-coupled electron transfer process. 
3.1.4.3. Summary and implication of aminyl radical and its resulting iminyl radicals 
In contrast to the ESR spectral results obtained using samples of 3′-AZT 22, 5'-azido-
5'-deoxythymidine, 2′,3′-AZddG, and of azidopentoses,42,73 that show the evidence of 
electron-induced π-type aminyl radical-mediated H-atom abstraction are not observed in 
the samples of AmdU, AmdC, AvdU, and AvdC. Rather, the π-type aminyl radicals, in 
AmdU, AmdC, AvdU, and AvdC undergo facile conversion to the σ-type iminyl radical. 
For AmdU and AmdC, the π-type RNH• to σ-type iminyl radical conversion is found to be 
bimolecular involving an α-azidoalkyl radical, while the corresponding conversion, 
observed for AvdU and AvdC is unimolecular (i.e., tautomerization).  
Owing to the high free radical scavenger concentrations in cells,9,16 the bimolecular 
conversion of the π-type RNH• to σ-type iminyl radical from AmdU 18 and AmdC 42 
(Scheme 20) should not take place as it has been observed in case of 5'-azido-5'-
deoxythymidine. However, the facile unimolecular tautomerization of the π-type RNH• to 
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σ-type iminyl radical from AvdU 21 and AvdC 43 (Scheme 21) should occur. Further, the 
reactivity of the σ-type iminyl radical from AvdU 21 and AvdC 43 would be lower than 
the iminyl radicals obtained from 18 and 42 owing to the positive inductive effect of its 
methyl group (Figure 26 and Scheme 21). Therefore, it is expected that the π-type RNH• 
from AmdU 18 and AmdC 42 should augment the radiation damage more effectively than 
the σ-type iminyl radical from AvdU 21 and AvdC 43. Tests of this hypothesis are reported 
in section 3.1.5. 
3.1.5. Radiosensitizing effect of 5-azidomethyl and 5-azidovinyl pyrimidine 
nucleosides in aerobic and hypoxic cells  
The radiation response of cells in the presence of 100 μM C5 azido-modified 
pyrimidine nucleosides in vitro was examined in both aerobic and hypoxic EMT6 cells.  
For the tests in aerobic cells, the cultures were treated with 100 μM azido compounds or 
vehicles for 48 h. For the test in hypoxic cells, hypoxic condition was applied for 4 h after 
the 44 h aerobic incubation with 100 μM azido compounds or vehicles. For the 
radiosensitizing effect tests, cells were irradiated with 7.5 Gy X-ray during the final few 
minutes of the 48 h aerobic incubation (aerobic cells) or of the 4 h hypoxic incubation 
(hypoxic cells). More experimental details are provided in section 4.4. The results are 
shown in Figure 27 and Table 4. 
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Figure 27. Radiosensitizing effect of 5-azidomethyl and 5-azidovinyl pyrimidine 
nucleosides at 100 μM concentration on EMT6 cells (A) normoxic, (B) hypoxic conditions 
AmdU 18 showed radiosensitizing effect under both normoxic and hypoxic 
environment with sensitization enhancement ratio (SER) at 7.5 Gy X-ray (SERSF7.5) of 4.57 
and 4.10, respectively (Figure 27, Table 4). These results showed that one electron-induced 
aminyl radicals in AmdU 18 augment radiation damage to cells. In hypoxic 
microenvironment, RNH• formed from electron addition to AmdU 18 can be involved in 
the H-atom abstraction reactions that might cause DNA-strand breaks and/or crosslink 
formation9,42,73 leading to lesions that can induce apoptosis of cancer cells.16,19,134-136 On 
the other hand, in the aerobic cells, the aminyl radical generated from AmdU 18 can react 
with oxygen to generate aminylperoxyl radical RNHOO• and eventually lead to aminoxyl 
(nitroxyl) radicals RNHO•,137 which also can lead to DNA damage.138,139 Other azido 
nucleoside tested showed lower radiosensitizing effect with SERSF7.5 index of 1.35 for 
AmdC 42 under hypoxic cells and 1.37 for AvdC 43 under aerobic cells. 
Reasons for the difference in radiosensitization shown between AmdU 18 and AmdC 
42 is unclear. Possible reasons include differences in drug uptake into cells, metabolic 
phosphorylation, and/or reactivity of the aminyl radical generated at the uracil and cytosine 
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base. The higher radiosensitizing effect of AmdU 18 than that of AvdU 21 and AvdC 43 
can be explained by the higher reactivity of -type RNH• from AmdU 18 than that of the 
-type iminyl radical from AvdU 21 and AvdC 43. The optimization of the radiosensitizing 
effect could involve increasing uptake of these azido-nucleosides into cancerous cells by 
designing more lipophilic prodrugs and/or skipping metabolic 5'-phosphorylation in cells 
by synthesizing their ProTides. 
Table 4. Radiosensitizing effect of azidomethyl and azidovinyl pyrimidine nucleosides at 
100 μM concentration in aerobic and hypoxic EMT6 cells 
 Aerobic Conditionsa 
X-Ray 0 Gy 7.5 Gy 
Cmpd Control AmdC AmdU AvdU AvdC Vehicle AmdC AmdU AvdU AvdC 
SF 1 1.135 0.577 1.145 0.753 0.352 0.449 0.077 0.502 0.256 
DERc 1 0.88 1.73 0.87 1.33 - - - - - 
SERSF7.5
d - - - - - 1 0.78 4.57 0.70 1.37 
 Hypoxic Conditionsb 
X-Ray 0 Gy 7.5 Gy 
Cmpd Control AmdC AmdU AvdU AvdC Vehicle AmdC AmdU AvdU AvdC 
SF 1 0.800 0.857 0.769 0.995 0.587 0.434 0.143 0.561 0.492 
DERc 1 1.25 1.17 1.30 1.00 - - - - - 
SERSF7.5
d - - - - - 1 1.35 4.10 1.05 1.19 
a Drugs or vehicles were added to the cultures for 48 h treatment under normoxic condition, 
followed by 0 or 7.5 Gy X-ray irradiation.  b Drugs or vehicles were added to the cultures for 44 h 
treatment under normoxic condtion and then for 4 h under hypoxic condition, followed by 0 or 7.5 
Gy X-ray. c DER (drug enhancement ratio) was defined as the ratio of survival fractions (SF) of 
vehicle and SF of azido compounds. d SERSF7.5 (sensitization enhancement ratio) was defined as 
the ratio of survival fractions at 7.5 Gy (SF7.5) of vehicle and SF7.5 of azido compounds. 
3.2. The 2-azido-2'-deoxyinosine as precursor to study elusive guanine-based aminyl 
radical 
3.2.1. Synthesis of 2-azido-2'-deoxyinosine 
The 2-azido-2'-deoxyinosine (2-N3dI, 44) was synthesized from 2'-deoxyguanosine 
(dG) as shown in Scheme 23. Acetyl protection of dG with acetic anhydride at 75 oC for 
4 h provided 3',5'-di-O-acetyl-2'-deoxyguanosine 80 in 81% yield. The attempts to convert 
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2-amino from 2'-deoxyguanosine (dG) directly to 2-azido via diazotransfer and 
diazotization were not successful (Scheme 22), which led to the requirement of protection 
of O6 with p-nitrophenethyl alcohol (NPEOH). The O6-NPE protection required absolute 
anhydrous reaction condition and thus all the starting materials were dried along with P2O5 
in a drying pistol (40 oC) for 12 hours and the solvent 1,4-dioxane was distillated with 
CaH2 and then collected into a dried flask filled with Ar and activated 3 A molecular sieves. 
The O6-NPE protection of 80 with p-nitrophenethyl alcohol via Mitsunobu reaction in the 
presence of triphenyl phosphite (Ph3P), diisopropyl azodicarboxylate (DIAD), and 
activated molecular sieves powder at room temperature overnight yielded 3',5'-di-O-acetyl-
O6-(p-nitrophenethyl)-2'-deoxyguanosine 81 in 72% yield. Activated powder molecular 
sieves are required for the reaction to happen and to give good yield under humid 
environment. 81 was easily converted to 82 in 74% yield by treatment with tert-butyl nitrite 
and trimethylsilyl azide (TMSN3) in ACN at -20°C for 12 h then at 0 °C for 24 h. Treatment 
of 82 with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) at room temperature for 3 h 
followed by treatment with NH3/MeOH  at room temperature overnight provided the final 
product 2-N3dI 44 in 83% yield.  
 
Scheme 22. Attempted one-step synthesis of 2-azido-2'-deoxyinosine 
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Scheme 23. Synthesis of 2-azido-2'-deoxyinosine 
3.2.2. The formation of 2-aminyl radical from 2-azido-2'-deoxyinosine and 
subsequent radical transfers characterized using electron spin resonance 
The ESR characterization of the formation of 2'-deoxyguanosin-N2-yl radical (dG(N2-
H)•, 45) on electron attachment to 2N3dI 44 is under investigation. The N2-center radical 
45 and its tautomers could be expected to be observed using ESR to offer direct evidence 
of electron-transfer process under γ-irradiation. 
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3.3. Design, synthesis, fluorescent properties, and cell imaging of 1H-1,2,3-triazol-4-
yl analogues of C5 pyrimidine and C8 purine nucleosides 
3.3.1. Synthesis of 5-(1H-1,2,3-triazol-4-yl) pyrimidine and 8-(1H-1,2,3-triazol-4-yl) 
purine nucleoside analogues 
3.3.1.1. Method A catalyzed by Ag2CO3  
As discussed in Section 3.1.2, during the synthesis of protected AvdC 65 (48%) from 
3',5'-di-O-acetyl-5-ethynyl-2'-deoxycytidine 63a119,140 (Scheme 13) also the fluorescent 
3',5'-di-O-acetyl-5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (diAc-5-TrzdC, 83) was 
obtained in low yield (7%; Table 5, Entry 1; Method A). Also as was noted above in Section 
3.1.2 the analogous hydroazidation of 3',5'-di-O-acetyl-5-ethynyl-2'-deoxyuridine 62110 
produced protected AvdU 64 (55%) as the only product without formation of the 
corresponding triazole product 84 (Table 5, Entry 2; Method A). 
Remarkably, contrary to the 5-ethynylpyrimidine nucleosides, hydroazidation of 
8-ethynylpurine nucleosides produced triazole adducts as major products. Thus, 
hydroazidation of 8-ethynyl-2'-deoxyadenosine 85141 with TMSN3 in the presence of 
Ag2CO3 produced 8-(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine (8-TrzdA, 46, 50%) as the 
major product in addition to the vinylazide 89 (8-AvdA, 15%; Table 6, Entry 1; Method 
A).  The estimated yield of 8-TrzdA 46 based on the TLC were approximately 70% (Table 
6) but due to the strong binding of triazoles to the silica gel, the products after silica gel 
column chromatography were isolated in relatively low yields. Interestingly treatment of 
3',5'-di-O-TBDMS-8-ethynyl-2'-deoxyadenosine 86141 by Method A provided 3',5'-di-O-
TBDMS-8-(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine (diTBDMS-8-TrzdA, 88, 30%; 
Table 6, Entry 2) as the only product without a trace of azidovinyl analogue 90. The 
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treatment of 8-ethynyl-2'-deoxyguanosine 87142 by Method A also yielded 8-(1H-1,2,3-
triazol-4-yl)-2'-deoxyguanosine (8-TrzdG, 47, 52%; Entry 3) as the sole product.  
Table 5. Synthesis of 5-(1H-1,2,3-triazol-4-yl) pyrimidine nucleoside analogues 
 
Entry SM Method Trz Yielda [%] azide Yielda [%] 
1 63a A  83 7 65 48 
2 62 A  84 0 64 55 
3 63a B 83 32 (50) 65 0 
4 63b B 48 10 (20) 43 0 
5 62 B 84 55 (85) 64 0 
6 77 B  39 50 (85) 3d 0 
7 77 Bb 39 42 (75) 3d 0 
8 63a C 83 65 (80) 65 0 
9 63b C 48 51 (85) 43 0 
10 62 C 84 81 (95) 64 0 
11 77 C 39 52 (90) 3d 0 
a Isolated yields; In parenthesis are estimated yields based on TLC; b Modified Method B: CuI, 2 eq. 
H2O, DMF, 90 oC, 5h.  
Since 5-triazolylpyrimidine and 8-triazolylpurine nucleosides show good fluorescent 
properties (section 3.3.4), it was significant to optimize reaction conditions to synthesize 
the triazolyl analogues of the four natural bases (i.e. dU, dC, dA, and dG) of DNA. To 
optimize the conditions to increase the percent yield of the triazoles and to be applicable 
for all four nucleosides, several strategies have been designed and performed. 
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Table 6. Synthesis of 8-(1H-1,2,3-triazol-4-yl) purine nucleoside analogues 
 
Entry 4 Method 5 Yieldb [%] 6 Yieldb [%] 
1 85 A 46 50 (70) 89 15 (25) 
2 86 A 88 30 (75) 90 0 
3 87 Aa 47 52 (90) 91 0 
4 85 B 46 17 (60) 89 0 
5 86 B 88 27 (70) 90 0 
6 87 B 47 31 (65) 91 0 
7 85 C 46 51 (85) 89 0 
8 86 C 88 58 (85) 90 0 
9 87 C 47 52 (80) 91 0 
   a Modified Method A: Ag2CO3, H2O, DMF, 80 oC, 4h.  
Alkynes bearing electron-withdrawing groups are better substrates for the direct 
addition to in-situ generated hydrazoic acid.102,143 Thus, to increase the yield for the 
preparation of the unsubstituted 5-triazol-4-yl pyrimidine nucleosides, insertion of 
electron-withdrawing group to the pyrimidine bases was considered. Initially, the electron-
deficiency of the pyrimidine nucleosides were attempted to be increased by preparing Boc-
protected analogues (Scheme 24 and Scheme 25). Thus, di-N4,N4-Boc-3',5'-di-O-acetyl-5-
ethynyl-2'-deoxycytidine (92, 70%) and N4-Boc-3',5'-di-O-acetyl-5-ethynyl-2'-
deoxycytidine (93, 10%) were synthesized by the treatment of 3',5'-di-O-acetyl-5-ethynyl-
2'-deoxycytidine 63a with (Boc)2O as shown in Scheme 24. Similarly, N
3-Boc-3',5'-di-O-
acetyl-5-ethynyl-2'-deoxyuridine (94, 52%) was prepared from 3',5'-di-O-acetyl-5-
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ethynyl-2'-deoxyuridine (62, Scheme 25). Unfortunately, hydroazidation of the Boc-
protected pyrimidine nucleosides 92-94 by Method A resulted in unstable fluorescent 
products which were proved by NMR not to be the expected triazoles. The structures need 
to be further identified. The electron-withdrawing modification on pyrimidine bases did 
change the electron density that further led to different products rather than triazoles.  
 
Scheme 24. Synthesis of 4-N-Boc protected 3',5'-di-O-acetyl-5-ethynyl-2'-deoxycytidine 
derivatives 92 and 93 
 
Scheme 25. Synthesis of 3-N-Boc-3',5'-di-O-acetyl-5-ethynyl-2'-deoxyuridine 94 
3.3.1.2. Method B catalyzed by CuI  
Cycloaddition of the 5-ethynyl nucleosides and TMSN3 in the presences of CuI as a 
catalyst102 was found to produce triazoles as the sole products without formation of the 
vinylazides (Table 5, Entries 3-7; Table 6, Entries, 4-6; Method B). Thus, treatment of 
protected 5-ethynyl-2'-deoxycytidine 63a with TMSN3 in the presence of CuI gave 
diAc-5-TrzdC 83 with increased yield (32%; Table 5, Entry 3; Method B). Analogous 
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treatment of the unprotected 5-ethynyl-2'-deoxycytidine 63b140 by Method B gave 
5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (5-TrzdC, 48) even though with low isolated 
yield (10%; Table 5, Entry 4). Treatment of the uracil counterparts 62 and 77 under 
analogous reaction conditions yielded 3',5'-di-O-acetyl-5-(1H-1,2,3-triazol-4-yl)-2'-
deoxyuridine (diAc-5-TrzdU, 84, 55%;Table 5, Entry 5) and 5-(1H-1,2,3-triazol-4-yl)-2'-
deoxyuridine (5-TrzdU, 39, 50%; Entry 6), respectively. In Method B, DMF/H2O (9:1) was 
used as solvent, in which H2O was required for the reaction to give good yield.
102 Treatment 
of 77 by modified Method B in the presence of 2 eq. of H2O in DMF (Entry 7) gave 39 
(42%) as sole product, which showed that stoichiometric amount of H2O was efficient for 
the reaction. It is noteworthy that 84 and 39 were not accessible under Ag2CO3 conditions 
(Method A). 
Treatment of the 8-ethynylpurine nucleoside analogues 85-87 with TMSN3 by Method 
B also yielded their corresponding 8-(1H-1,2,3-triazol-4-yl)-2'-deoxypurine nucleosides 46 
(17%), 88 (27%), and 47 (31%; Table 6, Entry 4-6). However, the isolated yields were 
lower than that of reactions using Method A with Ag2CO3 as catalyst. There were more 
unwanted by-products below the triazole products on TLC, which meanwhile troubled the 
purification. After purification by regular column chromatography, further purification by 
HPLC (C18; A: 100% ACN, B: 5% ACN/H2O; 0% A → 15% A in 30 min, flow rate = 2 
mL/min) was required to obtain pure triazoles.  
The explanation of substantial differences of reactions with various substrates and 
different catalysts (Ag2CO3 and Cu (I)) are still unclear. 
 
 
68 
 
3.3.1.3. Method C catalyzed by CuSO4/sodium ascorbate 
The relatively low yields of 83 and 48 from Method B using CuI as catalyst was due to 
the oxidation of Cu (I) to Cu (II) during the reaction, which was indicated by the color 
change of the reaction mixture from brown to dark green. To avoid the loss of catalytic 
ability of Cu (I), Method C employing in situ generation of Cu (I) from CuSO4/sodium 
ascorbate was proved to be a better strategy for the synthesis of triazolyl nucleosides (Table 
5, Entry 8-11; Table 6, Entries 7-9; Method C). The reaction mixtures stayed brown during 
the 5-hours reaction, which indicated the invariable catalytic activity of the in-situ 
generated Cu(I). Thus, the treatment of 63a with TMSN3 in the presence of CuSO4/sodium 
ascorbate gave 83, which had a better yield (Table 5, 65%; Entry 8) than that of reaction 
using CuI as catalyst (32%; Table 5, Entry 3). Compared to the Entry 4, the synthesis of 
5-TrzdC 48 using CuSO4/sodium ascorbate provided a much better yield of 51% (Entry 9). 
It is worth noting that the estimated yield based on the TLC was 85%. The hydroazidation 
of 62 by Method C gave 84 with quantitative conversion yield (Entry 10). When 77 was 
treated with TMSN3 by Method C, similar yield of 5-TrzdU 39 (52%; Entry 11) was 
obtained compared to Entry 6 using Method with CuI as catalyst.  
The treatment of the 8-ethynylpurine nucleoside analogues 85-87 with TMSN3 by 
Method C gave their corresponding 8-(1H-1,2,3-triazol-4-yl)-2'-deoxypurine nucleosides 
46 (51%; Table 6, Entry 7), 88 (58%; Entry 8), and 47 (52%; Entry 9), which were 
obviously much better than that given by Method B using CuI as catalyst. The unwanted 
by-products below the triazole products on TLC were much less. 
The substrate scope of Method C for the synthesis of N-unsubstituted triazoles would 
be broad rather than just ethynyl nucleosides. Three presentative p-substituted 
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phenylacetylene, i.e. 4-ethynylanisole 95a (CH3O-, EDG), phenylacetylene 95b (H-, 
neutral), and 4-ethynyl-α,α,α-trifluorotoluene 95c (F3C-, EWG) were chosen and applied 
to this CuSO4/sodium ascorbate catalyzed procedure, and thus affording the corresponding 
triaozles in good yields (63-83%, 96a-96c, Table 7). It is noteworthy that phenylacetylene 
modified with electron-withdrawing group at the p-position promotes the formation of 
triazole, which matched the proposal reported.102,144 
Table 7. Synthesis of p-substituted phenyl triazoles via cycloaddition catalyzed by 
CuSO4/sodium ascorbate (Method C) 
 
Entry 95 Method 96 Yieldb [%] 
1 95a C 96a 63 (80) 
2 95b C 96b 73 (90) 
3 95c C 96c 83 (95) 
In summary, the fluorescent sugar-protected/unprotected N-unsubstituted triazolyl 
analogues of the four natural bases of DNA can be readily prepared with good yields from 
the treatment of their corresponding 5- or 8-ethynyl-2'-deoxynucleosides with TMSN3 in 
the presence of CuSO4/sodium ascorbate as catalyst. Reactions catalyzed by CuI can also 
give triazole adducts as major products but suffered from the relatively low yield because 
of the loss of catalytic activities of Cu (I) to Cu (II) after oxidation. The synthesis of 8-(1H-
1,2,3-triazol-4-yl)-2'-deoxyguanosine using Ag2CO3 as catalyst gave comparable yield and 
easier purification.   
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3.3.1.4. Reaction mechanism study 
A tentative reaction mechanism to give the triazoles as sole products might involve first 
formation of vinylazide followed by 1,5-electrocyclization and tautomerization. However, 
attempts to validate this mechanism were performed by treatment of AvdU 21 under 
Method C and treatment of 8-AvdA 89 under Method A (Scheme 26) and were proved that 
vinyl azide did not undergo cyclization to 1,2,3-triazoles. Thus, the mechanism involving 
a [3+2] cycloaddition of the alkyne with in-situ generated HN3 seems more probable 
(Scheme 27). The terminal alkyne substrate 97 reacts with Cu (I) or Ag (I) and forms metal 
activated alkyne 98, which further reacts with hydrazoic acid 99 in-situ generated from 
TMSN3 and H2O to produce intermediate 100. Protonation of 100 yields the final product 
N-unsubstituted 1,2,3-triazol-4-yl nucleosides 101 and releases Cu (I) or Ag (I) as catalyst. 
 
Scheme 26. Attempted conversion of vinylazides to triazoles 
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Scheme 27. Mechanism for the formation of N-unsubstituted 1,2,3-triazoles 
3.3.2. Stabilities of N-unsubstituted triazolyl nucleosides 
The metabolic phosphorylation by kinase in cells and the following incorporation of 
modified nucleosides into DNA usually requires incubation of the cells with the 
compounds for more than one hour.145,146 Typically, the incubation time is one or two days 
or even longer. For animal test, the whole process may need several days. As a result, the 
biological applications demand the compounds be stable under physiological conditions. 
The chemical stabilities of 8-TrzdA 46, 8-TrzdG 47, 5-TrzdC 48, and 5-TrzdU 39 were 
evaluated in D2O/DMSO-d6 (500 µL/50 µL) by monitoring the decomposition using 
1H NMR. The samples were kept in a 37 oC oil bath in the dark (covered with aluminum 
foil). The 1H NMR spectra were recorded at 0 h, 20h, and 48 h. The 1H NMR spectra of 
8-TrzdA was shown in Figure 28A and the fraction remaining of the four compounds over 
the time was shown in Figure 28B. The results showed that 8-TrzdA 46, 8-TrzdG 47, 
5-TrzdC 48, and 5-TrzdU 39 were very stable and exhibited no detectable decomposition 
in aqueous solution after 48 h at 37 oC. 
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Figure 28. Stability of triazolyl nucleosides at 37 °C in aqueous solution 
(A) 1H NMR of 8-TrzdA in D2O solution (10% DMSO) incubated at 37 
oC for 0 h, 20 h, 
and 48 h. (B) Fraction remaining of 8-TrzdA, 8-TrzdG, 5-TrzdU, and 5-TrzdC in D2O 
solution (10% DMSO) incubated at 37 oC vs. time 
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3.3.3. Inhibition of cell proliferation 
For effective metabolic labeling, the cytotoxicity of the labeling probe is an important 
consideration.146 Moreover, I was also interested in the potential application in anticancer 
of this group of novel nucleosides. Thus, 8-TrzdA 46, 8-TrzdG 47, 5-TrzdC 48, and 
5-TrzdU 39 were examined for their antiproliferative activity in HEL, HeLa, Vero, and 
MDCK cells. The results showed that all the compounds exhibited no cytotoxicity with 
CC50 > 100 µM.   
3.3.4. Fluorescent properties of triazolyl nucleosides 
The normalized fluorescence emission, absorption, and excitation spectra for the four 
1H-1,2,3-triazol-4-yl nucleosides in methanol were shown in Figure 29. Their 
photophysical data are summarized in Table 8. As expected, 8-TrzdA 46 with the C4 of 
triazolyl attaching to the C8 of adenine exhibits the high quantum yield (ΦF) of 44%. 
8-TrzdA 46 emits at 300-480 nm with the maximum emission at 355 nm. The diTBDMS-
protected 8-TrzdA analogue 88 exhibits matching fluorescent properties with a ΦF of 48%, 
which is reasonable since protection at sugar moiety does not change to the conjugated 
system and thus no difference would be expected. Similarly, the emission of 8-TrzdG 47 
starts at 300 nm but extends to 540 nm and the maximum emission is at 364 nm. Compared 
to the ΦF of 8-TrzdA 46, the ΦF of 8-TrzdG 88 is a little bit smaller as 9%.  
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Figure 29. Normalized fluorescence emission, absorption, and excitation spectra for (A) 
8-TrzdA, (B) 8-TrzdG, (C) 5-TrzdC, and (D) 5-TrzdU in MeOH 
Table 8. Photophysical data for 8-TrzdA (46), 8-TrzdG (47), 5-TrzdC (48), 5-TrzdU (39), 
and their analogues 
Comp'd  83 48 84 39 46 88 47 
εmax (M-1 cm-1) 4150 18750 10700 12400 17950 14100 14800 
λmax (abs) (nm) 293 295 291 291 287 285 283 
λmax (exc) (nm) 259 311 239 238 295 232 299 
λmax (exc) (nm) 312 254 294 302 235 292 - 
λmax (emi) (nm) 421 407 400 408 355 355 364 
Stokes shift (nm) 128 112 109 117 68 70 81 
ΦF 0.02  0.02 0.003 0.004 0.44 0.48 0.09 
τ1 (ns) 0.46 0.10 0.05 0.14 0.69 1.01 0.61 
τ2 (ns) 4.48 4.35 1.59 1.06 2.07 2.82 3.22 
τaverage (ns) 4.20 3.72 0.82 0.805 1.55 2.22 2.47 
f1 (%) 0.07 0.15 0.50 0.27 0.37 0.33 0.28 
f2 (%) 0.93 0.85 0.50 0.73 0.63 0.67 0.71 
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In contrast, the 5-pyrimidine analogues 5-TrzdU 39 and 5-TrzdC 48 showed a large 
Stokes shift of ~110 nm with the maximum emission approximately at 408 nm and much 
lower quantum yields. 5-TrzdC 48 emits at 320-550 nm (ΦF = 2%), while 5-TrzdU 39 emits 
at 320-500 nm (ΦF = 0.3%). Even though the quantum yield of 5-TrzdU is relatively low, 
it is still good enough to show bright fluorescence in solution and in cells (see cell imaging 
results in section 3.3.5). Similarly, the acetyl-protection at sugar doesn't alter the 
fluorescent properties of the triazolyl pyrimidine nucleosides.  
All triazoles showed biphasic fluorescence decay. The four unprotected triazoles 
present a fast lifetime of 0.1-4.4 ns (Table 8). 5-TrzdC 48 shows the longest lifetime of 
4.35 ns and longest average life time of 3.7 ns. 8-TrzdA (63%), 8-TrzdG (71%), 5-TrzdC 
(85%), and 5-TrzdU (73%) showed the larger contribution of the long lifetime (τ2).  
The application of these fluorescent nucleosides with the minimalistic modification at 
heterocyclic bases to cell imaging and DNA modifications will be discussed below.  
3.3.5. Cell imaging 
Primary mouse astrocytes were treated with vehicle (0.05% DMSO) or 10, 100, 1000 
uM of triazoles (with 0.05% DMSO) for 24 hours. The live cells were imaged using FV10i 
Confocal Laser Scanning Microscope from Olympus. The selected cell images were shown 
in Figure 30. In the negative controls, background fluorescence was indistinguishable in 
cells (Figure 30A). Due to the relatively high λ (exc) of the excitation filter at 405 nm while 
the λmax (exc) of those triazoles were at around 290-310 nm, the fluorescence was somewhat 
weak in Figure 30B-E. Nevertheless, we could still observe clear blue fluorescence from 
the triazoles in the cytosol of live cells rather than in the nucleus, which match our previous 
result on live cell imaging using in-situ generated fluorescent triazoles in cells.51 
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Figure 30. Fluorescence microscopy images and phase photos of primary mouse astrocytes 
cells treated with 8-TrzdA, 8-TrzdG, 5-TrzdC, and 5-TrzdU 
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To further prove that the fluorescent triazoles showed fluorescence in the cytosol, 
3T3-L1 mouse pre-adipocytes (Zen-bio #SP-L1-F) transfected with pMX-puro-GFP were 
employed to show clearly the edge of cells and to localize the cell nucleus with its green 
fluorescence. 3T3-L1 mouse pre-adipocytes transfected with pMX-puro-GFP were treated 
with the vehicle (0.05% DMSO), 200 uM of 8-TrzdA, or 200 uM of 5-TrzdU (with 0.05% 
DMSO) for 24 hours. Fixed cells were mounted with ProLong™ Gold Antifade Mountant 
(Thermo Fisher Scientific) and observed under the Olympus FV 1200 confocal microscope 
(Ex/Em = 473/519 nm for imaging of GFP; Ex/Em = 405/461 nm for triazoles). Figure 31 
showed clearly the cells and the nucleus. In the negative controls, background fluorescence 
was indistinguishable in cells incubated without any triazoles. The fluorescent 8-TrzdA 
(Figure 31B) and 5-TrzdU (Figure 31C) were localized at cytosol. 
 
Figure 31. Fluorescence microscopy images of fixed pMX-puro-GFP transfected 3T3-L1 
mouse pre-adipocytes treated with 8-TrzdA and 5-TrzdU 
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The reasons why the fluorescent stain was only found in cell cytosol rather than in the 
nucleus is still unclear. The possible reasons may be a) The triazolyl nucleosides are not 
substrates for polymerases, b) the triazoles are sensitive to the microenvironment and the 
fluorescence is quenched after being incorporated into duplex DNA.  
3.3.6. Polymerase-catalyzed incorporation of 8-TrzdA into DNA and fluorescent 
sensitivities to varied microenvironments 
3.3.6.1. Synthesis of TrzdATP 
The 8-TrzdATP 102 was synthesized following the triphosphorylation reported in 
section 3.1.3. The reaction of 8-TrzdA 46 with POCl3 in the presence of proton sponge 
followed by addition of TBAPP 73 and then TBA yielded 8-TrzdATP (102, 30%, Scheme 
28) after DEAE-Sephadex purification. The phosphates were characterized by 1H (Figure 
32A), 13C, 31P NMR (Figure 32B) as well as HR-MS (details at experimental section 4.1.4). 
 
Scheme 28. Synthesis of TrzdATP 
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Figure 32. 1H (A) and 31P (B) NMR of 8-TrzdATP 
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3.3.6.2. Enzymatic incorporation of 8-TrzdATP into DNA  
To determine the reasons leading to fluorescent stain localization to the cell cytosol 
rather than in the nucleus, 8-TrzdATP 102 was prepared to investigate if it could be 
substrate for polymerases and also to test the changes of fluorescent properties of the 
triazoles before and after being incorporated into duplex DNA (Figure 33).  
 
Figure 33. Proposed incorporation of 8-TrzdATP into DNA 
3.4. Antiviral and cytostatic evaluation of 5-(1-halo-2-sulfonylvinyl) and 5-(2-furyl) 
uracil nucleosides 
The work on section 3.4 as well as experimental section 4.1.5, 4.7 and 4.8 was 
published as an original paper at Arch Pharm/Wiley (Z. Wen, S. H. Suzol, J. Peng, Y. Liang, 
R. Snoeck, G. Andrei, S. Liekens, S. F. Wnuk, Archiv der Pharmazie 2017, 350, e1700023-
n/a).147  
3.4.1. Chemistry 
Tetrabutylammonium fluoride (TBAF)-mediated direct C-H arylation of 5-iodouracil 
nucleosides (103 or 105) with furan yielded 5-(fur-2-yl)-2'-deoxyuridine 106 (73%)111 or 
2',3',5'-tri-O-acetyl-5-(fur-2-yl)uridine 107 (67%, Scheme 29). Treatment of 5-iodo-2'-
deoxyuridine 103 with 2-heptylfuran gave 2'-deoxy-5-(5-heptylfur-2-yl)uridine 108 (61%) 
as a single isomer. Analogous cross-coupling of the protected 2'-deoxyuridine 104 or 
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uridine 105 with 2-heptylfuran provided regioselectively acetyl protected 5-(5-heptylfur-
2-yl) derivatives 109 (60%) and 110 (55%). Deacetylation of 110 with methanolic 
ammonia afforded 5-(5-heptylfur-2-yl)uridine (111; 81%). Esterification of 106 with 
undecanoic anhydride yielded 5'-O-undecanoyl- and 3',5'-di-O-undecanoyl-5-(fur-2-yl)-2'-
deoxyuridine 112 and 113. Analogously 108 was converted to 5-(5-heptylfur-2-yl) esters 
114 and 115.  
 
Scheme 29. Synthesis of 5-(fur-2-yl)- or 5-(5-heptylfur-2-yl)uracil nucleosides by direct 
C-H arylation 
For the synthesis of 5'-monoesters of the 5-furyl substituted uridines (e.g., 119 and 120), 
I have developed a three-step protocol starting from 2',3'-O-isopropylideneuridine 116 
(Scheme 30). Thus, treatment of 116 with undecanoic acid in the presence of DCC gave 
2',3'-O-isopropylidene-5'-O-undecanoyluridine (117) in 90% yield. Iodination of 117 with 
ICl in CH2Cl2 yielded 5'-O-undecanoyl-5-iodouridine (118). Direct C-H cross-coupling of 
118 with furan or 2-heptylfuran in the presence of TBAF111 gave 5'-O-undecanoyl-5-(fur-
2-yl)uridine (119, 63%) or 5'-O-undecanoyl-5-(5-heptylfur-2-yl)uridine (120, 44%), 
respectively.  
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Scheme 30. Synthesis of 5-(fur-2-yl)- or 5-(5-heptylfur-2-yl)uridine and their 5'-esters 
The 5-vinyl sulfone analogues: (E)-5-(1-bromo-2-tosylvinyl)-2'-deoxyuridine (121), 
(E)-3',5'-di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (122), (E)-5-(1-chloro-2-
tosylvinyl)uridine (123), (E)-5-(1-bromo-2-tosylvinyl)uridine (124), (E)-1-(β-D-
arabinofuranosyl)-5-(1-chloro-2-tosylvinyl)uracil (125), (E)-5-(1-propylthio-2-
tosylvinyl)-2'-deoxyuridine (126), and (E)-5-(1-propylthio-2-tosylvinyl)uridine (127) were 
prepared as reported.110  The 5-heteroarene analogues: 3',5'-di-O-acetyl-5-(fur-2-yl)-2'-
deoxyuridine (128), 5-(fur-2-yl)uridine (129), 1-(β-D-arabinofuranosyl)-5-(fur-2-yl)uracil 
(130), 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-(fur-2-yl)uracil (131), 5-(thiophen-2-
yl)uridine (132), and 5-(5-methylthiophen-2-yl)uridine (133) were prepared as reported111  
(Figure 34).  
 
Figure 34. Structures of 5-(1-substituted-2-tosylvinyl) 121-127 and 5-(2-heteroaryl) 128-
133 uracil nucleosides tested 
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3.4.2. Inhibition of cell proliferation 
The C5 substituted pyrimidine nucleosides (106-115, 119-133) were first examined for 
their antiproliferative activity in murine leukemia (L1210), human leukemia (CEM) and 
human cervical carcinoma (HeLa) cells. From the (β-halo)vinyl sulfones tested (121-125), 
only the acetyl protected 2'-deoxyuridine (β-chloro)vinyl sulfone 122 inhibited  the growth 
of these cell lines in the lower M range (Table 9). From the 5-(fur-2-yl) analogues tested 
(106-115, 119, 120, 128-131), the 2'-deoxy-5-(5-heptylfur-2-yl)uridine 108 inhibited  the 
growth of CEM cell lines in the M range.  
Table 9. Inhibitory effects of 5-(1-substituted-2-tosylvinyl) and 5-(2-heteroaryl)uracil 
nucleosides on the proliferation of murine leukemia cells (L1210), human T-lymphocyte 
cells (CEM), and human cervix carcinoma cells (HeLa) 
Compound 
IC50
a
 (µM) 
L1210 CEM HeLa 
106 > 100 > 100 32 ± 1 
107 > 100 80 ± 8 > 100 
108 48 ± 6 16 ± 4 > 100 
109 65 ± 10 36 ± 3 > 100 
110 88 ± 17 53 ± 1 > 100 
111 95 ± 8 42 ± 2 > 100 
114 > 100 93 ± 4 > 100 
115 > 100 78 ± 16 > 100 
119 43 ± 8 70 ± 2 64 ± 5 
122 5.6 ± 4.7 11 ± 10 23 ± 8 
125 > 100 > 100 > 100 
127 > 100 > 100 93 ± 14 
129 > 100 60 ± 27 83 ± 25 
130 > 100 > 100 > 100 
131 40 ± 10 63 ± 3 > 100 
132 > 100 86 ± 6 > 100 
133 > 100 > 100 > 100 
   a 50% inhibitory concentration. 
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3.4.3. Antiviral activity 
The antiviral activity of all compounds was tested against a broad range of DNA and 
RNA viruses and the human immunodeficiency (HIV) virus. Some of the compounds 
proved active against herpesviruses though they were less potent than the reference anti-
herpesvirus drugs (Table 10). The 5-(5-heptylfur-2-yl) (108) and 3',5'-Di-O-acetyl-5-(5-
heptylfur-2-yl) (109) derivatives inhibited the replication of human cytomegalovirus 
(HCMV) and varicella-zoster virus (VZV) bearing a wild-type thymidine kinase (TK+) 
with 50% effective concentrations (EC50's) in the range of 10-20 µM. Compound 108 was 
equally active against TK+ and TK-deficient (TK-) VZV strains while compound 109 failed 
to inhibit a TK- VZV mutant virus. Neither compound 108 nor 109 were able to decrease 
herpes simplex virus 1 (HSV-1) and 2 (HSV-2) induced cytopathic effect. In contrast, the 
5-(fur-2-yl)uracil nucleoside 106 emerged among the compounds synthesized as the most 
potent inhibitor of the HSV-1 TK+ strain Kos with an EC50 of 4 µM. Compound 106 was 
less active against HCMV, HSV-2 and the VZV TK+ Oka strain than against HSV-1 while 
it lacked activity against TK- HSV-1 and VZV. The spectrum of activity of compound 130 
only included HSV-1 and VZV TK+ strains. The (β-chloro)vinyl sulfone 122 showed an 
EC50 of 4 µM for the Oka strain (VZV TK
+) and marginal activity against HCMV. Except 
for compound 108 that displayed antiviral activity against parainfluenza virus (Table 11), 
none of the compounds showed activity against the other tested viruses. 
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Table 10. Anti-herpesvirus activity of 5-(1-substituted-2-tosylvinyl) and 
5-(2-heteroaryl)uracil nucleosides in HEL (human embryonic lung) fibroblasts 
Compound 
Cytotoxicity 
(µM) 
EC50 (µM)a   
MCCb 
HSV-1 
(KOS) 
HSV-2 
(G) 
HSV-
1  TK- 
(KOS 
ACVr) 
HCMV 
(AD-
169)  
HCMV 
(Davis) 
VZV 
TK+ 
(Oka) 
VZV 
TK- 
(07-1) 
106 >100 4 ± 0 47 ± 37 >100 45 20 32 >100 
108 100 >100 >100 >100 10 20 13 ± 2 12 ± 5 
109 100 >100 >100 >100 10 ± 2 12 ± 4 20 >20 
122 100 >100 >100 >100 >20 20 4 >20 
130 >100 14 ± 8 >100 >100 >100 >100 25 >100 
Acyclovir >440 
0.4 ± 
0.1 
0.3 ± 
0.1 
110 ± 
104 
ND ND 
0.7 ± 
0.1 
44 ± 7 
Brivudin >300 
0.04 ± 
0 
188 ± 
88 
27 ± 
32 
ND ND 
0.02 ± 
0.01 
29 ± 
10 
Ganciclovir >350 
0.06 ± 
0.04 
0.07 ± 
0.03 
4.4 ± 
3.4 
7.9 ± 
2.4 
4.3 ± 
3.6 
ND ND 
Cidofovir >350 
2.7 ± 
1.0 
1.5 ± 
0.7   
1.4 ± 
0.9 
0.9 ± 
0.6 
0.8 ± 
0.6 
ND ND 
a Required to reduce virus-induced cytopathogenicity by 50%. 
b Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of 
normal cell morphology. 
 
Table 11. Activity of 5-(5-heptylfur-2-yl)-2'-deoxyuridine against Parainfluenza virus 
Compound 
Cytotoxicity (µM) EC50 (µM)a 
MCCb Parainfluenza-3 virus 
108 >100 14 ± 8 
 a Required to reduce virus-induced cytopathogenicity by 50%. 
 b Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable 
  alteration of normal cell morphology. 
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4. EXPERIMENTAL SECTION 
4.1. Synthesis 
4.1.1. General Procedure 
1H (400 MHz) and 13C (100.6 MHz) NMR spectra were recorded in solutions of CDCl3 
unless otherwise noted. Reaction progress was monitored by TLC on Merck Kieselgel 
60-F254 sheets with product detection by 254-nm light. Products were purified by column 
chromatography using Merck Kiselgel 60 (230-400 mesh) or by automated flash 
chromatography using a CombiFlash system. Reagent grade chemicals were used and 
solvents were dried by reflux and distillation from CaH2 under N2 unless otherwise 
specified. All reactions were carried out under the Argon atmosphere.  
4.1.2. Synthesis of pyrimidine nucleosides with azidomethyl and azidovinyl 
modification at C5 position and their 5'-phosphates 
5-Azidomethyl-2'-deoxyuridine 5'-monophosphate (AmdUMP, 19). Phosphoryl 
chloride (11.2 μL, 18.4 mg, 0.12 mmol) was added to a stirred solution of AmdU 1840 (28.3 
mg, 0.1 mmol) and proton sponge (32 mg, 0.15 mmol) in trimethyl phosphate (1 mL) at 0 
oC. The resulting mixture was stirred at 0 oC for 30 min and then quenched by adjusting 
the pH to 7.5 with 2 M TEAB buffer. The residue was dissolved in water (5 mL) and was 
extracted with EtOAc (3 x 5 mL). The water layer was evaporated and coevaporated with 
mixture of EtOH/H2O (1:1, 5 mL).  The residue was column chromatographed (DEAE–
Sephadex®, TEAB 0.1 M → 0.4 M) and the appropriate fractions were evaporated in 
vacuum and coevaporate 5 times with mixture of EtOH/H2O (1:1, 10 mL) to remove excess 
of TEAB salt to give AmdU monophosphate triethylammonium salt 19. (25.5 mg, 70.4%): 
1H NMR (D2O) δ 2.36-2.39 (m, 2H, H2',2''), 3.99-4.08 (m, 2H, H5',5''), 4.16-4.20 (m, 1H, 
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H4'), 4.18 (s, 2H, CH2), 4.55-4.59 (m, 1H, H3'), 6.31 (t, J = 6.4 Hz, 1H, H1'), 8.09 (s, 1H, 
H6); 31P NMR (D2O) δ 1.16 (s); 13C NMR (D2O) δ 39.1, 47.0, 64.6, 71.0, 85.6, 85.8, 109.6, 
141.0, 151.5, 165.2; HRMS calcd for C10H14N5O8P [M-H]- 362.05072, found 362.05042. 
5-Azidomethyl-2'-deoxyuridine 5'-triphosphate (AmdUTP, 20). Phosphoryl 
chloride (11.2 μL, 18.4 mg, 0.12 mmol) was added to a stirred solution of AmdU 1840 (28.3 
mg, 0.1 mmol) and proton sponge (32 mg, 0.15 mmol) in trimethyl phosphate (1 mL) at 0 
oC. The resulting mixture was stirred at 0 oC for 30 min. 0.5 M tributylammomium 
pyrophosphate solution in DMF (1 mL, 0.5 mmol) and then tributylamine (71.2 μL, 55.6 
mg, 0.3 mmol) were added to the reaction mixture and stirred at 0 oC for 2 min. The reaction 
was quenched by adjusting the pH to 7.5 with 2 M TEAB buffer. The residue was dissolved 
in water (5 mL) and was extracted with EtOAc (3 x 5 mL). The water layer was evaporated 
and coevaporated with mixture of EtOH/H2O (1:1, 5 mL). The residue was column 
chromatographed (DEAE–Sephadex®, TEAB 0.1 M → 0.6 M) and the appropriate 
fractions were evaporated in vacuum and coevaporate 5 times with mixture of EtOH/H2O 
(1:1, 10 mL) to give AmdU triphosphate triethylammonium salt 20. (39.5 mg, 75.6%). 1H 
NMR (D2O) δ 2.37-2.41 (m, 2H, H2',2''), 4.20 (s, 2H, CH2), 4.20-4.29 (m, 3H, H4',5',5''), 
4.64-4.67 (m, 1H, H3'), 6.32 (t, J = 6.0, 1H, H1'), 8.06 (s, 1H, H6); 31P NMR (D2O) δ -
23.25 (t, J = 19.7, 1P, β), -11.64 (d, J = 19.8, 1P, α), -10.80 (d, J = 19.8, 1P, γ); 13C NMR 
(D2O) δ 38.9, 47.1, 65.4, 70.8, 85.5, 85.8, 109.7, 141.0, 151.5, 165.2; HRMS calcd for 
C10H16N5O14P3 [M-H]- 521.98338, found 521.98262. 
5-(1-Azidovinyl)-2'-deoxyuridine (AvdU, 21). Procedure A. Step a: Ag2CO3 (5.5 mg, 
0.02 mmol) was added to a solution of 62110 (67.3 mg, 0.2 mmol), TMSN3 (52.5 μL, 46 
mg, 0.4 mmol), and H2O (7 μL, 7 mg, 0.4 mmol) in DMF (2 mL). The resulting mixture 
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was stirred at 80 oC for 1 hour. After cooling to ambient temperature, the volatiles were 
evaporated under the reduced pressure and the residue was column chromatographed 
(hexane/EtOAc 50:50) to give 64 (39 mg, 52%): 1H NMR δ 2.07 (s, 6H, Ac), 2.33-2.46 (m, 
2H, H2',2''), 4.24-4.29 (m, 3H, H4', 5',5''), 5.06 (s, 1H, =CH2), 5.19-5.21 (m, 1H, H3'), 6.00 
(s, 1H, =CH2), 6.14 (t, J = 6.4 Hz, 1H, H1'), 7.83 (s, 1H, H6), 11.73 (s, 1H, NH); 
13C NMR 
δ 20.37, 20.81, 36.71, 63.75, 74.19, 81.84, 85.36, 101.58, 107.30, 136.87, 138.33, 149.26, 
160.88, 170.09, 170.17. Step b: Methanolic ammonia (4 mL) was added to 64 (38.9 mg, 
0.1 mmol) in 2 mL MeOH and the resulting mixture was stirred at 0 oC → r.t for 12 hours. 
Volatiles were evaporated and the residue was column chromatographed (EtOAc/MeOH 
95:5) gave AvdU 21 (27.4 mg, 90%): UV (MeOH) λmax 227, 248 (sh), 286 nm (ε 10650, 
7600, 8700), λmin 204, 264 nm (ε 4050, 7200); 1H NMR (DMSO-d6) δ 2.09-2.19 (m, 2H, 
H2' & 2''), 3.54-3.64 (m, 2H, H5' & 5''), 3.82 (q, J = 3.1, 1H, H4'), 4.23-4.27 (m, 1H, H3'), 
5.00 (d, J = 0.7 Hz, 1H, =CH2), 5.11 (t, J = 4.5 Hz, 1H, 5'-OH), 5.28 (d, J = 4.2 Hz, 3'-OH), 
5.91 (d, J = 0.8 Hz, 1H, =CH2), 6.16 (t, J = 6.4 Hz, 1H, H1'), 8.26 (s, 1H, H6), 11.60 (s, 
1H, NH); 13C NMR (DMSO-d6) δ 40.2, 61.0, 70.3, 84.8, 87.6, 101.3, 107.1, 137.3, 139.4, 
149.4, 161.0; HRMS calcd for C11H13N5O5Na [M+Na]
+ 318.0809, found 318.0784. 
5-Azidomethyl-2'-deoxycytidine (AmdC, 42). Step a: TIPBS-Cl (59 mg, 0.2 mmol) 
was added to a stirring solution of 5440 (67 mg, 0.13 mmol), DMAP (2 mg, 0.016 mmol), 
and triethylamine (27 µL, 19.7 mg, 0.2 mmol) in CH2Cl2 (1.5 mL) at ambient temperature. 
After 1 h, the residue was partitioned between CH2Cl2 and H2O. The organic layer was 
washed with NaHCO3/H2O and brine. Then 2.5 mL THF and 4 mL of aq. NH3 was added 
into the reaction residue and stirred at rt overnight. The volatiles were evaporated and the 
residue was partitioned between EtOAc and saturated brine and was column 
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chromatographed (CHCl3/MeOH, 0:100 → 85:15) to give 55 (57.4 mg, 86%) of sufficient 
purity to be used in next step: 1H NMR (DMSO-d6) δ 0.07 (s, 6H, 2 x CH3), 0.08 (s, 6H, 2 
x CH3), 0.87 (s, 9H, 3 x CH3), 0.88 (s, 9H, 3 x CH3), 2.00-2.07 (m, 1H, H2'), 2.15 (ddd, J 
= 13.6, 6.5, 3.4 Hz, 1H, H2''), 3.71-3.72 (m, 2H, H5',5''), 3.82 (q, J = 4.2 Hz, H4'), 4.22 (s, 
2H, CH2N3), 4.32-4.35 (m, 1H, H3'), 6.14 (t, J = 6.8 Hz, H1'), 7.13 (s, 1H, NH), 7.54 (s, 
1H, NH), 7.70 (s, 1H, H6); 13C NMR (DMSO-d6) δ -5.5, -5.0, -4.8, 17.6, 17.9, 25.6, 25.7, 
40.0, 47.3, 62.8, 72.2, 84.8, 86.9, 100.0, 141.4, 154.4, 164.0 Step b: 1 M TBAF/THF (330 
uL, 0.33 mmol) was added to a stirring solution of 55 (57.4 mg, 0.11 mmol) in THF (5 
mL). After 4 h, volatiles were evaporated and the residue was column chromatographed 
(CHCl3/MeOH, 100:0→85:15) and further purified by HPLC (C18; A: 100% ACN, B: 5% 
ACN/H2O; 0% A → 5% A in 30 min, flow rate = 2 mL/min) to give 42 (27.3 mg, 88%): 
UV (MeOH) λmax 206, 276 nm (ε 18 000, 6300), λmin 256 nm (ε 4800); 1H NMR (DMSO-d6) 
δ 1.91-1.98 (m, 1H, H2'), 2.14 (ddd, J = 13.4, 5.9, 3.5 Hz, H2''), 3.52-3.62 (m, 2H, H5',5''), 
3.78 (q, J = 4.0 Hz, 1H, H4'), 4.19-4.23 (m, 1H, H3'), 4.23 (s, 2H, CH2N3), 5.01 (t, J = 4.8 
Hz, 1H, 5'-OH), 5.22 (d, J = 4.0 Hz, 1H, 3'-OH), 6.12 (t, J = 6.1, 1H, H1'), 7.12 (s, 1H, 
NH), 7.49 (s, 1H, NH), 7.97 (s, 1H, H6); 13C NMR (DMSO-d6) δ 40.4, 47.4, 61.3, 70.2, 
85.0, 87.3, 99.9, 142.0, 154.6, 164.0; HRMS calcd for C10H14N6O4Na [M+Na]
+ 305.0969, 
found 305.0969. 
5-(1-Azidovinyl)-2'-deoxycytidine (AvdC, 43).  Method A. Step a: Treatment of 
63a119 (297 mg, 0.88 mmol) with TMSN3 by procedure A, step a, (column chromatography; 
CHCl3/MeOH, 100:0 → 90:10) gave 3',5'-di-O-acetyl-5-(1-azidovinyl)-2'-deoxycytidine 
65 (169 mg, 51%): 1H NMR δ 2.03 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.32-2.42 (m, 2H, H2',2''), 
4.19-4.28 (m, 3H, H4',5',5''), 5.06 (d, J = 1.5 Hz, 1H, =CH2), (d, J = 1.4 Hz, 1H, =CH2), 
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5.16-5.18 (m, 1H, H3'), 6.15 (t, J = 6.5 Hz, 1H, H1'), 7.05 (s, 1H, NH), 7.64 (s, 1H, NH), 
7.69 (s, 1H, H6). Step b:  Treatment of 65 (160 mg, 0.42 mmol) with methanolic ammonia 
by Procedure A, step b, (HPLC, C18; A: 100% ACN, B: 5% ACN/H2O; 0% A → 5% A in 
50 min, flow rate = 2 mL/min; Rt = 15.6 min)  gave AvdC 43 (59 mg, 48%): UV (MeOH) 
λmax 213, 244 (sh), 283 nm (sh) (ε 18500, 10800, 5350); 1H NMR (DMSO-d6) δ 1.98-2.00 
(m, 1H, H2'), 2.16 (s, J = 3.8, 1H, H2''), 3.52-3.63 (m, 2H, H5' & 5''), 3.79 (q, J = 3.3, 1H, 
H4'), 4.20-4.23 (m, 1H, H3'), 5.00 (d, J = 1.7 Hz, 1H, =CH2), 5.05 (d, J = 1.7 Hz, 1H, 
=CH2), 5.06 (s, 1 H, 5'-OH), 5.22 (s, 1H, 3'-OH), 6.11 (t, J = 7.1 Hz, 1H, H1'), 6.93 (s, 1H, 
NH), 7.52  (s, 1H, NH), 8.05 (s, 1H, H6); 13C NMR (DMSO-d6) δ 40.7, 60.9, 70.0, 85.2, 
87.4, 101.8, 103.5, 139.2, 141.5, 154.1, 162.4; HRMS calcd for  C11H14N6O4Na [M+Na]
+ 
317.0969, found 317.0976.  
Method B. Treatment of 5-ethynyl-2'-deoxycytidine 63b120 (40 mg, 0.16 mmol) with 
TMS-N3 by procedure A step a (column chromatography; CHCl3/MeOH, 95:5 → 85:15) 
gave 43 (16 mg, 34%). 
Method C. TIPBSCl (68 mg, 0.22 mmol) was added to a stirring solution of 64 (56.7 
mg, 0.15 mmol), DMAP (2.3 mg, 0.018 mmol), and TEA (32 µL, 22.8 mg, 0.22 mmol) in 
CH2Cl2 (1.5 mL) at ambient temperature. After 1 h, the residue was partitioned between 
CH2Cl2 and H2O. The organic layer was washed with NaHCO3/H2O and brine. Then 3 mL 
THF and 4.5 mL of aq. NH3 was added into the reaction residue and stirred at rt overnight. 
The volatiles were evaporated and the residue was column chromatographed 
(CHCl3/MeOH, 100:0 → 85:15) to give 43 (28 mg, 63%).  
3',5'-di-O-acetyl-5-azidomethyl-2'-deoxyuridine (diAcAmdU, 56). Into a solution 
of AmdU 1840 (85 mg, 0.3 mmol) and 4-dimehtylaminopyridine (3.7 mg, 0.03 mmol) in 3 
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mL acetonitrile was added triethylamine (209 µL, 151.8 mg, 1.5 mmol). The resulting 
mixture was stirred for 5 min. Acetic anhydride (85 µL, 91.9 mg, 0.9 mmol) was added 
and the reaction mixture was stirred at room temperature for 1 h. The volatiles were 
evaporated and the residue was dissolved in EtOAc and was extracted with NaHCO3 
aqueous solution. The organic layer was collected and dried over Na2SO4. The volatiles 
were evaporated under the reduced pressure and the residue was column chromatographed 
(hexane/EtOAc 70:30 → 40:60) to give 56 (71.3 mg, 65%): 1H NMR δ 2.11-2.20 (m, 1H, 
H2'), 2.12 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.53 (ddd, J = 14.2, 5.3, 1.7 Hz, 1H, H2''), 4.13 
(d, J = 5.2 Hz, 1H, CH2N3), 4.24 (d, J = 3.9 Hz, 1H, CH2N3), 4.27-4.33 (m, 2H, H4',5'), 
4.42 (dd, J = 12.6, 5.3 Hz, 1H, H5''), 5.21-5.24 (m, 1H, H3'), 6.31 (dd, J = 9.3, 6.0 Hz, 1H, 
H1'), 7.56 (s, 1H, H6), 9.04 (s, 1H, NH). 13C NMR δ 20.9, 21.1, 38.0, 47.3, 64.0, 74.3, 77.4, 
82.7, 85.5, 110.5, 137.2, 149.9, 162.2, 170.5, 170.6.   
5-(Dimethoxymethyl)-2'-deoxyuridine (58). The solution of thymidine 41 (72.7 mg, 
0.3 mmol), NaHCO3 (25.2 mg, 0.3 mmol), and Na2S2O8 (213 mg, 0.9 mmol) in H2O/MeCN 
(2:3, 4 mL) was degassed for 15 min. Tosyl azide (69 µL, 88.8 mg, 0.45 mmol) was added 
into the resulting mixture and then the reaction was stirred under 80 oC for 1 h. After the 
reaction, the temperature was lower down to room temperature and 0.5 mL aqueous 
solution Na2S2O3 (268mg, 1.08 mmol) and NaI (45 mg, 0.3 mmol) was added to quench 
the excess Na2S2O8. The volatiles were evaporated and the residue was column 
chromatographed (CHCl3/MeOH, 100:0→85:15) and further purified by HPLC (C18; A: 
100% ACN, B: 5% ACN/H2O; 0% A → 5% A in 60 min, flow rate = 2 mL/min) to give 
58 (58.1 mg, 64%):  1H NMR (DMSO-d6) δ 2.02-2.09 (m, 1H, H2'), 2.14 (ddd, J = 13.3, 
6.1, 3.4 Hz, H2''), 3.22 (s, 3H, CH3), 3.24 (s, 3H, CH3), 3.52-3.58 (m, 2H, H5',5''), 3.80 (q, 
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J = 3.3 Hz, 1H, H4'), 4.20-4.25 (m, 1H, H3'), 4.97 (t, J = 4.7 Hz, 1H, 5'-OH), 5.17 (s, 1H, 
CH), 5.25 (d, J = 4.2 Hz, 1H, 3'-OH), 6.16 (t, J = 6.9, 1H, H1'), 7.92 (s, 1H, H6), 11.39 (s, 
1H, NH).  
5'-DMT-5-azidomethyl-2'-deoxyuridine (5'-DMTAmdU, 59). AmdU 1840 (337 mg, 
1.19 mmol) and 4,4'-dimethoxytrityl chloride (484 mg, 1.43 mmol) were dissolved in 6 mL 
of pyridine. The resulting solution was stirred at rt for 2 h. The volatiles were removed. 
The residue was dissolved in EtOAc and washed with NaHCO3 solution followed by 
saturated NaCl solution and was column chromatographed (hexane/EtOAc/ triethylamine, 
70:30:2 → 80:20:2) to give compound 5'-DMT-5-azidomethyl-2'-deoxyuridine 59 (501.8 
mg, 72%): 1H NMR (CD2Cl2) δ 2.28-2.33 (m, 1H, H2'), 2.41 (ddd, J = 13.9, 6.2, 3.9 Hz, 
1H, H2''), 3.36-3.40 (m, 3H, CH2,H5',5''), 3.59 (d, J = 15.0, 1H, CH2), 3.79 (s, 6H, 2xOCH3), 
4.04 (q, J = 3.3, 1H, H4'), 4.60 (quin, J = 3.3, 1H, H3'), 6.32 (dd, J = 7.7, 6.2 Hz, 1H, H1'), 
6.84-6.88 (m, 4H, Ph), 7.26-7.34 (m, 7H, Ph), 7.39-7.41 (m, 2H, Ph), 7.75 (s, 1H, H6); 13C 
NMR (CD2Cl2) δ 41.6, 47.4, 55.8, 64.0, 72.7, 85.6, 86.8, 87.6, 110.2, 113.9, 127,8, 128.6, 
128.7, 130.7, 135.6, 136.1, 139.5, 145.1, 150,5, 159,5; HRMS calcd for C31H31N5O7Na 
[M+Na]+ 608.2116, found 608.2127. 
3'-CEP-5'-DMT-5-azidomethyl-2'-deoxyuridine (3'-CEP-5'-DMTAmdU, 60). 
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (54 μL, 56.8 mg, 0.24 mmol) was 
added to a solution of 5'-DMT-5-azidomethyl-2'-deoxyuridine 59 (117 mg, 0.2 mmol) and 
DIPEA (52 μL, 38.8 mg, 0.3 mmol) in DCM (2 mL). The resulting solution was stirred at 
rt for 10 min. The residue was diluted with CH2Cl2 and washed with saturated NaHCO3 
solution followed by brine solution and the organic layer was dried with anhydrous Na2SO4. 
The solvent was removed with high vacuum evaporator under ice/acetone bath (-10 oC). 
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The residue was column chromatographed (hexane/EtOAc/triethylamine, 50:50:2 → 
40:60:2) to give compound 3'-CEP-5'-DMT-5-azidomethyl-2'-deoxyuridine 60 (118 mg, 
75%): 1H NMR (CD2Cl2) δ 1.17 (d, J = 2.2 Hz, 6H, 2xCH3), 1.19 (d, J = 2.0 Hz, 6H, 
2xCH3), 2.31-2.38(m, 1H, H2'), 2.46 (t, J = 6.4 Hz, 2H, CH2CN ), 2.46-2.54 (m, 1H, H2''), 
3.32 (d, J = 13.4, 1H, CH2N3), 3.37 (dd, , J = 10.6, 3.1 Hz, 1H, H5'), 3.46 (dd, , J = 10.6, 
2.8 Hz, 1H, H5''), 3.57 (d, J = 13.4 , 1H, CH2N3), 3.55-3.71 (m, 4H, OCH2, 2xCH ), 3.79 
(s, 6H, OCH3), 4.19 (q, J = 2.6, 1H, H4'), 4.70 (ddd, J = 13.6, 6.4, 3.1 Hz, 1H, H3'), 6.33 
(dd, J = 7.3, 6.3 Hz, 1H, H1'), 6.84-6.88 (m, 4H, ph), 7.27-7.35 (m, 7H, ph), 7.40-7.42 (m, 
2H, ph), 7.81 (s, 1H, H6) ); 31P NMR (CD2Cl2) δ 148.85 (s); 13C NMR (CD2Cl2) δ 24.9, 
40.6, 47.4, 55.8, 59.0, 63.6, 73.8, 85.7, 86.4, 87.6, 110.2, 113.9, 118.2, 127.8, 128.6, 128.8, 
130.8, 135.9, 136.0, 139.6, 145.0, 150.4, 159.5, 163.0; HRMS calcd for C40H48N7O8PNa 
[M+Na]+ 808.3194, found 808.3154.  
5-Formyl-2'-deoxyuridine (67) and 5-azirinyl-2'-deoxyuridine (68) from the UV 
decomposition of AvdU 21. The solution of AvdU 21 (16.3 mg, 0.055 mmol) in 5 mL 
MeOH in a dark box was irradiated by a 254 nm UV lamp (UVG-11, 4 W, 0.16 Amps) for 
1.5 h. , The volatiles were evaporated under the reduced pressure and the residue was 
column chromatographed (CHCl3/MeOH, 100:0 → 95:5) to give 5-formyl-2'-deoxyuridine 
(67, 5.7 mg, 40.7%) and 5-azirinyl-2'-deoxyuridine (68, 5.1 mg, 34.7%). 5-Formyl-2'-
deoxyuridine (67) has 1H NMR (DMSO-d6) δ 2.12-2.29 (m, 2H, H2',2''), 3.56-3.66 (m, 2H, 
H5',5''), 3.86 (q, J = 3.2 Hz, 1H, H4'), 4.22-4.26 (m, 1H, H3'), 5.12 (t, J = 5.2 Hz, 1H, 5'-
OH), 5.28 (d, J = 4.4 Hz, 1H, 3'-OH), 6.09 (t, J = 6.4, 1H, H1'), 8.71 (s, 1H, H6), 9.76 (s, 
1H, CHO), 11.75 (s, 1H, NH).  13C NMR (DMSO-d6) δ 40.6, 60.7, 69.8, 85.9, 87.9, 110.7, 
147.1, 149.5, 161.6, 186.1. 5-Azirinyl-2'-deoxyuridine (68) has 1H NMR (DMSO-d6) δ 
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1.27 (d, J = 8.4 Hz, 1H, azirinyl), 1.31 (d, J = 8.4 Hz, 1H, azirinyl), 2.20-2.30 (m, 2H, 
H2',2''), 3.57-3.71 (m, 2H, H5',5''), 3.84 (q, J = 3.2 Hz, 1H, H4'), 4.27 (quin, J = 5.6 Hz, 
1H, H3'), 5.21 (t, J = 4.8 Hz, 1H, 5'-OH), 5.29 (d, J = 4.4 Hz, 1H, 3'-OH), 6.12 (t, J = 6.0, 
1H, H1'), 8.81 (s, 1H, H6), 11.82 (s, 1H, NH).  13C NMR (DMSO-d6) δ 14.7, 40.6, 60.3, 
69.2, 85.6, 87.7, 101.1, 148.3, 149.4, 158.0, 159.4.  
5'-DMT-5-(1-azidovinyl)-2'-deoxyuridine (69). AvdU 21 (24.8 mg, 0.084 mmol) and 
4,4'-dimethoxytrityl chloride (34 mg, 0.1 mmol) were dissolved in 0.5 mL of pyridine. The 
resulting solution was stirred at rt for 2 h. The volatiles were removed. The residue was 
dissolved in EtOAc and washed with NaHCO3 solution followed by saturated NaCl 
solution and was column chromatographed (hexane/EtOAc/ triethylamine, 70:30:2) to give 
compound 5'-DMT-5-(1-azidovinyl)-2'-deoxyuridine 69 (30 mg, 60%): 1H NMR (CD2Cl2) 
δ 2.23 (m, J = 13.7, 7.2, 6.4 Hz, 1H, H2'), 2.42 (ddd, J = 13.7, 6.4, 4.0 Hz, 1H, H2''), 3.33 
(dd, J = 10.2, 4.0 Hz, 1H, H5'), 3.44 (dd, J = 10.4, 4.0 Hz, 1H, H5''), 3.78 (s, 6H, 2xOCH3), 
4.05 (q, J = 3.5 Hz, 1H, H4'), 4.43 (quin, J = 3.3 Hz, 1H, H3'), 4.92 (d, J = 2.0 Hz, 1H, 
CH2), 6.10 (d, J = 1.8 Hz, 1H, CH2), 6.28 (dd, J = 7.3, 6.0 Hz, 1H, H1'), 6.82-6.85 (m, 4H, 
Ph), 7.21-7.35 (m, 7H, Ph), 7.43-7.46 (m, 2H, Ph), 7.97 (s, 1H, H6); 13C NMR (CD2Cl2) δ 
41.3, 55.6, 63.9, 72.5, 85.8, 86.6, 87.1, 101.5, 108.8, 113.5, 127.3, 128.2, 128.4, 130.4, 
136.0, 136.1, 137.0, 138.2, 145.0, 149.6, 159.2, 160.9, 171.2.  
3'-CEP-5'-DMT-5-(1-azidovinyl)-2'-deoxyuridine (70) (not obtained after column 
due to the Staudinger reaction). 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (9 
μL, 9.5 mg, 0.04 mmol) was added to a solution of 5'-DMT-5-(1-azidovinyl)-2'-
deoxyuridine 69 (20 mg, 0.033 mmol) and DIPEA (9 μL, 6.5 mg, 0.05 mmol) in DCM (1 
mL). The resulting solution was stirred at rt for 10 min. The residue was diluted with 
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CH2Cl2 and washed with saturated NaHCO3 solution followed by brine solution and the 
organic layer was dried with anhydrous Na2SO4. The solvent was removed with high 
vacuum evaporator under ice/acetone bath (-10 oC). The residue was column 
chromatographed (hexane/EtOAc/triethylamine, 70:30:2) to give compound, which was 
characterized as non-70(16.4 mg, 63%). The NMR data of the isomer with higher Rf of 
0.71 after column are provided: 1H NMR (CD2Cl2) δ 1.19-1.20 (m, 12H, 4xCH3), 2.47-
2.65 (m, 4H, CH2CN, H2',2''), 3.30-3.46 (m, 2H, H5',5''), 3.39 (s, 6H, OCH3), 3.95-4.04 
(m, 4H, OCH2, 2 x CH), 4.30-4.33 (m, 1H, H4'), 4.88 (d, J = 2.0 Hz, CH2), 4.92-4.96 (m, 
1H, H3'), 6.06 (d, J = 2.0 Hz, CH2), 6.31(dd, J = 8.8, 5.6 Hz, 1H, H1'), 6.82-6.84 (m, 4H, 
ph), 7.21-7.36 (m, 7H, ph), 7.42-7.47 (m, 2H, ph), 8.02 (s, 1H, H6); 31P NMR (CD2Cl2) δ 
7.52 (s, major) 148.85 (s); Based on the 1H and 31P NMR, it was concluded that the 
phosphoramidite was oxidized to P (IV) through the Staudinger reaction.  
5-Azidomethyl-2'-deoxycytidine triphosphate (AmdCTP, 74). POCl3 (19 μL, 31.2 
mg, 0.2 mmol) was added to a stirred solution of AmdC 42 (24 mg, 0.085 mmol) and proton 
sponge (54.6 mg, 0.255 mmol) in trimethyl phosphate (1 mL) at 0 oC. The resulting mixture 
was stirred at 0 oC for 30 min. 0.5 M tributylammomium pyrophosphate solution in DMF 
(1.275 mL, 0.5 mmol) and then tributylamine (90.9 μL, 70.9 mg, 0.38 mmol) were added 
to the reaction mixture and stirred at 0 oC for 2 min. The reaction was quenched by 
adjusting the pH to 7.5 with 2 M TEAB buffer. The residue was dissolved in water (5 mL) 
and was extracted with EtOAc (3 x 5 mL). The water layer was evaporated and 
coevaporated with mixture of EtOH/H2O (1:1, 5 mL). The residue was column 
chromatographed (DEAE–Sephadex®, TEAB 0.1 M → 0.6 M) and the appropriate 
fractions were evaporated in vacuum and coevaporate 5 times with mixture of EtOH/H2O 
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(1:1, 10 mL) to give AmdC triphosphate triethylammonium salt 74. (10.2 mg, 23%). 1H 
NMR (D2O) δ 2.36-2.43 (m, 1H, H2'), 2.49 (ddd, J = 14.4, 6.7, 4.4 Hz, 1H, H2''), 4.19-4.28 
(m, 3H, H4',5',5''), 4.41 (d, J = 15.0, 1H, CH2N3), 4.48 (d, J = 14.6, 1H, CH2N3), 4.61-4.64 
(m, 1H, H3'), 6.24 (t, J = 5.9, 1H, H1'), 8.33 (s, 1H, H6); 31P NMR (D2O) δ -23.41 (t, J = 
19.7, 1P, β), -11.72 (d, J = 20.5, 1P, α), -10.93 (d, J = 20.0 Hz, 1P, γ); 13C NMR (D2O) δ 
39.6, 47.4, 65.1, 70.3, 86.2, 86.9, 101.9, 144.6, 148.0, 158.3; HRMS calcd for 
C10H16N5O14P3 [M-H]- 520.99937, found 520.99934. 
5-Acetyl-2'-deoxyuridine triphosphate (75). POCl3 (22.4 μL, 36.8 mg, 0.24 mmol) 
was added to a stirred solution of AvdU 21 (59 mg, 0.2 mmol) and proton sponge (64.3 
mg, 0.3 mmol) in trimethyl phosphate (1.5 mL) at 0 oC. The resulting mixture was stirred 
at 0 oC for 30 min. 0.5 M tributylammomium pyrophosphate solution in DMF (2 mL, 1 
mmol) and then tributylamine (142.5 μL, 111.2 mg, 0.6 mmol) were added to the reaction 
mixture and stirred at 0 oC for 2 min. The reaction was quenched by adjusting the pH to 
7.5 with 2 M TEAB buffer. The residue was dissolved in water (5 mL) and was extracted 
with EtOAc (3 x 5 mL). The water layer was evaporated and coevaporated with mixture of 
EtOH/H2O (1:1, 5 mL). The residue was column chromatographed (DEAE–Sephadex®, 
TEAB 0.1 M → 0.6 M) and further purified by HPLC (C18; A: 20 mM TEAA buffer (pH 
= 7.1, in ACN/H2O = 1:1), B: 20 mM TEAA buffer (pH = 7.1, in H2O); 0% A → 25% A 
in 20 min, flow rate = 1 mL/min then stay with 25% A for 40 min). The appropriate 
fractions were evaporated in vacuum and coevaporate 5 times with mixture of EtOH/H2O 
(1:1, 5 mL). to give 5-acetyl-2'-deoxyuridine triphosphate triethylammonium salt 75125 
(23.4 mg, 23%). 1H NMR (D2O) δ 2.40-2.53 (m, 5H, H2',2'', CH3), 4.22-4.25 (m, 2H, 
H5',5''), 4.28-4.30 (m, 1H, H4'), 4.64-4.67 (m, 1H, H3'), 6.25 (t, J = 6.0, 1H, H1'), 8.65 (s, 
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1H, H6); 31P NMR (D2O) δ -23.35 ("s", 1P, β), -11.64 ("s", 1P, α), -10.97 ("s", 1P, γ); 13C 
NMR (D2O) δ 28.7, 39.5, 65.5, 70.4, 86.4, 87.1, 112.3, 148.5, 150.5, 162.4, 197.8. 
5-Ethynyl-2'-deoxyuridine triphosphate (78). POCl3 (44.7 μL, 73.6 mg, 0.48 mmol) 
was added to a stirred solution of 5-ethynyl-2'-deoxyuridine 77110 (100 mg, 0.4 mmol) and 
proton sponge (128. 6 mg, 0.6 mmol) in trimethyl phosphate (3 mL) at 0 oC. The resulting 
mixture was stirred at 0 oC for 30 min. 0.5 M tributylammomium pyrophosphate solution 
in DMF (4 mL, 2 mmol) and then tributylamine (285 μL, 222.4 mg, 1.2 mmol) were added 
to the reaction mixture and stirred at 0 oC for 2 min. The reaction was quenched by 
adjusting the pH to 7.5 with 2 M TEAB buffer. The residue was dissolved in water (10 mL) 
and was extracted with EtOAc (3 x 10 mL). The water layer was evaporated and 
coevaporated with mixture of EtOH/H2O (1:1, 5 mL). The residue was column 
chromatographed (DEAE–Sephadex®, TEAB 0.1 M → 0.6 M) and the appropriate 
fractions were evaporated in vacuum and coevaporate 5 times with mixture of EtOH/H2O 
(1:1, 10 mL) to give 5-ethynyl-2'-deoxyuridine triphosphate triethylammonium salt 78 
(104 mg, 53%). 1H NMR (D2O) δ 2.28-2.37 (m, 2H, H2',2''), 3.55 (s, 1H, CH), 4.09-4.16 
(m, 3H, H4',5',5''), 4.53-4.56 (m, 1H, H3'), 6.20 (t, J = 6.8, 1H, H1'), 8.15 (s, 1H, H6); 31P 
NMR (D2O) δ -23.46 (t, J = 20.9, 1P, β), -11.68 (d, J = 19.9, 1P, α), -10.86 (d, J = 20.7, 
1P, γ); 13C NMR (D2O) δ 38.8, 65.3, 70.6, 83.4, 85.6, 85.8, 98.7, 145.6, 150.5, 164.5. 
4.1.3. Synthesis of 2-azido-2'-deoxyinosine 
3',5'-di-O-acetyl-2'-deoxyguanosine (80). Acetyl anhydrite (1.5 mL, 1.65 g, 16.5 
mmol) was added to a solution of 2'-deoxyguanosine (dG,1.3 g, 5 mmol) and pyridine (1.5 
ml) in DMF (4 mL). The resulting mixture was stirred at 75 oC for 4h. After cooling to 
ambient temperature, the volatiles were evaporated under the reduced pressure and the 
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residue was column chromatographed (CHCl3/MeOH, 100:0 → 85:15) to give 80148 (1.4 g, 
81%): 1H NMR (DMSO-d6) δ 2.04 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.42-2.48 (m, 1H, H2'), 
2.88-2.95 (m, 1H, H2''), 4.16 (m, 3H, H4',5',5''), 5.28-5.29 (m, 1H, H3'), 6.13 (dd, J = 8.4, 
5.6 Hz, 1H, H1'), 6.52 (s, 2H, NH2), 7.92 (s, 1H, H8), 10.69 (s, 1H, NH).   
3',5'-di-O-acetyl-O6-(p-nitrophenethyl)-2'-deoxyguanosine (81). 3',5'-di-O-acetyl-
2'-deoxyguanosine 80 (703 mg, 2 mmol), PPh3 (840 mg, 3.2 mmol), p-nitrophenethyl 
alcohol (500 mg, 3 mmol), and activated molecular sieves were dispersed in 40 mL 
1,4-dioxane and stirred for 30 min. Then DIAD (630 μL, 646 mg, 3.2 mmol) was added to 
the mixture and stirred at room temperature overnight. Molecular sieves were filtrated and 
the volatiles were evaporated under reduced pressure. The solid residue was washed with 
Et2O to remove triphenylphosphate and then column chromatographed (CHCl3/MeOH, 
100:0 → 95:5) to give 81148 (720 g, 72%): 1H NMR (DMSO-d6) δ 2.02 (s, 3H, Ac), 2.08 
(s, 3H, Ac), 2.43-2.47 (m, 1H, H2'), 2.97-3.04 (m, 1H, H2''), 3.25 (t, , J = 7.2 Hz, 2H, CH2),   
4.16-4.22 (m, 2H, 5',5''), 4.28 (t, J = 6.4 Hz, 1H, H4'), 4.67 (t, , J = 6.8 Hz, 2H, CH2), 5.30-
5.33 (m, 1H, H3'), 6.22 (dd, J = 7.6, 6.4 Hz, 1H, H1'), 6.53 (s, 2H, NH2), 7.63 (d, J = 8.4 
Hz, 2H, Ph), 8.07 (s, 1H, H8), 8.18 (d, J = 8.4 Hz, 2H, Ph).  
3',5'-di-O-acetyl-2-azido-O6-(p-nitrophenethyl)-2'-deoxyinosine (82). 3',5'-di-O-
acetyl-O6-(p-nitrophenethyl)-2'-deoxyguanosine 81 (200 mg, 0.4 mmol) was dissolved in 
5 mL acetonitrile. The mixture was cooled down to -10 oC (acetone/ice bath) and then tert-
butyl nitrite (264 μL, 206 mg, 2 mmol) and trimethylsilyl azide (TMSN3, 262 μL, 230 mg, 
2 mmol) were added. The resulting mixture was kept in -20 oC freezer and 12 h and then 4 
oC refrigerator for 24 h.  The volatiles were evaporated under the reduced pressure and the 
residue was column chromatographed (CHCl3/MeOH, 100:0 → 95:5) to give 82 (155.4 mg, 
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74%): 1H NMR (DMSO-d6) δ 1.99 (s, 3H, Ac), 2.09 (s, 3H, Ac), 2.56 (ddd, J = 14.4, 6.4, 
3.2 Hz, 1H, H2'), 3.04-3.11 (m, 1H, H2''), 3.29-3.30 (m, 2H, CH2),  4.16-4.30 (m, 3H, 
H4',5',5''), 4.81 (t, , J = 6.8 Hz, 2H, CH2), 5.38-5.41 (m, 1H, H3'), 6.35 (t, J = 6.4 Hz, 1H, 
H1'), 7.63 (d, J = 9.2 Hz, 2H, Ph), 8.18 (d, J = 8.0 Hz, 2H, Ph), 8.49 (s, 1H, H8). 
2-azido-2'-deoxyinosine (2-N3dI, 44). To a solution of 82 (79 mg, 0.15 mmol) in 
acetonitrile was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 449 μL, 456 mg, 3 
mmol). The resulting mixture was stirred at room temperature for 3 h. The volatiles were 
evaporated under the reduced pressure and dried under high vacuum. 2 mL MeOH was 
added to the reaction residue and cooled down to 0 oC (ice bath), followed by adding 3 mL 
NH3/MeOH. The resulting mixture was stirred at 0 
oC to room temperature overnight.  The 
volatiles were evaporated under the reduced pressure and the residue was column 
chromatographed (CHCl3/MeOH, 100:0 → 85:25) and further purified by HPLC (C18; A: 
100% ACN, B:  100% H2O; 0% A then 0% A → 5% A in 30 min, flow rate = 2 mL/min) 
to give 44149 (36.6 mg, 83%): 1H NMR (DMSO-d6) δ 2.21 (ddd, J = 12.9, 6.3, 3.1 Hz, 1H, 
H2'), 2.68 (ddd, J = 13.7, 8.6, 6.3 Hz, 1H, H2''), 3.49-3.55 (m, 1H, H5'), 3.59-3.64 (m, 1H, 
H5''), 3.86 (q, J = 4.3 Hz, 1H, H4'), 4.37-4.40 (m, 1H, H3'), 5.24-5.29 (m, 2H, 3'OH,5'OH), 
6.29 (dd, J = 7.8, 5.9 Hz, 1H, H1'), 8.03 (s, 1H, H8); 13C NMR (DMSO-d6) δ 39.2, 48.6, 
62.0, 71.1, 83.4, 87.8, 115.1, 137.6, 150.4, 152.2, 156.3. MS (ESI): m/z calcd for 
[C10H12N7O4]+, 294.1; found 294.3. 
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4.1.4. Preparation of triazolyl nucleoside analogues 
3',5'-di-O-acetyl-5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (diAc-5-TrzdC, 83) 
Procedure A using Ag2CO3 as catalyst 
Ag2CO3 (2.8 mg, 0.01 mmol) was added to a solution of 63a
119 (33.5 mg, 0.1 mmol), 
azidotrimethylsilane (26.3 μL, 23 mg, 0.2 mmol), and H2O (3.6 μL, 3.6 mg, 0.2 mmol) in 
DMF (1 mL). The resulting mixture was stirred at 80 oC for 1 hour. After cooling to 
ambient temperature, the volatiles were evaporated under the reduced pressure and the 
residue was column chromatographed (CHCl3/MeOH, 100:0 → 90:10) to give 83 (2.6 mg, 
7%): UV (MeOH) λmax 208, 238, 293 nm (ε 13050, 9400, 4150), λmin 225, 271 nm (ε 8350, 
3150); 1H NMR (DMSO-d6) δ 1.99 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.36 (ddd, J = 14.1, 
5.8, 2.0 Hz, 1H, H2''), 2.47-2.44 (m, 1H, H2'), 4.23-4.20 (m, 1H, H4'), 4.35-4.26 (m, 2H, 
H5', 5''), 5.22-5.20 (m, 1H, H3'), 6.21 (dd, J = 7.6, 6.2 Hz, 1H, H1'), 7.67 (s, 1H, NH), 7.90 
(s, 1H, NH), 8.07 (s, 1H, H6), 8.24 (s, 1H, CH), 15.28 (s, 1H, NH); 13C NMR (DMSO-d6) 
δ 20.5, 20.7 (Ac), 36.6 (C2'), 63.7 (C5'), 74.3 (C3'), 81.6 (C4'), 86.0 (C1'), 97.2 (C5), 126.9 
(triazolyl), 139.8 (C6), 153.6 (C4), 162.4 (C2), 170.0, 170.2 (Ac); HRMS (ESI): m/z calcd 
for C15H19N6O6 [M+H]
+ 379.1361; found 379.1372. 
Procedure B using CuI as catalyst 
The stirred solution of 63a (33.5 mg, 0.1 mmol) in 1 mL DMF/H2O (9/1) was degassed 
with argon for 15 min. Azidotrimethylsilane (26.3 μL, 23 mg, 0.2 mmol) and CuI (1 mg, 
0.005 mmol) were added to the solution, which was further degassed for another 5 min. 
The resulting mixture was stirred at 90°C for 5 h. After cooling to ambient temperature, 
the volatiles were evaporated and the residue was column chromatographed (CHCl3/MeOH, 
100:0 → 90:10) to give 83 (12.0 mg, 32%) with the spectroscopic data as described above. 
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Procedure C using CuSO4/sodium ascorbate as catalyst 
63a (33.5 mg, 0.1 mmol) and CuSO4•5H2O (2.5 mg, 0.01 mmol) were dissolved in 
1 mL DMF/H2O (9/1) at ambient temperature. The stirred solution was degassed with 
argon for 15 min. Azidotrimethylsilane (26.3 μL, 23 mg, 0.2 mmol) and sodium ascorbate 
(4 mg, 0.02 mmol) were added to the solution, which was further degassed for another 5 
min. The resulting mixture was stirred at 90°C for 5 h. After cooling to ambient temperature, 
the volatiles were evaporated and the residue was column chromatographed (CHCl3/MeOH, 
100:0 → 90:10) to give 83 (24.6 mg, 65%) with the spectroscopic data as described above. 
5-(1H-1,2,3-triazol-4-yl)-2'-deoxyuridine (5-TrzdU, 39). Treatment of 77110 (25.1 
mg, 0.1 mmol) with CuI by Procedure B (column chromatography; CHCl3/MeOH, 100:0 
→ 85:15) gave 39 (14.8 mg, 50%): UV (MeOH) λmax 231, 292 nm (ε 12400, 11450), λmin 
259 nm (ε 3700); 1H NMR (DMSO-d6) δ 2.18 (dd, J = 6.3, 4.7 Hz, 2H, H2',2''), 3.63-3.55 
(m, 2H, H5',5''), 3.84 (q, J = 3.4 Hz, 1H, H4'), 4.31-4.25 (m, 1H, H3'), 5.04 ("s", 1H, 3'-OH), 
5.29 (d, J = 4.1 Hz, 1H, 5'-OH), 6.22 (t, J = 6.6 Hz, 1H, H1'), 8.14 (s, 1H, NH), 8.49 (s, 
1H, H6), 11.68 (s, 1H, 3-NH), 15.10 (s, 1H, NH); 13C NMR (DMSO-d6) δ 39.7 (C2'), 61.3 
(C5'), 70.5 (C3'), 84.7 (C1'), 87.6 (C4'), 136.4 (C6), 149.7 (C2), 161.3 (C4); HRMS (ESI): 
m/z calcd for C11H14N5O5 [M+H]
+ 296.0989; found 296.0983. 
Treatment of 77 (25.1 mg, 0.1 mmol) with CuI by modified Procedure B with 2 
equivalents of H2O and DMF as solvent (column chromatography; CHCl3/MeOH, 100:0 
→ 85:15) gave 39 (12.5 mg, 42%) with the spectroscopic data as described above. 
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Treatment of 77 (25.1 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; CHCl3/MeOH, 100:0 → 85:15) gave 39 (15.3 mg, 52%) with 
the spectroscopic data as described above. 
8-(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine (8-TrzdA, 46). Treatment of 85141 (27.5 
mg, 0.1 mmol) with Ag2CO3 by Procedure A (column chromatography; CHCl3/MeOH, 
100:0 → 85:15) gave 46 (15.4 mg, 50%): UV (MeOH) λmax 203, 228, 287 nm (ε 15900, 
16050, 17950), λmin 213, 250 nm (ε 13800, 5100); 1H NMR (DMSO-d6) δ 2.20 (ddd, J = 
12.9, 5.9, 1.7 Hz, 1H, H2''), 3.18-3.12 (m, 1H, H2'), 3.55-3.49 (m, 1H, H5''), 3.72-2.69 (m, 
1H, H5'), 3.90 (q, J = 3.7 Hz, 1H, H4'), 4.51-4.46 (m, 1H, H3'), 5.27 (d, J = 3.7 Hz, 1H, 3'-
OH), 5.80-5.77 (m, 1H, 5'-OH), 7.08 (t, J = 7.2 Hz, 1H, H1'), 7.48 (s, 2H, NH2), 8.13 (s, 
1H, H2), 8.42 (s, 1H, NH), 15.64 (s, 1H, NH); 13C NMR (DMSO-d6) δ 38.1 (C2'), 62.4 
(C5'), 71.5 (C3'), 85.9 (C1'), 88.4 (C4'), 119.4 (C5), 130.3 (triazolyl), 141.5 (C8), 149.8 
(C4), 152.1 (C2), 156.2 (C6); HRMS (ESI): m/z calcd for C12H14N8O3Na [M+Na]
+  
341.1081; found 341.1062. 
Treatment of 85 (27.5 mg, 0.1 mmol) with CuI by Procedure B (column 
chromatography; CHCl3/MeOH, 100:0 → 85:15; HPLC: C18, A: 100% ACN, B: 5% 
ACN/H2O; 0% A → 15% A in 30 min, flow rate = 2 mL/min) gave 46 (5.3 mg, 17%) with 
the spectroscopic data as described above. 
Treatment of 85 (27.5 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; CHCl3/MeOH, 100:0 → 85:15; HPLC: C18, A: 100% ACN, B: 
5% ACN/H2O; 0% A → 15% A in 30 min, flow rate = 2 mL/min) gave 46 (16.2 mg, 51%) 
with the spectroscopic data as described above. 
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8-(1H-1,2,3-triazol-4-yl)-2'-deoxyguanosine (8-TrzdG, 47). Treatment of 87142 (29.1 
mg, 0.1 mmol) with Ag2CO3 by Procedure A (column chromatography; CHCl3/MeOH, 
100:0 → 80:20) gave 47 (17.4 mg, 52%): UV (MeOH) λmax 205, 283 nm (ε 14450, 14800); 
λmin 238 (ε 2600); 1H NMR (DMSO-d6) δ 2.13-2.07 (m, 1H, H2''), 3.19-3.12 (m, 1H, H2'), 
3.50 (dd, J = 11.7, 5.3 Hz, 1H, H5''), 3.65 (dd, J = 11.8, 4.8 Hz, 1H, H5'), 3.81-3.78 (m, 
1H, H4'), 4.44-4.38 (m, 1H, H3'), 5.05 ("s", 1H, 5'-OH), 5.18 (d, J = 3.7 Hz, 1H, 3'-OH), 
6.43 (s, 2H, NH2), 8.34 (t, J = 7.8 Hz, 1H, H1'), 10.83 (s, 1H, NH), 15.42 (s, 1H, NH); 
13C 
NMR (DMSO-d6) δ 37.4 (C2'), 62.3 (C5'), 71.4 (C3'), 84.8 (C1'), 88.0 (C4'), 117.6 (C5), 
128.8 (triazolyl), 151.9 (C4), 153.1 (C2), 154.0 (C6), 156.5 (C8); HRMS (ESI): m/z calcd 
for C12H15N8O4 [M+H]
+,  335.1211; found 335.1214. 
Treatment of 87 (29.1 mg, 0.1 mmol) with CuI by Procedure B (column 
chromatography; CHCl3/MeOH, 100:0 → 80:20; HPLC: C18, A: 100% ACN, B: 5% 
ACN/H2O; 0% A → 15% A in 30 min, flow rate = 2 mL/min) gave 47 (10.2 mg, 31%) 
with the spectroscopic data as described above. 
Treatment of 87 (29.1 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; CHCl3/MeOH, 100:0 → 80:20; HPLC: C18, A: 100% ACN, B: 
5% ACN/H2O; 0% A → 15% A in 30 min, flow rate = 2 mL/min) gave 47 (26.0 mg, 52%) 
with the spectroscopic data as described above. 
5-(1H-1,2,3-triazol-4-yl)-2'-deoxycytidine (5-TrzdC, 48). Treatment of 63b120 (25.1 
mg, 0.1 mmol) with CuI by Procedure B (column chromatography; CHCl3/MeOH, 100:0 
→ 80:20) gave 48 (2.9 mg, 10%): UV (MeOH) λmax 207, 238, 296 nm (ε 18750, 13900, 5 
500), λmin 224, 273 nm (ε 11900, 3500);  1H NMR (DMSO-d6) δ 2.14-2.08 (m, 1H, H2''), 
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2.21 (ddd, J = 13.2, 6.1, 4.7 Hz, 1H, H2'), 3.66-3.59 (m, 1H, H5''), 3.75-3.68 (m, 1H, H5'), 
3.82 (q, J = 3.3 Hz, 1H, H4'), 4.30-4.24 (m, 1H, H3'), 7.68 (s, 1H, 3'-OH), 5.29 (s, 1H, 
5'-OH), 6.18 (t, J = 6.1 Hz, 1H, H1'), 7.68 (s, 1H, NH), 7.80 (s, 1H, NH), 8.07 (s, 1H, NH), 
8.60 (s, 1H, H6), 15.18 (s, 1H, NH), 13C NMR (DMSO-d6) δ 40.9 (C2'), 60.6 (C5'), 69.5 
(C3'), 85.4 (C1'), 87.3 (C4'), 96.4 (C5), 128.0 (triazolyl), 140.1 (C6), 153.7 (C4), 162.2 
(C2); HRMS (ESI): m/z calcd for C11H15N6O4 [M+H]
+  295.1149; found 295.1160. 
Treatment of 63b (25.1 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; CHCl3/MeOH, 100:0 → 80:20) gave 48 (15.0 mg, 51%) with 
the spectroscopic data as described above. 
3',5'-di-O-acetyl-5-(1H-1,2,3-triazol-4-yl)-2'-deoxyuridine (diAc-5-TrzdU, 84). 
Treatment of 62110 (33.6 mg, 0.1 mmol) with CuI by Procedure B (column chromatography; 
CHCl3/MeOH, 100:0 → 92:8) gave 84 (20.8 mg, 55%): UV (MeOH) λmax 231, 293 nm (ε 
10700, 9600), λmin 258 nm (ε 2900); 1H NMR (DMSO-d6) δ 2.08 (s, 3H, CH3), 2.13 (s, 
3H, CH3), 2.46-2.36 (m, 2H, H2',2''), 4.26-4.22 (m, 2H, H5', 5''), 4.31-4.27 (m, 1H, H4'),  
5.26-5.21 (m, 1H, H3'), 6.25 (t, J = 6.3 Hz, 1H, H1'), 8.18 (s, 1H, NH), 8.31 (s, 1H, H6), 
11.82 (s, 1H, 3-NH), 15.19 (s, 1H, NH); 13C NMR (DMSO-d6) δ 20.7, 20.8 (Ac), 36.7 (C2'), 
63.8 (C5'), 74.2 (C3'), 81.7 (C4'), 84.9 (C1'), 105.5 (C5), 135.8 (C6), 149.6 (C2), 161.2 
(C4), 170.1, 170.4 (Ac); HRMS (ESI): m/z calcd for [C15H18N5O7]
+, 380.1201; found 
380.1208. 
Treatment of 62 (33.6 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; CHCl3/MeOH, 100:0 → 92:8) gave 84 (30.6 mg, 81 %) with the 
spectroscopic data as described above. 
105 
 
3',5'-diTBDMS-8-(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine (diTBDMS-8-TrzdA, 
88). Treatment of 86141 (50.4 mg, 0.1 mmol) with Ag2CO3 by Procedure A (column 
chromatography; hexane/EtOAc 50:50 → 0:100) gave 88 (16.4 mg, 30%): UV (MeOH) 
λmax 225, 285 nm (ε 17 500, 14 100), λmin 247 nm (ε 3 900); 1H NMR (DMSO-d6) δ -0.08 
(s, 3H, CH3), -0.02 (s, 3H, CH3), 0.170 (s, 3H, CH3), 0.173 (s, 3H, CH3), 0.80 (s, 9H, 3 x 
CH3), 0.94 (s, 9H, 3 x CH3), 2.28-2.35 (m, 1H, H2'), 3.73 (dd, J = 11.3, 5.4 Hz, 1H, H5'), 
3.83-3.90 (m, 1H, H2''), 3.96 (dd, J = 11.3, 5.9 Hz, 1H, H5''), 4.05 ("q", J = 4.9, 1H, H4'), 
5.05 (q, J = 5.9 Hz, 1H, H3'), 6.72 (t, J = 6.9 Hz, 1H, H1'), 8.37 (s, 1H, H2), 8.53 (s, 1H, 
Htrz); 13C NMR (DMSO-d6) δ -5.4 (CH3), -5.3 (CH3), -4.6 (CH3), -4.4 (CH3), 18.2 (CH3), 
18.5 (CH3), 25.98 (CH3), 26.01 (CH3), 37.2 (C2'), 62.9 (C5'), 72.5 (C3'), 85.3 (C1'), 87.8 
(C4'), 119.7 (C5), 133.1(Htrz), 143.8 (C8), 151.0 (C4), 152.8 (C2), 155.4 (C6); HRMS 
calcd for C24H43N8O3Si2 [M+H]
+ 547.2991, found 547.3004.  
Treatment of 86 (50.4 mg, 0.1 mmol) with CuI by Procedure B (column 
chromatography; hexane/EtOAc 50:50 → 0:100) gave 88 (14.8 mg, 27%) with the 
spectroscopic data as described above. 
Treatment of 86 (50.4 mg, 0.1 mmol) with CuSO4/sodium ascorbate by Procedure C 
(column chromatography; hexane/EtOAc 50:50 → 0:100) gave 88 (31.7 mg, 58%) with 
the spectroscopic data as described above. 
8-(1H-1,2,3-triazol-4-yl)-2'-deoxyadenosine 5'-triphosphate (8-TrzdATP, 102). 
Phosphoryl chloride (28 μL, 46 mg, 0.3 mmol) was added to a stirred solution of 8-TrzdA 
46 (48 mg, 0.15 mmol) and proton sponge (80 mg, 0.375 mmol) in trimethyl phosphate 
(2 mL) at 0 oC. The resulting mixture was stirred at 0 oC for 30 min. 0.5 M 
tributylammomium pyrophosphate solution in DMF (1.5 mL, 0.75 mmol) and then 
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tributylamine (106.8 μL, 83.4 mg, 0.45 mmol) were added to the reaction mixture and 
stirred at 0 oC for 2 min. The reaction was quenched by adjusting the pH to 7.5 with 2 M 
TEAB buffer. The residue was dissolved in water (5 mL) and was extracted with EtOAc 
(3 x 5 mL). The water layer was evaporated and coevaporated with mixture of EtOH/H2O 
(1:1, 5 mL). The residue was column chromatographed (DEAE–Sephadex®, TEAB 0.1 M 
→ 0.6 M) and the appropriate fractions were evaporated in vacuum and coevaporate 5 
times with mixture of EtOH/H2O (1:1, 10 mL) to give 8-TrzdATP triethylammonium salt 
102. (33.4 mg, 30%). 1H NMR (D2O) δ 2.33 (ddd, J = 13.4, 6.5, 3.9, 1H, H2'), 3.22-3.26 
(m, 1H, H2''), 4.04-4.10 (m, 1H, H5'), 4.14 (q, J = 5.2 Hz, 1H, H4'), 4.18-4.24 (m, 1H, H5''), 
4.66 (quin, J = 3.9 Hz, 1H, H3'), 6.74 (t, J = 7.8, 1H, H1'), 8.20 (s, 1H, H2), 8.41 (s, 1H, 
Trz); 31P NMR (D2O) δ -23.22 (t, J = 21.0, 1P, β), -11.34 (d, J = 21.0, 1P, α), -10.22 (d, J 
= 21.0, 1P, γ); 13C NMR (D2O) δ 36.2, 65.2, 70.6, 84.3, 84.8, 118.6, 128.8, 136.1, 143.0, 
149.9, 152.6, 155.0; HRMS calcd for C12H16N8O12P3 [M-H]
- 557.0106, found 557.0091. 
4.1.5. Synthesis of 5-(1-halo-2-sulfonylvinyl) and 5-(2-furyl) uracil nucleoside 
analogues 
2',3',5'-Tri-O-acetyl-5-(fur-2-yl)uridine (107). Procedure B. Furan (0.7 mL, 680 mg, 
10 mmol) and TBAF (1 M/THF, 3.5 mL, 3.5 mmol) were added to a stirred solution of 
105150 (248 mg, 0.5 mmol) in DMF (5 mL) containing 
tris(dibenzylideneacetone)dipalladium (22.9 mg, 0.025 mmol) at ambient temerature. The 
resulting suspension was stirred for 1 h at 100oC. The volatiles were evaporated under 
reduced pressure and the residue was dissolved in EtOAc and washed with saturated 
NaHCO3/H2O and brine and the organic layer was dried over anhydrous Na2SO4. The 
residue was column chromatographed (CHCl3/MeOH, 95:5) to give 107 (146 mg, 67%): 
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1H NMR δ 2.10 (s, 3H, CH3), 2.15 (s, 3H, CH3), 2.22 (s, 3H, CH3), 4.38-4.40 (m, 3H, 
H4',5',5''), 5.38-5.42 (m, 2H, H2',3'), 6.24-6.28 (m, 1H, H1'), 6.47 (dd, J = 3.3, 1.8 Hz, 1H, 
furan), 7.09 (d, J = 3.4, 1H, furan), 7.33 (d, J = 1.4, 1H, furan), 7.91 (s, 1H, H6), 9.20 (s, 
1H, NH); 13C NMR  δ 20.5, 20.7, 20.8, 64.6, 70.9, 73.0, 80.6, 86.8, 108.4, 110.2, 112.3, 
132.5, 141.3, 145.6, 149.6, 157.8, 169.77, 169.83, 170.4; HRMS calcd for C19H21N2O10 
[M+H]+ 437.1191, found 437.1178. 
5-(5-Heptylfur-2-yl)-2'-deoxyuridine (108). Treatment of 5-iodo-2'-deoxyuridine 
103111 (53 mg, 0.15 mmol) with 2-heptylfuran (0.29 mL, 249 mg, 1.5 mmol) as described 
by Procedure B (column chromatography; hexane/EtOAc, 20:80) gave 108 (35 mg, 61%): 
UV (MeOH) λmax 256, 326 nm (ε 14 250, 11 300), λmin 287 nm (ε 4000); 1H NMR 
(DMSO-d6) δ 0.86 (t, J =6.7 Hz, 3H, CH3), 1.24-1.31 (m, 8H, 4 x CH2), 1.60 (quin, J = 6.7 
Hz, 2H, heptyl), 2.17 ("dd", J = 6.6, 4.9 Hz, 2H, H2',2''), 2.60 (t, J = 7.4 Hz, 2H, CH2), 
3.60-3.62 (m, 2H, H5',5''), 3.83 (q, J = 3.3 Hz, 1H, H4'), 4.29 (quin, J = 4.2, 1H, H3'), 5.05 
(t, J = 5.0 Hz, 1H, 5'-OH), 5.28 (d, J = 4.1 Hz, 1H, 3'-OH), 6.11 (d, J = 3.1 Hz, 1H, furan), 
6.21 (t, J = 6.6 Hz, 1H, H1'), 6.72 (d, J = 3.1 Hz, 1H, furan), 8.27 (s, 1H, H6), 11.58 (s, 1H, 
NH); 13C NMR δ 14.2, 22.1, 27.0, 28.6, 31.1, 39.4, 60.8, 70.3, 84.5, 87.4, 105.7, 106.8, 
108.6, 133.6, 144.5, 149.6, 154.8, 160.0; HRMS calcd for C20H29N2O6 [M+H]
+ 393.2020, 
found 393.2023. 
3',5'-Di-O-acetyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (109). Treatment of 104118 
(150 mg, 0.34 mmol) with 2-heptylfuran (0.6 mL, 565 mg, 3.4 mmol) as described by 
Procedure B (column chromatography; hexane/EtOAc, 80:20 → 60:40) gave 109 (86 mg, 
60%): 1H NMR δ 0.87 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.37 (m, 8H, 4 x CH2), 1.61 (q, J = 
7.4 Hz, 2H, CH2), 2.11 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.25 ("ddd", J = 16.6, 8.7, 2.2 Hz, 
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1H, H2'), 2.50-2.57 (m, 1H, H2"), 2.59 (t, J = 7.5 Hz, 2H, CH2), 4.30-4.34 (m, 1H, H4'), 
4.38-4.42 (m, 2H, H5',5"), 5.28 ("dt", J = 6.4, 1.6 Hz, 1H, H3'), 6.05 (d, J = 3.3 Hz, 1H, 
furan), 6.40 (dd, J = 8.6, 5.5 Hz, 1H, H1'), 6.98 (d, J = 3.3 Hz, 1H, furan), 7.85 (s, 1H, H6), 
9.30 (s, 1H, NH); 13C NMR δ 14.2 (CH3), 20.9, 21.1 (Ac), 22.8, 28.1, 28.2, 29.2, 29.3, 31.9 
(CH2), 38.1(C2'), 61.2 (C5'), 74.7 (C3'), 82.7 (C4'), 85.7 (C1'), 107.4 (furan), 108.2 (C5), 
111.0 (furan), 131.3 (C6), 143.8, 149.4 (furan), 156.2 (C2), 159.9 (C4), 170.3, 170.5 (Ac); 
HRMS calcd for C24H32N2NaO8 [M+Na]
+ 499.2056, found 499.2078.  
2',3',5'-Tri-O-acetyl-5-(5-heptylfur-2-yl)uridine (110). Treatment of 2',3',5'-tri-O-
acetyl-5- iodouridine 105 (400 mg, 0.8 mmol) with 2-heptylfurane (1.5 mL, 665 mg, 4.0 
mmol) by Procedure B (column chromatography; hexane/EtOAc, 50:50) gave 110 (236 
mg, 55%): 1H NMR δ 0.88 (t, J = 6.7 Hz, 3H, CH3), 1.25-1.34 (m, 8H, 4 x CH2), 1.62 (quin, 
J = 7.8 Hz, 2H, CH2), 2.10 (s, 3H, Ac), 2.15 (s, 3H, Ac), 2.18 (s, 3H, Ac), 2.59 (t, J = 7.8 
Hz, 2H, CH2), 4.38-4.40 (m, 3H, H4',5',5''), 5.40-5.44 (m, 2H, H2',3'), 6.05 (d, J = 3.6 Hz, 
1H, furan), 6.21 (d, J = 5.5 Hz, 1H, H1'), 6.99 (d, J = 3.3 Hz, 1H, furan), 7.75 (s, 1H, H6), 
9.03 (s, 1H, NH); 13C NMR δ 14.0 (CH3), 20.4, 20.6, 20.8 (Ac), 22.6, 28.0, 28.1, 29.0, 29.2, 
31.7 (CH2), 63.4 (C5'), 70.8 (C3'), 72.7 (C2'), 80.4 (C4'), 87.0 (C1'), 107.3 (furan), 108.5 
(C5), 111.2 (furan), 131.2 (C6), 143.5, 149.4 (furan), 156.1 (C2), 160.0 (C4), 169.7, 169.7, 
170.1 (Ac); HRMS calcd for C26H35N2O10 [M+H]
+ 535.2286, found 535.2288. 
5-(5-Heptylfur-2-yl)uridine (111). Methanolic ammonia (6.4 mL) was added to 110 
(100 mg, 0.19 mmol) in 1.6 mL MeOH and the resulting mixture was stirred at 0 oC → rt 
for 12 hours. Volatiles were evaporated and the residue was column chromatographed 
(EtOAc/MeOH, 95:5) to give 111 (62 mg, 81%): UV (MeOH) λmax 254, 326 nm (ε 13 600, 
10 950), λmin 287 nm (ε 3850); 1H NMR (DMSO-d6) δ 0.86 (t, J = 6.6 Hz, 3H, CH3), 1.24-
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1.31 (m, 8H, 4 x CH2), 1.60 (quin, J = 6.9, 2H, CH2), 2.60 (t, J = 7.3 Hz, 2H, CH2), 3.60 
(ddd, J = 12.0, 4.8, 3.1 Hz, 1H, H5'), 3.68 (ddd, J = 12.0, 4.8, 2.9 Hz, 1H, H5''), 3.89-3.91 
(m, 1H, H4'), 4.02 (q, J = 4.8 Hz, 1H, H3'), 4.10 (q, J = 5.0 Hz, 1H, H2'), 5.11 (d, J = 5.2 
Hz, 1H, 3'-OH), 5.15 (t, J = 4.8 Hz, 1H, 5'-OH), 5.44 (d, J = 5.6 Hz, 1H, 2'-OH), 5.86 (d, 
J = 4.8 Hz, 1H, H1'), 6.11 (d, J = 3.1 Hz, 1H, furan), 6.73 (d, J = 3.1 Hz, 1H, furan), 8.36 
(s, 1H, H6), 11.60 (s, 1H, NH). 13C NMR (DMSO-d6) δ 13.9, 22.0, 27.2, 27.3, 28.3, 28.5, 
31.2 (heptyl), 60.6 (C5'), 69.9 (C3'), 74.0 (C2'), 84.9 (C1'), 88.3 (C4'), 105.9 (C5), 106.7 
(furan), 108.7 (furan), 133.9 (C6), 144.5 (furan), 149.6 (furan), 154.7 (C2), 160.1 (C4); 
HRMS calcd for C20H29N2O7 [M+H]
+ 409.1969, found 409.1982.  
5'-O-Undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (112). Treatment of 106111 (25 mg, 
0.08 mmol) with undecanoic anhydride by Procedure A (column chromatography; 
hexane/EtOAc, 100:0 → 70:30) gave 112 (18 mg, 52%) and 113 (5 mg, 10%) in addition 
to unchanged 106 (~15%; TLC). Compound 112 had: 1H NMR δ 0.88 (t, J = 7.1 Hz, 3H, 
CH3), 1.22-1.40 (m, 14H, 7 x CH2), 1.60 ("quin", J = 7.3 Hz, 2H, CH2), 2.10-2.17 (m, 1H, 
H2'), 2.35 (t, J = 7.6 Hz, 2H, CH2), 2.50 (ddd, J =13.7, 6.3, 3.9 Hz, 1H, H2''), 3.05 (br s, 
1H, 3'-OH), 4.15 (q, J = 3.9, 1H, H4'), 4.25 (dd, J = 12.1, 3.3 Hz, 1H, H5'), 4.36-4.42 (m, 
2H, H3',5"), 6.26 (t, J = 6.3 Hz, 1H, H1'), 6.60 (dd, J = 3.3, 1.8 Hz, 1H, furan), 7.05 (d, J 
= 3.5 Hz, 1H, furan), 7.38 (d, J = 1.2 Hz, 1H, furan), 8.25 (s, 1H, H6), 8.38 (s, 1H, NH); 
HRMS calcd for C24H34N2NaO7 [M+Na]
+ 485.2264; found 485.2271. 
3',5'-Di-O-undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (113). Treatment of 106111 (25 
mg, 0.08 mmol) with undecanoic anhydride (84 mg, 0.24 mmol) by Procedure A (6 h) gave 
113 (38.5 mg, 77%): 1H NMR δ 0.82-0.91 (m, 6H, 2 x CH3), 1.20-1.40 (m, 28H, 14 x CH2), 
1.60-1.68 (m, 4H, 2 x CH2), 2.24 (ddd, J = 14.6, 8.6, 6.5 Hz, 1H, H2'), 2.33-2.40 (m, 4H, 
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2 x CH2), 2.54 (ddd, J = 14.1, 5.6, 1.3 Hz, 1H, H2"), 4.30 ("q", J = 2.7 Hz, 1H, H4'), 4.36 
(dd, J  = 12.2, 2.8 Hz, 1H, H5'), 4.45 (dd, J  =11.8, 3.5 Hz, 1H, H5"), 5.27 ("dt", J = 6.4, 
1.6 Hz, 1H, H3'), 6.40 (dd, J  = 8.8, 6.1 Hz, 1H, H1'), 6.47 (dd, J = 3.3, 1.8 Hz, 1H, furan), 
7.05 (d, J = 3.4 Hz, 1H, furan), 7.33 (d, J = 1.6 Hz, 1H, furan), 8.00 (s, 1H, H6), 8.95 (s, 
1H, NH); 13C NMR δ 14.5, 23.0, 25.1, 25.2, 29.3, 29.4, 29.6, 29.7, 29.9, 32.3, 34.1, 34.3, 
34.5, 39.0 (C2'), 64.0 (C5'), 74.6 (C3'), 83.2 (C4'), 86.0 (C1'), 108.0 (C5), 110.0 (furan), 
112.5 (furan), 133.0 (C6), 142.0 (furan), 146.0 (furan), 149.5 (C2), 160.2 (C4), 173.2, 
173.4 (C=O); HRMS calcd for C35H54N2NaO8 [M+Na]
+ 653.3778, found 653.3778. 
5'-O-Undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (114). Treatment of 108 (25 
mg, 0.064 mmol) with undecanoic anhydride by Procedure A (hexane/EtOAc, 100:0 → 
80:20) gave 114 [17 mg, 48%; TLC (CHCl3/MeOH, 95:5), Rf = 0.50), 115 (4.7 mg, 10%; 
Rf = 0.90) and unchanged 108 (~15%, TLC; Rf = 0.10). Compound 114 had: 
1H NMR δ 
0.85-0.90 (m, 6H, 2 x CH3), 1.28-1.31 (m, 22H, 11 x CH2), 1.54-1.64 (m, 4H, 2 x CH2), 
2.13-2.16 (m, 1H, H2'), 2.27-2.32 (m, 2H, CH2), 2.46 (ddd, J =13.9, 6.4, 4.3 Hz, 1H, H2''), 
2.56 (t, J = 7.4 Hz, 2H, CH2), 2.98 (s, 1H, 3'-OH), 4.19 (q, J = 3.5, 1H, H4'), 4.28 (dd, J = 
12.3, 3.4 Hz, 1H, H5'), 4.33-4.41 (m, 2H, H3',5"), 6.05 (d, J = 3.2 Hz, 1H-furan), 6.28 (t, 
J = 6.4 Hz, 1H, H1'), 6.90 (d, J = 3.2 Hz, 1H-furan), 8.10 (s, 1H, H6), 8.44 (s,1H, NH); 13C 
NMR δ 14.2, 22.9 (CH3), 24.9, 28.1, 28.2, 29.2, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9, 
32.1, 34.2, 34.3, 34.4 (CH2), 40.7 (C2'), 63.6 (C5'), 71.8 (C3'), 84.4 (C4'), 85.5 (C1'), 108.2 
(C5), 110.6 (furan), 113.0 (furan), 129.0 (furan), 133.0 (C6), 149 (C2), 156.0 (furan), 159.6 
(C4), 174.0 (C=O); HRMS calcd for C31H48N2NaO7 [M+Na]
+ 583.3359, found 583.3375. 
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Note: Also isolated from column chromatography was a product (2 mg, 5%; TLC, Rf = 
0.55) whose structure was tentatively assigned as 3'-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-
deoxyuridine [1H NMR δ 5.39 ("dt", J = 8.1, 1.6 Hz, 1H, H3'). 
3',5'-Di-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (115). Treatment of 
108 (25 mg, 0.064 mmol) with undecanoic anhydride (65 mg, 0.19 mmol) by Procedure A 
(6 h) gave 115 (36 mg, 80%). Compound 115 had: 1H NMR δ 0.83-0.92 (m, 9H, 3 x CH3), 
1.22-1.38 (m, 36H, 18 x CH2), 1.55-1.70 (m, 6H, 3 x CH2), 2.25 (ddd, J  = 14.7, 8.5, 6.6 
Hz, 1H, H2'), 2.30-2.40 (m, 4H, 2 x CH2), 2.53-2.57 (m, 1H, H2"), 2.60 (t, J = 7.6 Hz, 2H, 
CH2), 4.31 (q, J = 3.0 1H, H4'), 4.38 (dd, J  = 12.2, 2.8 Hz, 1H, H5'), 4.42 (dd, J  =11.3, 3.8 
Hz, 1H, H5"), 5.26 ("dt", J  = 6.8, 1.6 Hz, 1H, H3'), 6.05 (d, J = 3.2 Hz, 1H, furan), 6.37 
(dd, J  = 8.8, 6.1 Hz, 1H, H1'), 6.95 (d, J = 3.3 Hz, 1H, furan), 7.88 (s, 1H, H6), 9.00 (s, 
1H, NH); HRMS calcd for C42H68N2NaO8 [M+Na]
+ 751.4873, found 751.4851. 
5'-O-Undecanoyl-5-(fur-2-yl)uridine (119). Step a. DDC (516 mg, 1.25 mmol) was 
added to a stirred solution of 2',3'-O-isopropylideneuridine 116 (142 mg, 0.5 mmol), 
undecanoic acid (163 mg, 0.875 mmol), and 4-dimethylaminopyridine (91.6 mg, 0.375 
mmol) in DMF (2 mL) at rt The resulting mixture was stirred at 60 oC overnight. Volatiles 
were evaporated and the residue was partitioned between EtOAc and 0.1 M HCl solution. 
The organic layer was washed with saturated solutions of NaHCO3 and brine and then was 
column chromatographed (hexane/EtOAc, 50:50) to give 2',3'-O-isopropylidene-5'-O-
undecanoyluridine (117; 203 mg, 90%) of sufficient purity to be used in next step: 1H NMR 
δ 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.65 (m, 22H, 8 x CH2, 2 x CH3), 2.31 (t, J = 7.5 Hz, 
2H, CH2), 4.26-4.38 (m, 3H, H4',5',5''), 4.80 (dd, J = 5.7, 3.8 Hz, 1H, H3'), 4.98 (dd, J = 
6.2, 1.4 Hz, 1H, H2'), 5.65 (d, J = 1.3 Hz, 1H, H1'), 5.72 (d, J = 8.2 Hz, 1H, H5), 7.28 (d, 
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J = 8.2 Hz, 1H, H6), 8.98 (s, 1H, NH). Step b. ICl (1M/CH2Cl2; 0.75 mL, 0.75 mmol) was 
added to a stirred solution of 117 (224 mg, 0.5 mmol) in CH2Cl2 (4.3 mL) at ambient 
temperature and the resulting mixture was stirred at 40 oC (oil-bath) overnight. The reaction 
solution was washed with 2% NaHSO3 until the color turn into light yellow. The organic 
layer was washed with saturated solutions of NaHCO3 and brine and then was column 
chromatographed (hexane/EtOAc, 60:40 → 10:90) to give 5'-O-undecanoyl-5-iodouridine 
(118; 66 mg, 25%): 1H NMR δ 0.87 (t, J = 6.6 Hz, 3H, CH3), 1.25-1.31 (m, 14H, 7 x CH2), 
1.67 (quin, J = 7.0 Hz, 2H, CH2), 2.42-2.57 (m, 2H, CH2), 4.22-4.48 (m, 5H, H2',3',4',5',5''), 
5.91 (d, J = 2.9 Hz, 1H, H1'), 8.02 (s, 1H, H6), 10.69 (s, 1H, NH). Step c. Treatment of 118 
(27 mg, 0.05 mmol) with furan by Procedure B (column chromatography; hexane/EtOAc, 
20:80) gave 119 (15 mg, 63%); 1H NMR δ 0.87 (t, J = 6.7 Hz, 3H, CH3), 1.23-1.25 (m, 
14H, 7 x CH2), 1.59 (quin, J = 6.8, 2H, CH2), 2.35 (t, J = 7.5 Hz, 2H, CH2), 4.24 ("t", J = 
4.9 Hz, 1H, H3'), 4.35-4.40 (m, 4H, H2',4',5',5''), 5.95 (d, J = 4.1 Hz, 1H, H1'), 6.40 (dd, J 
= 3.3, 1.8 Hz, 1H, furan), 6.97 (d, J = 3.2 Hz, 1H, furan), 7.27 ("s", 1H, furan), 7.96 (s, 1H, 
H6), 9.89 (s, 1H, NH); HRMS calcd for C24H35N2O8 [M+H]
+ 479.2388, found 479.2397 
5'-O-Undecanoyl-5-(5-heptylfur-2-yl)uridine (120). Treatment of 118 (27 mg, 0.05 
mmol) with 2-heptylfurane (96 μL, 83 mg, 0.5 mmol) by Procedure B (column 
chromatography; hexane/EtOAc, 30:70) gave 120 (13 mg, 44%):  1H NMR (DMSO-d6) δ 
0.82-0.87 (m, 6H, 2 x CH3), 1.18-1.30 (m, 22H, 11 x CH2), 1.48 (quin, J = 6.9, 2H, CH2), 
1.58 (quin, J = 7.2, 2H, CH2), 2.22-2.37 (m, 2H, CH2), 2.58 (t, J = 7.5 Hz, 2H, CH2), 3.95 
(q, J = 5.0 Hz, 1H, H3'), 4.08-4.13 (m, 2H, H2',4'), 4.22 (dd, J = 12.5, 2.2 Hz, 1H, H5'), 
4.30 (dd, J = 12.5, 5.6 Hz, 1H, H5''), 5.32 (d, J = 5.9 Hz, 1H, 3'-OH), 5.54 (d, J = 5.0 Hz, 
1H, 2'-OH), 5.82 (d, J = 5.3 Hz, 1H, H1'), 6.14 (d, J = 3.4 Hz, 1H, furan), 6.77 (d, J = 3.7 
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Hz, 1H, furan), 7.78 (s, 1H, H6), 11.68 (s, 1H, NH); 13C NMR (DMSO-d6) δ 13.87 (CH3), 
13.90 (CH3), 22.0, 24.4, 27.3, 27.4, 28.35, 28.37, 28.58, 28.61, 28.8, 28.9, 31.18, 31.23, 
33.2 (CH2), 63.4 (C5'), 69.9 (C3'), 73.3 (C2'), 81.5 (C4'), 88.9 (C1'), 101.1 (C5), 106.9 
(furan), 109.2 (furan), 132.8 (C6), 144.3 (furan), 149.5 (furan), 154.7 (C2), 160.0 (C4), 
172.6 (C=O); HRMS calcd for C31H49N2O8 [M+H]
+ 577.3483, found 577.3509 
4.2. Polymerase-catalyzed synthesis of azidomethyl-modified DNA 
Materials of enzymatic reactions  
  All DNA primers and templates were synthesized by Integrated DNA Technologies 
(Coralville, IA). The radionucleotides [-32P] ATP (6000 mCi/mmol) was purchased from 
MP biomedicals Inc. (Santa Ana, CA). T4 polynucleotide kinase and deoxynucleoside 5’-
triphosphates (dNTPs) were purchased from Thermo Scientific (Pittsburgh, PA). Micro 
Bio-Spin TM 6 Columns were from Bio-Rad (Hercules, CA). All other chemicals were 
from Thermo Scientific (Pittsburgh, PA) and Sigma-Aldrich (St. Louis, MO). Purified 
human DNA polymerase β (pol β), flap endonuclease 1 (FEN1) and DNA ligase I (LIG I) 
were purified according to the procedures described previously.151,152  The Klenow 
fragment of E. Coli DNA polymerase I  (Pol I) was purchased from New England Biolabs 
(Ipswitch, MA).  
Oligonucleotide substrates 
 Substrates with an upstream primer annealed to the template strand were designated 
as open template substrates. The substrates were made by annealing an upstream primer 
(31nt) with the template strand (71 nt) at a molar ratio of 1:3. The substrate containing one-
nucleotide gap were made by annealing an upstream primer and downstream primer (Table 
12, Downstream primer 1) with the template strand at the molar ratio of 1:3:3. The open 
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template and one-nucleotide gap substrates were employed to mimic the intermediates 
formed during DNA replication. The substrate containing one-nucleotide gap with a 
5'-sugar at the downstream strand were made by annealing an upstream primer, a 
downstream primer with a 5’-tetrahydrofuran (THF), an analogue of a sugar (Table 12, 
Downstream primer 2) with the template strand at a molar ratio of 1:3:3. Substrates were 
labeled with -32P at the 5’-end of the upstream primers. Template 1 was designed for 
incorporation of AmdUTP 20, whereas Template 2 was for AmdCTP 74. 
Table 12. Oligonucleotide Sequences of primers and templates for polymerase-catalyzed 
synthesis of azido-modified DNA 
Oligonucleotide  nt Sequence (5’-3’) 
Upstream primer 31 GCA GTC CTC TAG TCG TAG TAG CAG ATC ATC A 
Downstream 
primer 1 
39 CAA CCG GCA TTA GGT GTA GTA GCT AGA CTT ACT CAT TGC 
Downstream 
primer 2 
39 THF CAA CCG GCA TTA GGT GTA GTA GCT AGA CTT ACT CAT TGC 
Template 1 71 GCA ATG AGT AAG TCT AGC TAC TAC ACC TAA TGC CGG TTG ATG 
ATG ATC TGC TAC TAC GAC TAG AGG ACT GC 
Template 2 71 GCA ATG AGT AAG TCT AGC TAC TAC ACC TAA TGC CGG TTG GTG 
ATG ATC TGC TAC TAC GAC TAG AGG ACT GC 
Note: THF denotes tetrahydrofuran, an abasic sugar analogue. 
Enzymatic activity assay and BER reconstitution assay 
Nucleotides incorporation by DNA polymerases was performed by incubating different 
concentrations of pol β or Klenow fragment with 25 nM 32P labeled substrates at 37°C for 
15 min. The enzymatic reactions were assembled with 50 μM AmdUTP 20 alone or with 
50 μM AmdUTP 20 along with 50 μM dATP, 50 μM dCTP and 50 μM dGTP. To examine 
if an AmdUTP residue can be directly incorporated into a double-strand DNA through 
DNA lagging strand maturation and base excision repair (BER) via ligation, ligation 
reactions with the gapped substrates were performed in the presence of various 
concentrations of pol β or Klenow fragment and 10 nM LIG I along with 50 μM AmdUTP 
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20 and 50 μM dATP, 50 μM dCTP and 50 μM dGTP. BER was reconstituted by incubating 
25 nM substrate containing a 5’-THF with 5 nM FEN1, 10 nM LIG I, 10 nM and 25 nM 
of pol β in the presence of 50 μM AmdUTP, 50 μM dATP, 50 μM dCTP and 50 μM dGTP. 
Reaction mixtures (20 μl) contained 5 mM Mg2+, 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 
0.1 mg/ml BSA, 0.1 mM EDTA and 0.01% NP-40. For the reactions that contained LIG I, 
2 mM ATP were included in the reaction mixtures. Reactions were terminated with 20 μl 
2X stopping buffer contained 95 % formamide and 10 mM EDTA. Reaction mixtures were 
subsequently denatured at 95 °C for 10 min. DNA synthesis and ligation products were 
separated in a 15% urea denaturing polyacrylamide gel and were detected by Pharos FX 
Plus PhosphorImager (Bio-Rad Laboratory, CA).  
Incorporation of a AmdCTP 74 by pol β was measured by incubating various 
concentrations of pol β (1 nM, 5 nM, 10 nM and 25 nM) with 25 nM open template 
substrate, one-nucleotide gap substrate and one-nucleotide gap substrate containing a 
5'-THF along with 50 μM of a AmdCTP. Substrates were 32P-labeled at the 5'-end of the 
upstream primer. 
4.3. ESR studies of aminyl radical and its conversion to iminyl radical 
Sample preparation and methods 
As per the well-established methodologies,42,73,153 transparent glassy samples of AmdU 
18, AmdC 42, AvdU 21, and AvdC 43 were prepared. Subsequently, γ-irradiation and ESR 
spectral analyses of these samples were performed.  
Compounds purchased: Lithium chloride (LiCl) (ultra-dry, 99.995% (metals basis)) 
was obtained from Alfa Aesar (Ward Hill, MA, USA). Deuterium oxide (D2O) (99.9 atom % 
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D) was purchased from Aldrich Chemical Company Inc. (Milwaukee, WI, USA). All 
compounds were used without further purification. 
Glassy sample preparation:    
(i) Preparation of homogeneous solutions: First, homogeneous solution was prepared by 
dissolving ca. 2.2 to 2.4 mg/mL of a compound (e.g., 18) in either 7.5 M LiCl in D2O. 
The native pH of 7.5 M LiCl in D2O is ca. 5 and pH of these solutions was not 
adjusted.73 
(ii) Preparation of glassy samples and their storage: Homogenous solutions of azido 
compounds were thoroughly bubbled with nitrogen gas. Subsequently, those solutions 
were immediately drawn into 4 mm Suprasil quartz tubes (Catalog no. 734-PQ-8, 
WILMAD Glass Co., Inc., Buena, NJ, USA). Thereafter, the quartz tubes containing 
these solutions were rapidly immersed in liquid nitrogen (77 K). Owing to rapid cooling 
at 77 K, the homogeneous liquid solutions formed transparent homogeneous glassy 
solutions. Subsequently, these transparent homogeneous glassy solutions of azido 
compounds were γ-irradiated at 77 K and were subjected to progressive annealing 
experiments along with ESR spectral studies. All glassy samples were stored in the 
dark at 77 K in Teflon containers prior to and after γ -irradiation. 
γ-Irradiation of glassy samples and their storage: As per our well-established 
methodology of γ-irradiation of glassy samples of DNA and RNA-models,42,73,153 the 
glassy samples were γ (60Co)-irradiated (absorbed dose = 375-500 Gy (1.5 to 2 h)) at 77 K 
and stored at 77 K in Teflon containers in the dark. Owing to 2.2 to 2.4 mg per mL of 7.5 
M LiCl glass (D2O) and as per our previous work with 3′-AZT42 and 
azidopentofuranoses,73 the radiation-produced prehydrated electrons in the glass153 are 
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scavenged by the azide solute and Cl2•¯ is formed owing to scavenging of radiation-
induced holes by the matrix (7.5 M LiCl).42,73,153  
Annealing of glassy samples: As per our previous studies,42,73,153 a variable temperature 
assembly that passed liquid nitrogen cooled dry nitrogen gas past a thermister and over the 
glassy sample was employed for annealing. Stepwise (either 5 K or 10 K step) annealing 
of each glassy sample was conducted in the range (140 – 170) K for 15 min. The matrix 
radical, Cl2•¯, did not react with sample.42,73,153 Thus, by employing ESR spectroscopy, we 
were able to study directly the formation of RNH• via reaction of radiation-produced 
prehydrated electron with azido compounds and subsequent reactions of RNH•. 
Electron Spin Resonance: As per ongoing studies in our laboratory,42,73,153 we used a 
Varian Century Series X-band (9.3 GHz) ESR spectrometer with an E-4531 dual cavity, 
9-inch magnet, and a 200 mW Klystron. For the field calibration, Fremy’s salt (gcenter = 
2.0056, A(N) = 13.09 G) was employed. All ESR spectra were recorded at 77 K and at 45 
dB (6.3 µW) as well as 40 dB (20 μW). We note here that recording of ESR spectra at 77 
K maximizes the signal height and allows for comparison of signal intensities.73 
Employing the Bruker programs (WIN-EPR and SimFonia) and our ongoing studies 
on DNA and RNA-radicals,73,153 anisotropic simulations of experimentally recorded ESR 
spectra were carried out. The ESR parameters (e.g., hyperfine coupling constant (HFCC) 
values, linwidth, etc.) were adjusted to obtain the “best fit” simulated spectrum that 
matched the experimental ESR spectrum well (see our previous works42,73,153). In addition, 
each ESR spectrum reported are obtained after subtraction of line components due to Cl2•¯. 
Method of theoretical Calculations: Employing optimized geometries of radicals, 
energies of radicals and hyperfine coupling constant (HFCC) values were calculated using 
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DFT/B3LYP/6-31+G** method in Gaussian 09. Theoretically predicted HFCC values 
obtained employing B3LYP/6-31+G** method agree well with those obtained using 
experiment.73,154 Jmol molecular modeling freeware was used to plot optimized molecular 
structures.155,129 
4.4. Radiosensitizing effect of 5-azidomethyl and 5-azidovinyl pyrimidine nucleosides 
in aerobic and hypoxic cells 
The radiation response of cells in the presence of azido-modified nucleosides in vitro 
was examined using exponentially growing monolayers in Perma-nox Contour dishes (Lux 
Scientific).156 Clonogenic assay was used to do cell death assay. EMT6 mouse cells were 
allowed to grow for 1 day to produce cultures in mid exponential growth. For the tests in 
aerobic cells, the cultures were treated with 100 μM azido compounds in DMSO in small 
volumes or vehicles for 48 h. For the test in hypoxic cells, after the 44 h treatment under 
aerobic condition, hypoxia was produced by placing uncovered dishes, containing the 
monolayers overlaid with 2 mL of medium containing azido compounds or vehicle, into a 
pressure vessel and gassing the vessel at 37 oC with a humidified mixture of 95% N2/5% 
CO2 for 4 h. The radiosensitizing effect tests were divided into following groups: (a) 
Control: without azido compounds and without irradiation treatment under aerobic or 
hypoxic condition. (b) Drug: the cultures were treated with 100 μM azido compounds in 
small volumes for 44 h under aerobic followed by 4 h under aerobic or hypoxic condition. 
(c) Drug and irradiation in aerobic cells: the cultures were treated with 100 μM azido 
compounds in small volumes or vehicles for 48 h and irradiated with 7.5 Gy radiation 
during the final few minutes of the 48 h incubation. Cells were irradiated with 320 kV 
X-rays produced by an XRAD irradiator (Precision X-ray, Branford CT, USA) at 12.5 mA, 
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2 mm Al filtration, and a dose rate of 2.4 Gy/min. (d) Drug and irradiation in hypoxic cells: 
the cultures were treated with 100 μM azido compounds in small volumes or vehicles for 
44 h under aerobic condition and then 4 h under hypoxia condition. Cultures were irradiated 
with 7.5 GY radiation. Cells were irradiated with 320 kV X-rays produced by an XRAD 
irradiator at 12.5 mA, 2 mm Al filtration, and a dose rate of 1.9 Gy/min.  
4.5. Fluorescent properties of triazolyl nucleosides 
The fluorescent properties of the four N-unsubstituted triazolyl nucleosides (8-TrzdA 
46, 8-TrzdG 47, 5-TrzdC 48, and 5-TrzdU 39) and their lipophilic analogues (diTBDMS-
8-TrzdA 88, diAc-5-TrzdU 84, and diAc-5-TrzdC 83) were determined following the 
general procedure reported in the paper reported from our group.51 Triazoles samples were 
tested with varying concentration. The whose absorbance at the excitation wavelength did 
not exceed 0.1 absorbance units. For determination of quantum yield ΦF, the absorbance 
of the sample solution was kept below 0.06. Quinine sulfate (ΦF = 0.55) in 100 mM H2SO4 
was used as reference standard to quantify the quantum yield. All the triazoles were soluble 
enough in the methanol and thus were prepared in HPLC grade methanol. The test was 
performed in a 2 × 10 mm quartz cuvette at room temperature. Absorption spectra were 
measured using Cary 100Bio UV-Visible Spectrophotometer. Steady-state excitation and 
emission spectra were investigated on a PC1 spectrofluorometer with bandwidth and slit 
width for ex/em set at 2 nm. Frequency-domain fluorescence lifetime were measured using 
a ChronosFD spectrofluorometer. Sample solutions were excited using a frequency 
modulated 280 nm LED. The emission was gathered with a 305 nm long-pass filter 
(Andover). 2,5-diphenyloxazole (τ = 1.4 ns) solution in EtOH was employed as a lifetime 
reference. A multiple-exponential decay model employing GlobalsWE software were used 
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to fit the modulation phase data. The residual and χ2 parameter were employed as criteria 
for goodness of fit. 
4.6. Cell microscopy studies of triazoles 
4.6.1. Using primary mouse astrocytes 
Primary mouse astrocytes were plated on coverslips and acclimated for 24 hours. 1 M 
stock solution of compounds were prepared in DMSO. The cells were treated with the 
vehicle (0.05% DMSO) or 10 uM, 100 uM, 1 mM of compounds (each with 0.05% DMSO) 
in 10% FBS P-S DMEM F-12 media for 24 hours. The cells were mounted using Prolong 
Mounting Medium. Nail polish was used to seal. The live cells were imaged using FV10i 
Confocal Laser Scanning Microscope from Olympus (10x & 60x objectives with 405 laser 
and phase contrast).  
4.6.2. Using mouse pre-adipocytes transfected with pMX-puro-GFP 
cDNA Construction and cell transfection. 
cDNA of GFP was cloned into the pMX-puro vector at EcoRI and NotI restriction sites 
and plasmid DNA was purified according to the QIAprep Spin Miniprep Kit. 
The pMX-puro-GFP vector was then transfected into the Plat-A (Cell Biolabs, INC. # RV-
102) monolayer using Lipofectamine® 2000 Transfection Reagent (Thermo Fisher 
Scientific). Plat-A cells were grown in Plat-A growth media (1% penicillin/streptomycin, 
1 µg/mL puromycin, 10 µg/mL blasticidin and 10% fetal bovine serum in Dulbecco’s 
modified Eagle’s medium (DMEM)) and incubated under a humid atmosphere containing 
5% CO2 under 37°C. 48h after transfection, the supernatant of Plat-A media was filtered 
with 0.2 nm filter and applied to 90% confluent 3T3-L1 cells grown in 3T3-L1 growth 
media (1% penicillin/streptomycin, 1% L-glutamine and 10% FBS in DMEM). After 24h 
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of incubation, 3T3-L1 cells been transfected with pMX-puro-GFP will be selected with the 
3T3-L1 selection media (5µg/mL puromycin in 3T3-L1 growth media). 
 Confocal Microscopy. 3T3-L1 mouse pre-adipocytes (Zen-bio #SP-L1-F) that have been 
transfected with pMX-puro-GFP were seeded on glass coverslips at 1.0 × 105 per 3.8 
cm2 well for 24 hours in 3T3-L1 selection media. Stock solution of 8-TrzdA 46 and 
5-TrzdU 39 were prepared in DMSO. Then the cells were treated with the vehicle (0.05% 
DMSO), 200 uM of 8-TrzdA, or 200 uM of 5-TrzdU (with 0.05% DMSO) in 3T3-L1 
selection media for 24 hours. After the 24h incubation, cells were washed with PBS and 
fixed in 4% paraformaldehyde for 20 minutes. Fixed cells were mounted with ProLong™ 
Gold Antifade Mountant (Thermo Fisher Scientific) and observed under the Olympus FV 
1200 confocal microscope. Ex/Em = 473/519 nm were used for imaging of GFP and Ex/Em 
= 405/461 nm were used for imaging of the triazoles, respectively. 
4.7. Proliferation Assays 
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 
cells/well in the presence of 5-fold dilutions of the compounds. After 4 days of incubation, 
the cells were trypsinized and counted by means of a Coulter counter (Analis, Belgium). 
Suspension cells (Mouse leukemia L1210 and human lymphoid CEM cells) were seeded 
in 96-well plates at 60,000 cells/well in the presence of the compounds. L1210 and CEM 
cells were allowed to proliferate for 48 h or 96 h, respectively and then counted. The 50% 
inhibitory concentration (IC50) was defined as the compound concentration required to 
reduce cell proliferation by 50%. 
 
 
122 
 
4.8. Antiviral Assays 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 
(HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to ACV 
(ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain 
Oka, TK- VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis, 
vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular 
stomatitis virus (VSV), Coxsackie B4, parainfluenza 3, influenza virus A (subtypes H1N1, 
H3N2), influenza virus B, Sindbis, reovirus-1, Punta Toro, human immunodeficiency virus 
type 1 strain IIIB and human immunodeficiency virus type 2 strain ROD. The antiviral, 
other than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or 
plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey cells 
(Vero), human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of 
virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) or with 20 or 100 
plaque forming units (PFU) (VZV or HCMV) in the presence of varying concentrations of 
the test compounds. Viral cytopathicity or plaque formation was recorded as soon as it 
reached completion in the control virus-infected cell cultures that were not treated with the 
test compounds. Antiviral activity was expressed as the EC50 or compound concentration 
required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. 
Cytotoxicity of the test compounds was expressed as the minimum cytotoxic concentration 
(MCC) or the compound concentration that caused a microscopically detectable alteration 
of cell morphology.  
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5. CONCLUSION 
In this dissertation, I explored the C5 azido-modified pyrimidine nucleosides (AmdU 
18, AvdU 21, AmdC 42, and AvdC 43) as potential radiosensitizer under normoxic and 
hypoxic environment. I also synthesized 2-azido-2'-deoxyinosine (2-N3dI, 44) for the site-
specific formation and characterization of the elusive 2'-deoxyguanosin-N2-yl radical 
(dG(N2-H)•, 45) to investigate the nucleic acid damage pathways induced by γ-radiolysis.  
Moreover, novel fluorescent N-unsubstituted 1,2,3-triazol-4-yl nucleosides (5-TrzdU 39, 
8-TrzdA 46, 8-TrzdG 47, and 5-TrzdC 48) were designed and synthesized as potential tools 
for investigating the perturbations to nucleic acids. 
Two classes of C5 azido-modified pyrimidine nucleosides were synthesized and 
explored as radiosensitizers. 5-Azidomethyl-2'-deoxyuridine (AmdU, 18) was prepared 
from thymidine and was converted to its cytosine counterpart (AmdC, 42). The 
5-(1-azidovinyl)-2'-deoxyuridine (AvdU, 21) and 5-(1-azidovinyl)-2'-deoxycytidine 
(AvdC, 43) have been prepared by the regioselective Ag-catalyzed hydroazidation of the 
5-ethynyl substrates with TMSN3. Using Yoshikawa protocol followed by coupling with 
pyrophosphate, the AmdU 18 and AmdC 43 were converted to their 5'-triphosphate, i.e. 
AmdUTP 20 and AmdCTP 74, which were enzymatically incorporated into DNA fragment 
during DNA replication and base excision repair (BER). γ-Irradiation-mediated 
prehydrated electrons formed in homogeneous aqueous glassy (7.5 M LiCl) systems in the 
absence of oxygen at 77 K led to site-specific formation of novel and neutral π-type aminyl 
radicals (RNH•) from AmdU 18, AmdC 42, AvdU 21, and AvdC 43. The ESR spectral 
studies and DFT calculations showed that RNH• undergo facile conversion to 
thermodynamically more stable σ-type iminyl radicals, R=N•. For AmdU 18 and AmdC 
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42, conversion of aminyl RNH• to iminyl radiacl R=N• was found to be bimolecular 
involving an α-azidoalkyl radical as intermediate. On the other hand, aminyl radicals RNH• 
derived from AvdU 21 and AvdC 43 tautomerized to the iminyl radical R=N•. Our work 
provides the first evidence for the formation of aminyl radical RNH• attached to C5 
position of azidopyrimidine nucleoside and its facile conversion to R=N• under a reductive 
environment. These aminyl and iminyl radicals can generate DNA damage via oxidative 
pathways. Owing to the high free radical scavenger concentrations in cells, the bimolecular 
conversion of the π-type RNH• to σ-type iminyl radical from 18 and 42 should not take 
place. However, the facile unimolecular tautomerization of the π-type RNH• to σ-type 
iminyl radical from 21 and 43 should occur. Therefore, it is expected that the π-type RNH• 
from 18 and 42 should augment the radiation damage more effectively than the σ-type 
iminyl radical from 21 and 43, which was proved by the radiosensitizing effect tests. AmdU 
18 showed radiosensitizing effect under both normoxic and hypoxic environment with 
SERSF7.5 of 4.57 and 4.10, respectively. Other azido-modified nucleosides tested showed 
lower radiosensitizing effect with SERSF7.5 of 1.35 for AmdC 42 under hypoxic cells and 
1.37 for AvdC 43 under aerobic cells. 
To explore the generation and reactivity of 2'-deoxyguanosin-N2-yl radical 
(dG(N2-H)•) postulated to be generated during the ambidient reactivity of the guanine 
moiety in 2'-deoxyguanosine towards hydroxyl radicals (HO•), I prepared 2-azido-2'-
deoxyinosine (2-N3dI, 44) serving as convenient substrate to generate site-specific elusive 
guaninyl aminyl radical. Using ESR, the structure of guaninyl aminyl radical and its 
subsequent reactions as well as DNA-hole transfer processes were investigated to 
understand nucleic acid damage pathways induced by γ-radiolysis. I synthesized the 
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2-azido-2'-deoxyinosine 44 by conversion of 2-amino group in the protected 
2'-deoxyguanosine into 2-azido group via diazotization reaction with tert-butyl nitrite 
followed by nucleophilic displacement with azide and deprotection.  
The fluorescent N-unsubstituted 1,2,3-triazol-4-yl analogues of the four natural bases 
of DNA (i.e. 5-TrzdU 39, 5-TrzdC 48, 8-TrzdA 46, and 8-TrzdG 47) have been synthesized 
by metal-catalyzed reactions between the 5-ethynylpyrimidine or 8-ethynylpurine 
nucleosides with trimethylsilyl azide (TMSN3). CuI catalyzed cycloaddition (DMF/H2O, 
90 oC, 5 h) gave 1,2,3-triazoles as sole products however in low to moderate yield (10% 
for 5-TrzdC to 50% for 5-TrzdU) due to the oxidation of Cu (I) to Cu (II) during the 
reaction. Combination of CuSO4/sodium ascorbate gave triazoles in improved yields (38% 
for 5-TrzdC to 52% for 5-TrzdU). Interestingly, Ag2CO3 catalyzed cycloaddition (DMF, 
2 eq. H2O, 80 
oC, 1 h) of 8-ethynylpurine nucleosides with TMSN3 produced 
8-triazolylpurines as sole products in good yields (8-TrzdG, 55%), while analogous 
cycloadditions of 5-ethynylpyrimidine nucleosides produced mixture of 
5-triazolylpyrimidine nucleosides (5-TrzdC, 7%) and the corresponding 
5-(1-azidovinyl)pyrimidine byproducts (5-(1-azidovinyl)-2'-deoxycytidine, 48%). The 
novel N-unsubstituted 1,2,3-triazol-4-yl nucleoside analogues showed excellent 
fluorescent properties in MeOH. The 8-purine analogue 8-TrzdA 46 exhibits the highest 
quantum yield of 44% while the 8-TrzdG 47 had quantum yield of 9%. In contrast, the 
5-pyrimidine analogues 5-TrzdU 39 and 5-TrzdC 48 showed a large Stokes shift of ~110 
nm with the maximum emission approximately at 408 nm and quantum yield of 2%. The 
fluorescent triazoles could enter living cells (primary mouse astrocytes and pre-adipocytes 
transfected with PMX-puro-GFG) and show fluorescence in the cytosol.  
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Transition metal-catalyzed halosulfonylation of 5-ethynyl uracil nucleosides provided 
(E)-5-(1-chloro-2-tosylvinyl)uridines. Tetrabutylammonium fluoride-mediated direct C-H 
arylation of 5-iodouracil nucleosides with furan or 2-heptylfuran gave 5-furyl-substituted 
nucleosides without the necessity of using the organometallic substrates. These two classes 
of 5-substituted uracil nucleosides as well their corresponding ester derivatives were tested 
against a broad range of DNA and RNA viruses and the human immunodeficiency virus 
(HIV). The 3',5'-di-O-acetyl-5-(E)-(1-chloro-2-tosylvinyl)-2'-deoxyuridine 122 inhibited 
the growth of L1210, CEM and HeLa cancer cells in the lower micromolar range. The 
(β-chloro)-vinyl sulfone 122 and 5-(5-heptylfur-2-yl)-2'-deoxyuridine 108 displayed 
micromolar activity against varicella zoster virus (VZV). The 5-(5-heptylfur-2-yl) analog 
108 and its 3',5'-di-O-acetyl-protected derivative showed similar activity against the 
cytomegalovirus (CMV). The 5-(fur-2-yl) derivatives of 2'-deoxyuridine and 
arabino-uridine inhibited the replication of herpes simplex virus (HSV) TK+ strains while 
the 5-(5-heptylfur-2-yl) derivative 108 displayed antiviral activity against the 
parainfluenza virus. 
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